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The association between smoking and rheumatoid arthritis (RA) is well established. The 
risk of developing RA is higher among smokers. Smoking may also affect the severity of 
disease and reduce the efficacy of medications. People with RA who smoke have an 
increased risk of comorbid disease from pulmonary disease and osteoporosis, and 
premature death from heart disease. The combination of negative health effects associated 
with smoking in people with RA make a compelling case for smoking cessation. Smokers 
with RA may have specific medical and psychosocial issues that are not being met by 
generic smoking cessation programmes. However, there has been little research that has 
addressed RA-related barriers to smoking cessation and to date there has been only one 
arthritis smoking cessation intervention published. This suggests a gap in research and 
identifies the need for further research on smoking cessation in RA. The aim of this thesis 
was to identify barriers to smoking cessation in RA and develop an intervention to aid 
smokers with RA to overcome these barriers. By qualitatively investigating disease-related 
issues that make smoking cessation difficult for people with RA, five barriers to smoking 
cessation were identified: 1) people with RA felt isolated and unsupported when attempting 
smoking cessation; 2) people with RA were often unaware of the detrimental effects of 
smoking on RA and hence did not perceive this as a reason to quit; 3) smoking was used as 
a distraction from the pain associated with RA; 4) people with RA found it difficult to 
exercise and hence saw themselves as unable to use exercise as an alternative distraction 
from smoking, and 5) smoking was used as a coping mechanism for the frustrations of 
living with RA. A twelve week smoking cessation intervention, addressing these five 




Arthritis Educators. The efficacy of the tailored intervention was assessed in a pilot 
randomised controlled trial. There was no significant difference in smoking abstinence 
rates at six months, although quit rates for both intervention (26%) and control groups 
(21%) were high compared to similar intensity smoking cessation programmes in the 
general population and the published arthritis smoking cessation study. The key support 
and advice from the Arthritis Educators were the most valued intervention components, 
followed by the specific smoking cessation components. There were common factors in the 
study that equally facilitated or impeded smoking cessation for all participants, including 
nicotine replacement therapy (NRT) as a shared treatment and the stress resulting from the 
Canterbury earthquakes. In addition, control group participants had independently 
developed their own strategies to control their smoking. The implications of this study are 
that although physical limitations and disease-associated factors adversely affect smoking 
cessation in RA, the lack of added benefit of a tailored smoking cessation intervention 
suggests a combination of brief advice and NRT is currently the best practice for supporting 
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Tobacco use remains one of the biggest public health threats around the world and is a 
major contributor to health inequalities. Smoking remains a leading cause of preventable 
morbidity and premature death [1]. Smoking cessation is a key health target in New Zealand 
(NZ), which reflects the major priority given by the NZ government to focus action and 
resources to better help smokers to quit [2]. To date, smoking cessation in the general 
population has received considerable attention and research has identified the most 
efficacious treatments, which include both pharmacological and behavioural interventions 
[3]. Smoking rates in the NZ general population are declining as more and more people are 
able to successfully quit [4]. However, there are some communities of smokers whose 
smoking rates remain high, thus health policy strategies have emerged that propose 
tailoring smoking cessation programmes to high-risk groups to increase the chances of 
quitting smoking long-term [5].  
 
1.2 Smoking Cessation in Rheumatoid Arthritis 
Traditionally smoking cessation interventions have been designed for smokers without 
long-term medical conditions [6]. The association between smoking and rheumatoid 
arthritis (RA) is well established [7]. Because smoking has been implicated in the 




population and thus meets the criteria for being defined as a ‘special population’ of smokers 
[8]. This definition includes understudied and undertreated smokers who have been 
underrepresented in smoking cessation research. Although smoking is a significant risk 
factor for developing RA and smoking cessation is recommended for people with RA to 
reduce risk of heart disease, pulmonary disease and osteoporosis, there has been little 
research that has addressed RA-related barriers to smoking cessation. It is feasible that 
people with RA could have specific medical and psychosocial issues that are not being met 
using traditional smoking cessation programmes. Importantly, there has been only one 
arthritis-specific smoking cessation intervention published to date [9]. This identifies the 
need for further research on smoking cessation in RA. This thesis addresses key issues for 
smoking cessation in people with RA in order to determine if a targeted programme 
designed to meet the medical and psychosocial needs of individual people with RA would 
be an effective strategy for use in clinical practice.  
 
1.3 Research Aim and Objectives 
The overall aim of this thesis is to identify barriers to smoking cessation in people with RA 
and develop an intervention to assist smokers with RA to overcome these barriers. A 
comprehensive literature review provides the background information necessary to 
undertake the research for this thesis. The original research in this thesis will be undertaken 
in three distinct phases of study to investigate the following objectives: 
 
Phase 1: Identify RA-specific barriers to smoking cessation in order to inform 




Phase 2: Translate the findings about smoking cessation needs of people with RA into a 
targeted intervention that could be used in clinical practice. 
Phase 3: Determine whether the targeted smoking cessation intervention programme 
tailored for individuals with RA increases smoking cessation rates at six months 
compared to standard smoking cessation advice.  
 Obtain participant feedback to ascertain which aspects of the intervention were 
most accepted. 
Identify the most useful aspects of the pilot study from all study participants. 
 
1.4 Research in Action 
The review in Chapter 2 is designed to provide a summary of the literature regarding the 
relationships between smoking and RA. The deleterious effects smoking has on the 
management of RA are explored in depth. Particular emphasis is given to disease outcomes 
that might be improved if an individual quit smoking, including the effects of smoking on 
disease progression, comorbidities, and RA medications. Gaps in research on smoking 
cessation in RA are highlighted and critiqued. 
 
The methods employed to further the objectives of this thesis as a whole are outlined in 
Chapter 3. Different methodological approaches were applied depending upon their 
appropriateness to the type of study outcome measurements required. The exploratory and 
evaluation phases of research both employed qualitative methodologies with support from 
quantitative data. Translating the findings from the first phase of exploratory research into 




approach between key stakeholders and researchers was utilised, with the remit of selecting 
and packaging intervention content and support. The CONSORT 2010 Clinical Trials 
Checklist provided the framework for reporting the findings from the pilot randomised 
controlled trial (RCT) [10]. The pilot study was quantitatively based and statistically 
analysed using SPSS software to compare study outcomes between groups.  
  
The first study phase designed to investigate disease-related issues that make smoking 
cessation difficult for people with RA is described in Chapter 4. This phase provided a 
valuable insight to the specific RA-related barriers to smoking cessation in a stratified 
sample of smoking and ex-smoking individuals with RA. By gaining an understanding of 
these specific factors from the perspective of individuals, the opportunity to plan an 
effective targeted intervention that may increase the chance of smoking cessation was 
facilitated. These ‘lived’ experiences provided the foundations for a smoking cessation 
intervention tailored for people with RA. 
 
The translation of the findings from the exploratory phase into a 12 week novel 
psychosocial smoking cessation intervention, tailored specifically to meet the goals and 
preferences of individual people with RA is outlined in Chapter 5. This intervention was 
developed in association with Arthritis New Zealand (NZ) and was designed to be used in 
clinical practice. It had two major methodological components: the intervention structure 
and intervention content. The intervention structure was designed using key components of 
existing evidence-based smoking cessation programmes as identified in a systematic 
literature review. The process for developing and refining resources for people with RA 
addressed the previously identified barriers for quitting smoking. This provided the 





Chapter 6 presents the results from testing the efficacy of the tailored intervention in a 
pilot study. People with RA who were current smokers were randomised on a 1:1 ratio into 
the control or the intervention arms of the study. All participants received the current 
standard of care for smoking cessation, the ‘ABC pathway’ however; those randomised to 
the intervention arm received additional advice, education and support from Arthritis NZ 
Educators as outlined in Chapter 5. 
 
To study implications for future practice and research, Chapter 7 presents an in depth 
exploration of the qualitative secondary outcomes of the pilot study. Feedback from study 
participants was analysed to evaluate what aspects of the smoking cessation intervention 
and overall study were most useful and valuable to the participants.  
 
Chapter 8 provides an overview and integration of the findings in the three phases of study 
to address the overall research aim and present the findings from the thesis study. The thesis 
will show that although physical limitations and disease-associated factors adversely affect 
smoking cessation in RA, the lack of added benefit of a tailored smoking cessation 
intervention suggests a combination of brief advice and nicotine replacement therapy 
(NRT), which is offered routinely and was the usual standard of care treatment for the 
control group (the ‘ABC pathway’), is the best practice supporting people with RA who 
wish to quit smoking. Adding a disease-specific educational component that outlines the 
relationship between RA and smoking may be beneficial. RA smokers with less education 





The study presented in this thesis adds to current literature on smoking cessation in RA 
because it tested the value of a smoking cessation programme for people with RA based 
upon comprehensive and intensive support, whilst allowing for the individualisation of the 
support package based on the needs and preferences of individual people with RA. Overall, 
this intervention enabled the targeting of smoking cessation barriers in people with RA by 
empowering them with problem-solving strategies, which may lead to improvements in life 





2 LITERATURE REVIEW 
 
2.1 Chapter Overview 
Identifying barriers to smoking cessation in RA and then developing an intervention to aid 
smokers with RA to overcome these barriers is the overarching aim of this thesis. The 
purpose of this review is to highlight how smoking is a significant health issue in people 
with RA, particularly the risk of premature death from comorbid cardiovascular disease 
(CVD) and justifies why smoking cessation in RA would be of particular benefit. The 
review identifies the gap in the literature pertaining to smoking cessation in RA. 
 
The review begins with an outline of the burden that smoking presents to the general 
population, with a strong emphasis on the health risks associated with smoking. The added 
burden of smoking with chronic disease is examined, and the discussion highlights the 
increased risk smoking poses to disease progression, recurrent events and death from 
smoking in smoking-related chronic diseases. The review then narrows its focus to describe 
RA including aetiology, pathophysiology, and known risk factors for development of the 
disease. Smoking is identified as a modifiable risk factor for RA, followed by an in depth 
examination of the deleterious impacts of smoking on health in established RA, particularly 
comorbid smoking-related diseases which can dramatically reduce people with RA’ quality 
of life and be associated with premature death. 
 
The focus of the review progresses to consider smoking cessation and the benefits of 




adopted by national and international governments to increase quitting in their populations 
including evidence-based smoking cessation interventions. Because smoking has such 
strong adverse associations with RA, quitting smoking is now viewed as an important 
modifiable risk for people with RA and one of the few areas that they can take control of 
their own health with potential to improve disease outcomes. However, there has been little 
research into smoking cessation in RA. Physical and disease-associated factors may make 
quitting smoking more difficult in people with RA and so particular prominence is given 
to identifying potential barriers that may be relevant to people with RA who smoke.  
 
2.2 The Burden of Smoking 
“It’s the most dangerous weapon of mass destruction. In fact, in your country, tobacco 
use is responsible for more deaths than World War II, HIV/AIDS, cocaine, heroin, 
alcohol, accidents, homicide and suicide – combined!” (Excerpt from an open letter 
from Indian cancer surgeon Prof Pankaj Chaturvedi to USA screenwriter Woody 
Allen) [11] 
 
Cigarette smoking is a highly prevalent and addictive habit that is the leading cause of 
preventable death and disability, and will kill an estimated one billion people during the 
21st century [1]. However, for each death caused by tobacco there are 20 smokers suffering 
from a smoking-related disease [12]. Smoking is directly related to six of the eight most 
frequent causes of death [1]. Overall, life-long smokers experience a higher prevalence of 
common diseases, a reduced quality of life, and die an average of 14 years earlier than non-




of smokers, a much higher rate than previously recognised, ultimately causing about five 
million premature deaths annually worldwide [14]. 
 
2.2.1  Definitions of Smoking Status 
The definitions of smoking status used by the national tobacco surveys in NZ are described 
in Table 2-1. These definitions are comparable with the definitions used in international 
surveys in Australia, Canada, United Kingdom (UK), and United States (USA), although 
the terminology for ‘ex-smoker’ is interchangeable with ‘former’ smoker [15]. Ninety 
percent of current smokers have been reported as persistent daily smokers, which 
demonstrates the major difference between the definitions of ‘current’ smoker versus 
‘daily’ smoker [16]. In this thesis, the term ‘current’ smoker will be used to identify the 
smoking status in people with RA. 
 
2.2.2 Definition of Smoking Prevalence  
The prevalence of smoking is determined by the number of current smokers in a specific 
population divided by the total population at a specific time [15]. Smoking prevalence is 
often referred to as a ‘smoking rate’ [15]. Prevalence of smoking in any population varies 
by socio-economic status (SES), ethnic group, age, gender, and level of education [17]. 
Smoking prevalence is higher in some population groups of smokers including those with 
smoking-related chronic illnesses such as CVD, chronic obstructive pulmonary disease 
(COPD), and diabetes [6, 18]. Because Australia, Canada, UK and USA have similar 






Table 2-1: Definitions of smoking status  
(Adapted from [15]) 
Smoking status and individual 
definitions 
Definition includes Definition excludes 
Smoking: smoking of tobacco via 




products e.g. cigars and 
pipes, marijuana, non-
smoked tobacco products 
‘Current smoker’: individual who 
has smoked greater than 100 
cigarettes in their lifetime and 




People who currently 
smoke less often than once 
a month 
‘Daily smoker’: individual who 
currently smokes at least once per 
day 
Daily smokers Weekly smokers 
Monthly smokers 
‘Non-daily smoker’: individual 
who currently smokes at least 




‘Ex-smoker’: individual who has 
smoked greater than 100 
cigarettes in their lifetime and 





‘Never smoker’: individual who 
has smoked less than 100 
cigarettes in their lifetime and 
does not currently smoke 
People who have never 
tried smoking 
People who may have 
experimented with 
smoking (up to 100 
cigarettes) 
All ever smokers 







2.2.3 New Zealand Smoking Prevalence 
Data from the 2013 NZ census show 15.1% (463,000) NZ adults were current smokers, a 
decrease from 19.9% (598,000) in 2006/7 [19, 20]. This equates to a real reduction of 23% 
over seven years. Smoking rates (prevalence) have been gradually decreasing in NZ (Figure 
2-1) and for the first time since 2006/7, there has also been a decrease in daily smoking for 
Māori (the indigenous population of NZ) from 42.2% to 32.7% [21]. Smoking is most 
prevalent among people living in the most deprived areas of NZ [19, 22] and the higher 
prevalence of smoking among Māori accounts for a significant proportion of the disparities 
in health seen between Māori and non-Māori in NZ [23]. International guidelines for 
smoking cessation have highlighted how specific groups of smokers face more difficulties 
with quitting, particularly those with long-term health conditions [6, 24]. Therefore, 
smoking cessation may also help close gaps in the health disparities that are seen in many 
long-term conditions including RA. 
 
 
Figure 2-1: Smoking prevalence trends in NZ by ethnicity from 1996 to 2013  
























2.2.4 The Addiction of Smoking 
“If it were not for the nicotine in tobacco smoke, people would be little more inclined 
to smoke than they are to blow bubbles” (M.A.H Russell, tobacco researcher, 1974) 
[27] 
 
Nicotine dependence is a recognised medical condition in the Diagnostic and Statistical 
Manual of the American Psychiatric Association where empirical data and observations 
provide checklist criteria to classify whether individuals are dependent or not dependent 
upon nicotine [28]. Most smokers use tobacco habitually because they become dependent 
upon nicotine. For much of the 20th century smoking was regarded as a socially learned 
habit and a personal choice. However, during recent decades, much more information has 
emerged on the fundamental role of nicotine dependence in sustaining smoking behaviour 
[27]. Although heroin and methamphetamine are more addictive when considering the 
proportion of users who will become dependent, nicotine causes more serious dependence 
because it is regarded as more difficult to quit [16].  
 
Nicotine from smoke is absorbed through the nose and the mucosal linings of the mouth 
and lungs, and transported in the blood to the brain [27]. Nicotine binds to brain tissues 
with a high affinity within about 10 seconds from inhalation [29]. The receptor binding 
capacity of nicotine in smokers is increased compared to non-smokers due to a higher 
number of nicotinic cholinergic receptors in the brain, which are up-regulated by the act of 
smoking [30]. Nicotine triggers the release of the neurotransmitter dopamine in the brain, 
which is responsible for the commonly described positive effects of smoking such as 




dissipate rapidly along with the associated feelings of pleasure and reward, thereby causing 
the smoker to smoke again. Withdrawal symptoms from nicotine include headaches, anger, 
depression, anxiety, and sleep disturbances [31]. If nicotine is removed from tobacco 
smoke, or the nicotine’s effects on the central nervous system are blocked 
pharmacologically, the desire to smoke eventually ceases. This is the model that underpins 
pharmacological smoking cessation therapies and is considered in more depth in section 
2.5.5 [27].  
 
Over time, continued nicotine exposure leads to a craving for more nicotine to feel the same 
positive effects from smoking [31]. The Fagerström Test for Nicotine Dependence (FTND) 
is a tool used to evaluate the level of physiological dependence on nicotine [32]. Higher 
levels of nicotine dependence are indicated by an earlier time of the first cigarette of the 
day, more frequent smoking in the morning, and a higher number of cigarettes smoked per 
day.  
 
However, pharmacological factors alone do not drive smoking behaviour. Social, 
economic, political, and personal aspects influence patterns of smoking prevalence and 
smoking cessation [27]. The habit of smoking is socially influenced due to the close 
coupling of behavioural rituals and the sensory aspects of smoking with nicotine uptake, 
which leads to secondary conditioning [27]. The habit of smoking is also linked to the sight 
of the packet, the smell of the smoke, and the “scratch” in the throat from inhaling [27]. 
Smoking habits can also be formed by behaviour and linked to activities of daily life, for 
example when having a cup of coffee or after a meal [33]. Emotions also play a role such 





2.2.5 Health Risks associated with Smoking 
“Cigarettes are not merely tobacco leaves rolled up in paper. The modern cigarette is 
the most highly engineered product meant to be taken into the human body” [34] 
 
Smoking tobacco harms nearly every organ in the body [35]. Because smoking has a 
fundamental role in the pathogenesis of many diseases, the health risks from tobacco have 
been widely investigated [36]. Most smoking-related deaths are from one of the three 
following types of disease: 1) CVD; 2) COPD, including emphysema and chronic 
bronchitis); and 3) cancers, particularly those of the lung, larynx and tongue [12, 13, 37, 
38]. On a global scale, smoking is responsible for over one third of all respiratory deaths, 
over one quarter of all cancer deaths, and about 15% of all CVD deaths [12]. 
 
2.2.6 Smoking and Chronic Disease 
Smoking has been causally linked with heart disease and lung cancer since the 1960’s [39, 
40]. Individuals with chronic diseases including COPD, CVD and cancers, have a higher 
smoking rate than the general population [18, 41]. In 2006 in the USA, the prevalence of 
current smoking among individuals with smoking-related chronic disease was 36.9% 
(range: 29.3–49.1%) compared to 19.3% of the general population (Table 2-2) [18, 42]. 
Individuals with chronic disease who currently smoke are at a higher risk of disease 





Table 2-2: Cigarette smoking prevalence in smoking-related chronic diseases 
(Adapted from [42]) 
Chronic Disease Smoking Prevalence 
(%) 
Smoking-related cancers (other than lung cancer) 38.8  
Coronary Heart Disease (CHD) 29.3 
Stroke 30.1 
Emphysema 49.1 
Chronic Bronchitis 41.1 
 
 
Rheumatoid arthritis is an example of a smoking-related chronic disease. Current- or past-
smoking is more prevalent amongst people with RA as shown by studies in several 
countries [44-47]. The importance of smoking in the aetiology of RA has been recognised 
for some years. More recently the impact of smoking and smoking cessation on RA disease 
activity, disease progression and response to treatment has been recognised as important. 
Smoking cessation is recommended in international RA treatment guidelines but there is 
little research on the RA related barriers to smoking cessation and ways to assist people 
with RA quit [48-50].  
 
2.3 The Burden of Rheumatoid Arthritis 
The purpose of this section is to provide a background on the epidemiology of RA and its 
burden in contemporary society. The term ‘burden’ when applied to RA refers to the impact 




and risk of premature death, and the impact on society resulting from the prevalence of the 
disease [51].  
 
2.3.1 Description of Rheumatoid Arthritis 
Rheumatoid arthritis is a chronic autoimmune inflammatory disease characterised by 
inflammation of the synovial lining of the joints. This leads to joint pain, swelling and 
stiffness [52]. Inadequately controlled, RA may result in irreversible joint damage [7, 53, 
54]. RA is associated with a higher premature mortality rate, particularly in women 
(standardised mortality ratio (SMR) 1.41, 95% confidence interval (CI) 1.22-1.61) 
compared to men (SMR 1.08, 95% CI 0.86-1.32) [55]. The increased mortality is largely 
caused by CVD and infections that become apparent eight to ten years after disease onset 
[55, 56]. Individuals with more severe RA disease (i.e. those with extra-articular 
manifestations such as rheumatoid nodules) have a greater than four-fold increase in 
mortality rates compared with the general population [54, 55, 57]. While mortality rates are 
decreasing over time due to the advances in disease management and medical treatments 
available, they remain elevated compared to the general population with 40-50% more 
premature deaths among people with RA, largely due to CVD [57].  
 
2.3.2 Diagnosis of Rheumatoid Arthritis 
There is no single ‘gold-standard’ diagnostic test for RA, so diagnosis is based on a 
combination of clinical features supported by laboratory tests. Because there are no 
definitive diagnostic tests for RA, classification criteria are used to define a group of 




classification criteria for RA were updated by a joint working group from the American 
College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
in 2010 [54]. Prior to this update, the 1987 American Rheumatism Association (ARA) 
criteria were used routinely, although they were criticised for their lack of sensitivity in 
early disease [54, 58]. The ACR/EULAR 2010 criteria for classification of RA are outlined 
in Table 2-3. The cut-point for RA classification is a total of ≥6 points. 
 
Table 2-3: ACR/EULAR 2010 standard classification criteria for RA 
(adapted from [52]) 
RA Features Number of points 
attributed 
Joint involvement   
• One medium-to-large joint  0 
• Two to ten medium-to-large joints  1 
• One to three small joints (large joints not counted)  2 
• Four to ten small joints (large joints not counted)  3 
• More than ten joints (at least one small joint)  5 
Serology   
• Negative RF and negative ACPA  0 
• Low positive RF or low positive ACPA  2 
• High positive RF or high positive ACPA  3 
Acute-phase reactants   
• Normal CRP and normal ESR  0 
• Abnormal CRP or abnormal ESR  1 
Duration of symptoms   
• Less than 6 weeks (0) 0 
• 6 weeks or more (1) 1 
RF=rheumatoid factor; ACPA=anti-cyclic citrullinated peptide antibody; CRP=C-






Some individuals may have RA despite not fulfilling the above criteria. Therefore, 
individuals can also be classified as having RA if they fulfil the following three criteria:  
1) Typical radiographic erosions. 
2) Long-standing disease that previously satisfied the American Rheumatism 
Association 1987 criteria [58]. 
3) Not fulfilling new criteria at initial presentation, but may do so as their condition 
evolves over time [54]. 
 
2.3.3 Aetiology of Rheumatoid Arthritis 
Although the exact aetiology of RA is still not entirely understood, it is considered to 
develop in genetically predisposed individuals after exposure to specific environmental 
factors [59]. Together these genetic and environmental factors interact to activate the 
immune system resulting in inflammation and in some cases production of the 
autoantibodies rheumatoid factor (RF) and/or anti-citrullinated peptide antibody (ACPA) 
[59, 60]. The development of these antibodies which are associated with RA can occur 
many years ahead of the development of clinical symptoms (pre-clinical autoimmunity) 
[61].  
 
2.3.4 Risk Factors for Developing Rheumatoid Arthritis 
Risk factors for developing RA include a combination of hormonal, genetic, environmental 
and lifestyle factors [62]. The following section examines each of these risk factors 




developing treatments, but also to understand how certain factors, e.g. smoking may have 
an impact on the efficacy on treatments. 
 
2.3.4.1 Hormonal and age risks for Rheumatoid Arthritis 
Rheumatoid arthritis is more prevalent in females than males [63]. This predominance 
suggests that sex hormones and reproductive factors may be involved in the aetiology of 
the disease. A number of hormonal risk factors have been suggested including age at 
menarche, parity, breastfeeding, use of oral contraceptives, and termination of pregnancy 
[64, 65]. However, results have been conflicting and no definitive association has been 
observed [66, 67].  
 
2.3.4.2 Genetic risks for Rheumatoid Arthritis 
Up to 60% of RA risk has been attributed to genetic factors [68]. This has been 
demonstrated through twin studies, family studies and genome-wide association studies 
[62]. RA was one of the first inflammatory diseases where major histocompatibility 
complex (MHC) class II genes, specifically the human leukocyte antigen beta chain (HLA-
DRB) complex, were related to disease risk [69-72]. The HLA-DRB1 gene provides 
instructions for making a protein that has a critical role in the immune system [73]. The 
MHC class II molecules are only found in antigen-presenting cells [74]. It has been nearly 
three decades since the existence of common structural features of these genes were 
identified and termed the ‘shared epitope’ (SE) [69]. The HLA-DRB1 SE alleles are 





2.3.4.3 Environmental and lifestyle risk factors for Rheumatoid Arthritis 
Environmental and other non-genetic factors account for the remaining 40% of the risk of 
developing RA, and interactions between genetic and environmental risk factors have been 
associated with the risk of developing RA [53]. This means RA risk models that use genetic 
and environmental risk factors will be more accurate in modelling the risk for developing 
RA than each alone [53]. Evidence also suggests that some risk factors are significant only 
in ACPA-positive disease [76]. Regular smoking and ACPA-positive RA is one example 
of a causal association, and as this is a major factor of interest in this thesis, it will be 
discussed in depth in section 2.4.1. Apart from smoking, other environmental and lifestyle 
risk factors, as listed below, are less certain and particularly difficult to generalise within 
RA [76]:   
 
1) Social class: relationships have been identified between lower level of education 
and a greater RA risk in some studies [77, 78], but this remains controversial 
because they may be confounded with other risks, such as smoking and other 
environmental exposures.  
2) Occupational exposure to silica dust, mineral oils and other immune system 
activators [79, 80]. 
3) Infections: the Epstein-Barr virus (EBV) has been associated with RA [81, 82]. 
4) Diet: caffeine, antioxidants and oily fish have been examined by many studies but 





2.3.5 Incidence and Prevalence of Rheumatoid Arthritis 
Rheumatoid arthritis is regarded as a common autoimmune disease affecting all ethnic 
groups. In prevalence studies, RA is more common in women than men [84]. The incidence 
of RA from European studies during the 1990’s was estimated at 13-36 per 100,000 women 
>19 years and 4-13 per 100,000 men [84, 85]. Estimates of the prevalence of RA range 
from 3-12 per 1,000 women and 1-6 per 1,000 men in Europe during the same time-frame 
[84]. World-wide, RA is prevalent in up to 0.5 to 1% of the adult population and usually 
begins in adults between the ages of 40 and 60 years, although it can occur at any age [7, 
51, 86-88]. There is scant data on the prevalence of RA in NZ but based upon the prevalence 
rates in comparable European countries, RA prevalence in NZ adults was estimated to be 
approximately 0.53% in 2010, making it the second most common form of arthritis [51]. 
Prevalence rates are broadly similar by gender across all ethnic groups in NZ [51].  
 
2.3.6 Pathophysiology of Rheumatoid Arthritis 
The pathogenesis of RA appears to involve both cellular and humoral immunity; although 
the specific role that each arm of the immune system plays in the initiation and perpetuation 
of the autoimmune disease process remains unclear [89]. The dominant cells in joints 
affected by RA are cartilage and synovial cells [52]. The overproduction by inflammatory 
cells of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α), 
interleukin-1, and interleukin-6 drives both synovial inflammation and subsequent joint 
damage [52]. Chronically affected joints are characterised by thickened synovium, [90]. 
Uncontrolled inflammation leads to cartilage damage and bone erosion. [90]. Section 2.3.11 




2.3.7 Subtypes of Rheumatoid Arthritis 
The division of RA into subtypes has been determined since the 1940s by the 
presence/absence of RF [72]. Contemporary studies have seen 70-75% of people with RA 
positive for RF [88]. More recently the presence/absence of the more specific anti-CCP 
antibodies (ACPA) has become recognised as an effective and informative marker for the 
subdivision of RA. Sixty percent of people with RA are ACPA-positive [91]. ACPA-
positive and ACPA-negative disease are believed to be genetically distinct, where HLA-
DRB1 SE alleles are restricted to ACPA-positive RA. In established RA, ACPA-positive 
individuals may also develop a more severe form of the disease. High levels of ACPA are 
associated with higher disease activity, worse radiographic progression, and more severe 
clinical outcomes [92].  
 
 
2.3.8 Articular Manifestations of Rheumatoid Arthritis 
Joints classically affected by RA include the small joints of the hands and feet as well as 
wrists, elbows, knees, ankle and cervical spine. Affected joints are swollen and painful [93]. 
Once acquired, RA persists and over time RA can lead to significant joint destruction with 
loss of function and ensuing disability. Joint damage starts early in the course of RA and 
once present is largely irreversible [94]. Persisting joint inflammation (disease activity) is 
an important predictor of progression of joint damage and the long-term requirement for 
joint replacement surgery [94]. Disease activity has also been shown to be the main 





Radiological progression and disease activity are used to ascertain the severity of RA in  
individuals and are important outcome measures in clinical trials or observational studies 
in RA [96]. Inflammatory activity in the joints leads to joint damage which is visible 
radiographically and can be monitored over time for progression. Radiographic damage 
correlates with physical function in people with RA [96]. Radiological progression and 
disease activity are important concepts because they frame the well-being of people with 
RA. While inflammation in joints fluctuates over time in individuals, the radiographic 
damage is considered to reflect cumulative joint inflammation over time [96]. Disease 
activity is used by health providers to quantify an individual’s status into either high or low 
disease activity, which is used to guide treatment aiming toward a state of low disease 
activity or remission [97].  
 
Radiographic progression in clinical trials or observational studies can be measured by the 
van der Heijde modification of the Sharp scoring system (SvdH) [96], which collects 
information on erosions and joint space narrowing. The SvdH is measured by the presence 
of erosions in 16 joints of hands and wrists (graded 0-5), six joints in the feet (graded 0-
10), and the presence of narrowing in joint spaces in 15 joints of hands and wrists (graded 
0-4), six joints in the feet (graded 0-4), giving a maximal range of 280 units for erosion and 
168 units for joins space narrowing, which adds up to 448 units for the total Sharp score 
(TSS) [96]. This measurement is taken at two subsequent time points and the difference 
between the two is the outcome measure. 
 
Because there is no definitive ‘best’ test for disease activity in RA, the ACR has 
recommended six tools for the systematic measurement of disease activity in RA (Table 2-




the Health Assessment Questionnaire (HAQ), which asks how much difficulty an   
individual has performing daily activities such as bathing, dressing and getting in and out 
of cars; 2) joint counts where a physician examines a specific number of joints (28) and 
tallies how many are swollen or tender; 3) laboratory tests that measure markers of 
inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP), and 4) validated composite disease activity scores such as the disease activity score  
(DAS28) that include variables from the preceding categories. 
 
Table 2-4: Summary of RA disease activity measures recommended by ACR 






1 PAS 3 HAQ, Pain VAS, Pt Global VAS 
1 PAS-II 3 HAQ-II, Pain VAS, Pt Global VAS 
1 RAPID-3 3 MDHAQ, Pain VAS, Pt Global VAS 
1 & 2  CDAI 4 28TJC, 28SJC, Pt Global VAS, Pr Global VAS 
1, 2 & 3 DAS28  4 28TJC, 28SJC,  ESR or CRP, Pt Global VAS 
1,2 & 3 SDAI  5 28TJC, 28SJC, Pt Global VAS, Pr Global VAS, 
CRP 
*PAS=Patient Activity Scale; RAPID-3=Routine Assessment of Patient Index Data; 
CDAI=Clinical Disease Activity Index; DAS=Disease Activity Score; ESR=Erythrocyte 
Sedimentation Rate; CRP=C-reactive protein; SDAI=Simplified Disease Activity Index; 
HAQ=Health Assessment Questionnaire; MDHAQ=multidimensional HAQ;  
VAS=visual analogue scale; Pt Global VAS= patient global assessment of disease 
activity; Pr Global VAS= provider global assessment of disease activity; 28TJC=28 
tender joint count; 28SJC=28 swollen joint count; 






2.3.9 Extra-articular Manifestations of Rheumatoid Arthritis 
Extra-articular manifestations of RA are systemic features of the disease that occur outside 
the joints and occur in about 40% of people with RA at some stage of their disease course 
[99]. Organs that may be affected include the eyes, heart, skin, lungs, and the 
gastrointestinal, nervous, and renal systems [93]. Extra-articular damage can occur at any 
stage after the onset of RA and is more common in males [100]. The most common extra-
articular manifestation of RA is subcutaneous rheumatoid nodules, which can affect up to 
30% of people with RA and typically occur in RF positive individuals [75]. Effects from 
systemic inflammation contribute significantly to the risk of disease-related premature 
death in RA [93]. Of particular importance, the presence of extra-articular manifestations 
in RA places individuals at an increased risk of developing CVD or severe infections [93]. 
A study that examined the trends in incidence of risk factors for extra-articular disease in 
609 people with RA over a 46 year period found the most frequent predictor of severe extra-
articular manifestations of RA disease was current or past smoking (risk ratio (RR) 2.94, 
95% CI 1.68-5.13) [101]. Other less strong predictors included an individual having a 
positive RF and the HLA-DRB1 SE [93, 101].  
 
2.3.10 Comorbidities Associated with Rheumatoid Arthritis 
Comorbidity refers to the presence of two or more illnesses in the same person where the 
appearance of illnesses may reflect a causal relationship or vulnerability between one 
disease and another [102]. Comorbidities may be associated with the underlying disease 
itself or the medications used to treat the underlying condition. Cardiovascular disease, 




significant health burden to the individual over and above the articular manifestations of 
the disease [75, 103]. Comorbid diseases in RA are a key cause of a higher mortality in 
people with RA compared to the general population. The leading causes of comorbid death 
in RA are CVD (31%) and pulmonary problems including respiratory infection (29%) 
[104]. The mean number of comorbidities per RA individual is 1.6, which increases with 
age [105]. Around 80% of people with RA have one or more comorbidities [106]. 
 
2.3.10.1 Cardiovascular Disease 
The prevalence of CVD in RA was measured in the 2005-6 Questionnaires in Standard 
Monitoring of Patients with RA Program (QUEST-RA) in 4,363 patients from 15 countries. 
Prevalence was estimated to be 9.3% (range 3.6 to 17.8%), with considerable variation 
found between different countries [107, 108]. In addition, having RA almost doubles the 
risk of myocardial infarction (MI) within the first 10 years after the onset of RA [109]. The 
predicted risk of CVD for people with RA is similar to individuals without RA who are 
around 10 years older, and similar to individuals who have diabetes mellitus [110]. The risk 
of CVD death is increased by 50% in people with RA [111].  
 
Traditional and non-traditional CVD risk factors are intimately interconnected and may act 
synergistically to increase CVD risk in people with RA [110, 112]. Traditional risk factors 
for CVD in RA include smoking, hypertension, dyslipidaemia, diabetes mellitus, and 
metabolic syndrome [110]. A paradox within RA is that a low body mass index (BMI) is 
associated with a three-fold increased risk of cardiovascular death rather than the more 




include systemic inflammation and medications used in the management of RA such as 
non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids [110].  
 
2.3.10.2 Chronic Obstructive Pulmonary Disease 
A recent population-based case-control study of 9,039 people with RA and 15,070 controls 
without RA estimated the prevalence of COPD in people with RA is 8.6% compared to 
4.4% in controls [113]. Chronic obstructive pulmonary disease is a collective term for 
conditions that impede the flow of air in the trachea and bronchi [114]. Symptoms include 
shortness of breath, cough, and phlegm. Smoking is the risk factor most strongly associated 
with COPD in the general population [114]. Current or ex-smokers make up 80% of 
individuals with COPD. The World Health Organisation estimates over 50 million people 
are affected world-wide (between 5 to 10% prevalence in the adult population), causing 
close to three million deaths annually [115]. The World Health Organisation also predicts 
that deaths from COPD are likely to increase by more than 30% in the next 10 years, unless 
tobacco smoke exposure is prevented. Although once developed COPD cannot be cured, 
but further deterioration can be prevented by smoking cessation. 
 
2.3.10.3 Osteoporosis 
Osteoporosis is a progressive bone disease characterised by a decrease in bone mass and 
density that can lead to an increased risk of bone fractures [75, 103]. The lifetime risk for 
a hip, vertebral or wrist fracture due to osteoporosis has been estimated to be between 30 
to 40% in developed countries, which is similar to the risk of CVD [116]. Osteoporosis has 




comorbidity in RA [117, 118]. The prevalence of osteoporosis is greater in postmenopausal 
female people with RA compared to premenopausal female people with RA or male people 
with RA of any age [118], and is doubled in people with RA as compared to the general 
population [119].  
 
Osteoporotic fractures of the hip incur the highest morbidity and mortality [116]. The risk 
of fractures in RA has been estimated to be increased 1.5-fold (95% CI 1.4-1.6) compared 
to healthy controls [120]. The increased risk of osteoporosis in RA is thought to be 
attributed to a number of RA disease-specific factors, including: disease activity, physical 
inactivity, low BMI, medication effects (particularly corticosteroids); and traditional risk 
factors such as smoking, postmenopausal status and an older age [116, 118, 120].  
 
2.3.10.4 Infections 
Infections of the skin, soft tissues, respiratory tract, and the bones and joints (septic 
arthritis) are a cause of significant morbidity and mortality in RA, although little is known 
about the rates of infections apart from septic arthritis [75, 103, 121]. A study in 2002 of 
609 people with RA designed to identify predictors of infections in people with RA reported 
a 70% increase in confirmed infections and 85% increase in infections requiring 
hospitalisation in a cohort of RA compared to non-RA [121]. Whether this is because 
people with RA are more predisposed to develop infections or whether infections in RA 
may take a more severe course is not known [122]. In that study statistically significant 
predictors of increased infection risk included: smoking (hazard ratio (HR) 1.4, 95% CI 
1.1-1.8, p=0.008); male gender (HR 1.4, 95% CI 1.1-1.9, p=0.016); comorbid COPD (HR 




4.4, p<0.001) [121]. As is evident from these statistics, extra-articular manifestations were 
the strongest predictor of infections in RA, although smoking also provides a significant 
risk [121]. 
 
It is possible that contemporary RA treatments might predispose individuals to infection, 
particularly the use of immunosuppressive drugs [75, 103, 121]. Studies of non-biologic 
disease-modifying anti-rheumatic drugs (DMARDs) use have shown either no increase, or 
a decrease in infections in people with RA but corticosteroid use (both alone or 
concomitantly with DMARDs) has been found to significantly increase the rate of both 
mild and serious infections (HR 1.9, 95% CI 1.5-2.5, p<0.001) [75, 103, 121]. 
 
2.3.10.5 Periodontitis 
Periodontitis is more common in smokers and more common in RA. It is also related to the 
same genes as RA and there may be a putative mechanistic link between periodontitis and 
RA via protein citrullination [123]. Smoking increases oral inflammation and the 
prevalence of a specific bacteria Prevotella gingivalis, which is a leading pathogen in 
chronic periodontitis [124]. Periodontitis is characterised by inflammatory destruction of 
the periodontal attachment and alveolar bone and ultimately causes tooth loss. In addition, 
periodontal pathogens have direct systemic access to blood circulation, which is thought to 






2.3.11 Medical Management of Rheumatoid Arthritis 
The primary goal of drug therapy in RA is to achieve rapid and sustained disease control 
to prevent long-term damaging effects on joint structure, function and mortality. The 
medical management of RA has changed over the last 15 years where the fundamental 
emphasis has moved toward controlling inflammation early and completely [54]. By 
controlling joint inflammation, joint damage and disability can be avoided thereby leading 
to improved outcomes [51, 54]. With modern treatment strategies remission or at the very 
least, low disease activity, are obtainable. The following table describes the therapeutic 
drugs that are currently used in the medical management of RA (Table 2-5).  
 
Table 2-5: Therapeutic drugs used in the management of RA 
(adapted from [52, 125])* 




Decrease in joint pain and stiffness and to 
improve joint function 
No role in preventing joint damage 
Glucocorticoids prednisone Decrease in joint pain and tenderness 
Decrease bone erosion 
DMARDs methotrexate  Decrease inflammatory disease activity 






Biological therapies adalimumab  Reduce inflammation  











Disease-modifying anti-rheumatic drugs are a group of heterogeneous agents grouped 
together by convention and use in RA. They typically take weeks to months to become 
effective. The DMARD methotrexate (MTX) has been regarded as the ‘gold standard’ 
treatment for RA since the 1990’s [126]. MTX is first line therapy unless there are contra-
indications, principally because it has a very high response rate (85%), low cost, ease of 
administration, and a predictable side-effect profile [127]. When MTX does not adequately 
control inflammation or when an individual has MTX related adverse effects, other 
DMARDs are available, including sulfasalazine, leflunomide, and hydroxychloroquine 
[127]. DMARDs in combination have yielded proven efficacy, e.g. MTX, sulfasalazine and 
hydroxychloroquine (‘triple therapy’) [52]. The choice of combination is a matter of 
clinical judgement, but in NZ this choice is influenced to some extent by the funding 
restrictions from the NZ Crown agency: the Pharmaceutical Management Agency 
(PHARMAC) that decides which medicines and related products are subsidised for use in 
NZ public hospitals and in the community [128]. 
 
The availability of new biological DMARDs has significantly improved RA management 
[51, 54]. Biological therapies are antibodies directed at specific cytokines or cell surface 
molecules [127]. In NZ the anti-TNF-α agents adalimumab, etanercept, and infliximab 
along with the anti-interleukin 6 agent tocilizumab and anti-CD20 agent rituximab are 
funded for use in RA [128]. Clinical trials of these agents show they are highly effective at 
controlling inflammation, and preventing the progression of joint damage. Adverse effects 
include reactivation of latent tuberculosis and serious infections [129].  
 
Non-steroidal anti-inflammatory drugs are still used widely in inflammatory and non-




ibuprofen, and naproxen [75, 130]. NSAIDs are used principally to reduce symptoms of 
pain and stiffness and improve joint function [75, 130]. They have no role in the prevention 
of joint damage. The most important mechanism of action is inhibiting prostaglandin 
production; prostaglandin E2 in particular is involved in pain signalling and the 
inflammatory process [75, 130]. However, the use of NSAIDs is associated with potential 
side effects including an increased risk of adverse CVD effects in people with RA [75, 
130]. A meta-analysis has shown that all NSAIDs are associated with some degree of 
increased CVD risk, e.g. rofecoxib was associated with the highest risk of MI (RR 2.1, 95% 
CI 1.3-3.6); ibuprofen was associated with the highest risk of stroke (RR 3.4, 95% CI 1.0-
11.6); and etoricoxib (RR 4.1, 95% CI 1.2-15.7) and diclofenac (RR 4.0, 95% CI 1.5-12.7) 
were associated with the highest risk of CVD death [131].  
 
Glucocorticoids were first used in the management of RA over 60 years ago. Short-term 
use reduces joint inflammation; long-term use may reduce joint damage but is associated 
with significant adverse effects including an increased risk of osteoporosis, CVD and 
infections [52]. Consequently, they are particularly useful as bridging therapy until 
DMARDs take effect.  
 
Contemporary treatment goals for RA are designed for rapid and sustained disease control; 
thereby avoiding long-term articular damage (joint structure and function), lessening the 
risks of associated RA comorbid conditions, and decreasing premature mortality. The next 
section explores in depth the relationships between smoking and RA, and the deleterious 
effects smoking has on the management of RA. Particular emphasis is given to disease 
outcomes that might be improved if an individual quit smoking and include disease 




2.4 The Burden of Smoking and Rheumatoid Arthritis 
Smoking has a direct and significant impact on RA in multiple respects. Smoking is 
implicated in the risk of developing RA. Significantly, once acquired smoking may increase 
the severity and mortality rates in RA. This section is particularly relevant to this thesis 
because it identifies compelling reasons for smoking cessation in RA.  
  
2.4.1 The Gene-environment Interaction and Smoking in Rheumatoid 
Arthritis 
The association between smoking and RA meets the Bradford Hill criteria for causation 
[132] with regard to strength, consistency, plausibility, evidence from cohort studies, 
coherence, temporality, and biologic gradient of association [133]. The risk of developing 
ACPA-positive RA was found to be significantly higher among smokers with two copies 
of the HLA-DR SE (RR 21.0, 95% CI 11.0-40.2) compared to those with one or no copies 
of the SE (RR 1.5, 95% CI 0.8-2.6) [134]. The amount of smoking is also associated with 
the risk of developing RA (Figure 2-2). An ACPA-positive individual with a 20 pack year 
smoking history and 2 copies of the SE has a 38 times higher risk of developing RA (OR 
37.6, 95% CI 18.3-77.4, p<0.0001) as compared to an ACPA-positive smoker with a 20 
year pack-year smoking history but no SE alleles (OR 1.9, 95% CI 1.1-3.5, p=0.11) [7]. 
The overall risk of developing RA while smoking is dose-related, stronger for carriers of 
the SE (significantly two copies of the SE), and selectively associated with the risk of 
ACPA-positive RA [36, 135, 136]. Overall, smoking is thought to contribute up to 25% of 
population risk of developing RA [135] and over 50% of RA cases can be attributed to 






Figure 2-2: Odds ratios for different amount of smoking in combination with different 
copies of SE alleles  
(adapted from [7]) 
 
Since smoking predisposes to ACPA-positive RA, a higher proportion of people with RA 
are smokers. Recent studies have reported 21-35% of individuals with RA are current 
smokers and between 50-69% are past or current smokers [137-140]. There is no evidence 
to suggest that male or female people with RA either take up or quit smoking differently 
when they develop RA [133].  Thus, a key issue for people who have already developed 
RA is whether smoking alters the course of the disease or its response to treatments. The 
following section focuses on the impact of smoking on established RA and considers the 
effects of smoking on disease activity and severity in RA, the major comorbidities of RA, 





















2.4.2 Impact of Smoking on Radiological Progression and Disease 
Activity on Rheumatoid Arthritis 
It remains unclear what specific effects smoking has on the severity and disease activity in 
RA, although there has been extensive research undertaken to ascertain this over the last 
20 years. Some studies suggest current smoking increases radiographic damage and/or 
disease activity, whilst others have reported that current smoking could have a protective 
effect due to the anti-inflammatory properties of nicotine (Table 2-6) [141]. These 
conflicting data have several explanations including methodological issues such as small 
sample sizes and short follow-up periods; differences in RA populations; and different 
measurements of smoking [142]. Importantly, in studies with small sample sizes or studies 
in early RA, the effect of smoking may be difficult to ascertain, particularly if there are few 
heavy smokers in the sample or the follow-up period is limited [142]. However, 
components of smoke have been shown to effect have pro-inflammatory effects in the 










Table 2-6: Effects of smoking on radiographic progression and disease activity in RA* 
Author, year and 
country 
Study method and objectives Number of 
patients 
Outcome measure Study findings 
Saag et al 
(1997), USA 
[144] 
Observational study to determine if smoking 
is associated with RA severity. 
Followed for 18 months. 
336  Disease severity 
(radiographs) 
Smokers with a >25 pack-year history 
were 2.4 times more likely to show 
radiographic erosions (p=0.02). 
Smoking may adversely influence the 




Cross-sectional study to determine: 
1) The degree to which RF+ associated with 
smoking. 
2) The quantitative effect of smoking on 
RF.  
3) If the effect of smoking on male and 
female is similar.  
4) Effect of smoking on disease status, 
severity and activity. 




Disease activity  
(swollen joint 
count) 
A dose dependent relationship found 
between smoking and radiographic 
progression after 20 years of smoking 
(p=0.05) 
No relationship between smoking and 
disease activity (p=0.70) 
Masdottir  et al  
(2000), Iceland 
[146] 
Cross-sectional study to examine the effect 
on smoking on the severity of RA. 







Smoking had an adverse effect on 
radiological progression in RA. 
Correlation between heavy smoking (≥20 
pack-years) and more radiological joint 
damage (p=0.02). 









Author, year and 
country 
Study method and objectives Number of 
patients 
Outcome measure Study findings 
Harrison et al 
(2001), UK 
[147] 
Longitudinal study to examine the influence 
of smoking on disease outcome at 3 years 
with newly presenting RA patients.  
Followed for 3 years. 






Smokers did not have higher levels of 
radiologic damage (p=0.65). 
 
Smokers had fewer swollen joints 
(p=0.11). 
Smoking may limit joint inflammation and 
damage.  
Mattey et al 
(2002), UK 
[148] 
Cross-sectional study to determine whether 
the relationship between smoking and 
disease severity in female RA patients is 
associated with polymorphism at the 







Ever having smoked was associated with a 
worse radiographic progression (p=0.05) 
and HAQ (p=0.02) than never smokers. 
Manfredsdottir 
et al (2006), 
Iceland [141] 
Prospective observational study to examine 
the effect of tobacco smoking and RF 
isotypes on disease activity and joint damage 
in early RA. 
2 year follow-up. 







Smoking status did not influence 
radiological progression (p=0.08). 
 
A gradient increase in disease activity 
(swollen and tender joint counts) observed 
from never smokers (p<0.001) to ex-










Author, year and 
country 
Study method and objectives Number of 
patients 
Outcome measure Study findings 




Longitudinal observational study to compare 
the rates of radiographic damage progression 
in current smokers and non-smokers in a 
large prospective RA cohort.  
3 years follow-up. 




Reduced radiographic progression among 
heavy smokers who smoked >1 pack/day 
(p<0.001), thus smoking does not 
accelerate RA disease progression. 
Westhoff et al 
(2008), 
Germany [150] 
Prospective observational study to 
investigate the influence of smoking on 
disease activity, and radiographic joint 
damage in RF+ and RF-negative patients 
with early RA.  
3 year follow-up. 






Smoking did not affect radiological 
progression. 
 
Smoking did not affect swollen joint count 
in either RF+ (p=0.17) or RF- patients 
(p=0.32). 
 
Mikuls et al 
(2008), USA 
[151] 
Observational study to examine the 
association of smoking with clinical and 
serological features in African Americans 
with recent-onset RA. 
300  Disease severity 
(radiographs) 
Dose-dependent smoking was associated 
with rheumatoid nodules, but not with 
radiographic erosions among African 
Americans with recent-onset RA (OR 1.4, 
95% CI 0.6-3.4). 
 
Ruiz-Esquide et 
al (2011), Spain 
[142] 
Prospective open-label study to analyse the 
effects of cigarette smoking on disease 
activity and radiographic damage in early 
RA. 
2 year follow-up. 





Smoking was an independent factor for 
radiographic progression in early RA 
(p=0.03). 









Author, year and 
country 
Study method and objectives Number of 
patients 
Outcome measure Study findings 
Soderlin et al 
(2011), Sweden 
[152] 
Observational study to assess the effects of 
smoking on disease outcome in a large cohort 
of patients with early RA. 
8 year follow-up. 
1787  Disease activity 
(DAS28) 
Current smokers had less improvement in 
DAS28 from baseline to 12 months 
(p=0.0001) compared to never or previous 
smokers but no difference in HAQ. 
Rojas-Serrano 
et al (2011), 
Mexico [153] 
Longitudinal study to determine factors 
associated with a failure to achieve ACR 50 
response. 
6 months follow-up in early RA. 
144  Clinical response 
 (ACR 50 non-
responders and 
responders) 
Smokers with RA appeared to have a 
worse prognosis in terms of achieving 
ACR 50 response (OR 3.6, 95% CI 1.2–
11.2, p<0.01). 
Vesperini et al 
(2013), France 
[154] 
Prospective observational study to 
investigate the initial response to treatment 
and risk of radiographic progression in 
current smokers and to analyse the influence 
of smoking cessation on outcomes in early 
RA.3 year follow-up. 





Smoking reduced the 1-year radiographic 
progression (OR 0.5, 95% CI 0.3-0.9 
p=0.03).  
Smoking status had no influence on 





Observational study to study clinical 
predictors for radiographic progression after 
1 year in an early RA trial. 1 year follow-up. 
311  Disease severity 
(radiographs) 
Current smoking status was a strong 
predictor of rapid radiographic progression 
in early RA (OR 2.2, 95% CI 1.1-4.5) 
compared to non-smokers. 
de Rooy et al 
(2014),  [140] 
Observational study of 6 cohorts to 
determine the effect of smoking on joint 
damage progression. Followed 3-15 years. 
3,158  Disease severity 
(radiographs) 
Smoking was associated with more 
radiologic progression (p=0.01) but the 
effect was mediated through ACPA. 
*HAQ= Health Assessment Questionnaire; ACPA=anti-cyclic citrullinated peptide antibody; RF+=rheumatoid factor positive;  





2.4.3 Impact of Smoking on Comorbidities and Extra-articular 
Manifestations on Rheumatoid Arthritis 
As described previously in this chapter, people with RA have a higher prevalence of the 
comorbid diseases CVD, COPD and osteoporosis than the general population and smoking 
is a significant additional risk factor for these comorbidities. Smoking has also been 
identified as the main predictor of severe extra-articular manifestations in RA [101]. Table 
2-7 summarises the effects of smoking on comorbid conditions and extra-articular 
manifestations in RA. Because smoking is a shared risk-factor for RA and many of its 
comorbidities, people with RA consequently suffer the morbidity of a cumulative disease 
burden as well as excess mortality [155]. The relationships between smoking and RA 
comorbid diseases are complex and are thought to involve interactions between smoking, 
ACPA and the SE [155].  
 
The risk of premature death from CVD in RA and the connections between CVD and 
smoking is an important consideration in the management of RA. Both smoking and RA 
cause inflammation, which is known to increase traditional CVD risk factors but it is 
difficult to untangle the independence or dependence of smoking as a CVD risk factor in 
RA [155] as demonstrated by the research in Table 2-7.  
 






Table 2-7: Effects of smoking on comorbid conditions in RA* 
Author, year and 
country 
Study method and objectives Number of 
patients 
Study findings 
Cardiovascular disease, smoking and RA 
Solomon et al 
(2004), USA [47] 
Observational study to examine the distribution 
of known CVD risk factors and biomarkers of 
CVD in RA in the Nurses’ Health Study. 




Women with RA were more likely to be past-
smokers (47% versus 38%) p<0.001.  
No other CVD risk factors differed between RA and 
non-RA. 
Chung et al (2005), 
USA [156] 
 
Observational study to compare the prevalence 
and severity of coronary artery atherosclerosis in 
early and established RA and non-RA. 
70 early RA  
71 RA  
86 non-RA 
More severe coronary artery calcification in 
established RA (OR 3.4, 95% CI 1.4-5.5, p=0.002) 
after adjusting for CVD risk factors. 
Prevalence and severity of coronary calcification 
increased in established RA and related to pack-
years of smoking (OR 1.02, 95% CI 1.00-1.04, 
p=0.04) and increased ESR (OR 1.02, 95% CI 1.00-
1.04, p=0.05). 
Naranjo et al 
(2008), Europe 
[107] 
Observational study to determine the prevalence 
of CVD morbidity in a large international sample 
of RA patients, its association with traditional 
CVD risk factors, clinical features of RA, and 
with the use of DMARDs. 
 
4,363  Ever-smoking was an independent risk factor for 
CVD morbidity (HR 1.6, 95% CI 1.2-2.1, p<0.001)  
 
Farragher et al 
(2008), UK [157] 
Prospective study to examine the role of the 
variants of the PTPN22 and HLA–DRB1 genes 




An interaction of smoking, SE alleles, and anti-CCP 
antibodies was observed and was associated with 
the greatest risk of death from CVD in RA (HR 7.8, 
95% CI 2.6–23.2). 
 






Author, year and 
country 
Study method and objectives Number of 
patients 
Study findings 
Gabriel et al 
(2010), USA [56] 
Retrospective cohort study to investigate the 
increased risk of CVD morbidity and mortality 
from traditional and RA specific factors.  
Follow-up between 14-16 years. 
 
822 RA  
603 non-RA 
Cigarette smoking significantly more prevalent in 
RA patients (p<0.001).  
Other traditional CVD risk factors did not differ 
between RA and non-RA patients. 
Innala et al (2011), 
Sweden [112] 
Five year prospective study to investigate:  
1) the presence of traditional and RA-related 
risk factors for CVD at the onset of RA and 
during the first five years following diagnosis  
2) Evaluated the potential for predicting CVD 
during the five-year follow-up period and the 
modulatory effect of pharmacological 
treatment. 
442  Smoking not statistically significant independent 
predictor for CV event (MI, CABG, TIA, DVT, PE 
and/or ruptured aortic aneurysm) in this cohort.  
Smoking is an independent risk factor for CVD in 
the general population. 
Smoking has a relatively small contribution to the 
overall CVD risk in patients with chronic 
inflammation.  
CV events were decreased by DMARD treatment. 
Chronic obstructive pulmonary disease, smoking and RA 
Wolfe (2000), USA 
[145] 
Cross-sectional study to determine: 
1) The degree to which RF+ associated with 
smoking. 
2) The quantitative effect of smoking on RF. 
3) If the effect of smoking is same for male and 
female. 
4) Effect of smoking on disease status, severity 
and activity. 
640  A linear quantitative relationship found between 
number of years of smoking and pulmonary disease 
(defined as patient reported pneumonia or lung 
problem) in RA (OR 4.55, 95% CI 2.25-9.20 
p=<0.001) 
 






Author, year and 
country 
Study method and objectives Number of 
patients 
Study findings 
Bieber et al (2013), 
Israel [113] 
Cross-sectional population-based case controlled 
study to assess the association between smoking, 
RA and COPD. 
9,039 RA  
15,070 non-
RA 
The proportion of individuals with COPD 
significantly higher in RA than non-RA subjects 
(8.6 versus 4.4%, p<0.0001). RA significantly 
associated with COPD (OR1.98, 95% CI 1.77-2.21, 
p<0.0001). 
Smoking more common in RA patients (29% vs 
24%, p<0.001, OR 1.27, 95% CI 1.20-1.35). 
 
Nannini et al 
(2013), USA [158] 
Population-based incident cohort of RA and non-
RA subjects to assess the incidence, risk factors, 
and mortality of COPD in RA 
594  RA and 
596 non-RA 
COPD more prevalent in RA patients who smoke 
(HR 4.4, 95% CI 2.1-9.0).  
Higher risk of developing COPD and higher risk of 
premature mortality from COPD in RA. 
 
Osteoporosis, smoking and RA 
Cooper et al 
(1995), UK [159] 
Case-controlled study to identify the risk of hip 
fracture in RA patients and those taking 
corticosteroids. 
300 RA  
600 Non-RA 
Hip fracture risk in all ever-smokers was increased 
compared to never-smokers (OR 1.7, 95% CI 1.2-
2.3). 
Hip fracture risk in ever-smoking RA patients was 
increased with corticosteroid use (OR 2.5, 95% CI 
1.1-5.9, p=0.04) but similar to RA never-smokers 










Author, year and 
country 
Study method and objectives Number of 
patients 
Study findings 
Extra-articular manifestations, smoking and RA 
Turesson et al 
(2003), USA 
[101] 
Observational study to investigate the incidence 
of extra-articular manifestations of RA and to 
examine possible predictors;  
Followed for mean 11.8 years 
609 RA Extra-articular RA occurred in 41% of patients and 
13% had severe extra-articular disease.  
Main predictors were smoking at diagnosis of RA 
(RR 2.9, 95% CI 1.7-5.1) and early disability (RR 
2.5, 95% CI 1.5-4.0). 
Nyhall-Wahlin et 
al (2006), Sweden 
[160] 
Nested case-control study to examine whether 
smoking is a risk factor for RA nodules in early 
RA and to quantify any effect. 
112 RA and  
224 non-RA  
Ever smoking associated with RA nodules in RF+ 
(OR 7.3, 95% CI 2.3-23.6, p=0.001).  
No obvious dose-dependency of smoking.  
 
Nyhall-Wahlin et 
al (2009) Sweden 
[138] 
Nested case-control study to identify patients 
with severe extra-articular manifestations in 
early RA and to investigate potential risk factors. 
Follow-up for mean of 91 months 
40 RA and  
120 non-RA 
Smoking (p=0.02) and RF (p<0.001) predicted the 
development of severe extra-articular RA. 
*HR=hazard ratio; RR=relative risk; OR=odds ratio; CI=confidence interval; AS=Ankylosing Spondylitis; PsA=Psoriatic Arthritis; 
IP=inflammatory polyarthritis; COPD=chronic obstructive lung disease; ESR=erythrocyte sedimentation rate; MI=myocardial infarction; 





2.4.4 Impact of Smoking on Medications to treat Rheumatoid Arthritis 
Optimising the suppression of RA disease activity using biologic and non-biologic 
DMARDs is viewed as key to disease management, and these therapies may be more 
effective if people with RA stop smoking [155]. Individuals with early RA who are current 
smokers are less likely to have a good response to MTX or TNF inhibitors than those who 
never smoked or those who smoked in the past [161]. Smoking may thus impact adversely 
on disease control by reducing the effects of medications used to treat RA. The use of the 
DMARDs (particularly MTX) or anti-TNF therapy enables inflammation to be controlled 
in RA and may therefore effectively reduce CVD events [162, 163]. This may be due either 
to smoking weakening the effects of medications increasing the risk of drug related adverse 
effects, or a higher medication requirement reflecting higher disease activity in smokers. 
The following Table 2-8 summarises the deleterious effects of smoking on therapies for 







Table 2-8: Effects of smoking on treatments in RA* 
Author, year 
and country 





Findings of study 
Alarcon et al 
(1997), USA 
[164] 
Case-control study to identify risk 
factors for MTX induced lung injury in 
RA. 
29 RA  
29 non-
RA 
Lung injury  
modified criteria 
of Searles and 
McKendry [165] 
MTX was associated with a risk of drug-induced 
pneumonitis and smoking increased this risk (OR 2.9, 
95% CI 1.0-8.5). 
 
 
Hyrich et al 
(2006), UK 
[166] 
Cross-sectional study to predict which 
RA patients will respond to TNF-α 
therapies;  
6 months follow-up. 
2,879  DAS28 Lower response rate among RA current smokers 
receiving infliximab (OR 0.8, 95% CI 0.6-1.0).  
No association between smoking and outcome seen in 
RA patients receiving etanercept (OR 1.1, 95% CI 0.8-
1.4). 
 
Naranjo et al 
(2008), 
Europe [107] 
Observational study to determine the 
prevalence of CVD morbidity in a 
large international sample of RA 
patients, its association with traditional 
CVD risk factors, clinical features of 
RA, and with the use of DMARDs. 
 





Prolonged use of treatments reduces the risk of CVD 
morbidity in RA p < 0.05):  
MTX    (HR 0.82, 95% CI 0.79-0.86) 
leflunomide   (HR 0.52, 95% CI 0.38-0.72) 
sulfasalazine   (HR 0.92; 95% CI 0.87 to 0.98) 
glucocorticoids  (HR 0.95; 95% CI 0.92 to 0.98) 



















Prospective observational study to 
investigate the influence of smoking 
on disease activity, drug need and 
radiographic joint damage in RF+ and 
RF- early RA.  
3 year follow-up. 
896  Drug therapy use At 3 years, the % of patients having a DMARD 
combination or ever having had biologics was higher 
in RF+ current smokers (35.8%) compared to  RF+ 
never-smokers (20.3%) p=0.02. 
The higher use of DMARDs may indicate smoking 
weakens the potency of these drugs. 
Mattey et al 
(2009), UK 
[167] 
Observational study to determine 
whether there is a quantitative 
relationship between smoking history 
and response to therapy with TNF 
antagonists in RA. 
Follow-up 1 year. 
154  DAS28 RA patients with a history of smoking more likely to 
show a poor response to TNF inhibitors at 3 months 
and 12 months (p=0.008 and 0.003, respectively).  
Response failure to TNF antagonists associated with 
intensity of previous smoking (pack years), 
irrespective of smoking status at initiation of anti-TNF 
therapy.  
van der 




Observational study to determine the 
prevalence of and predictive factors for 
DMARD-free sustained remission 
from 2 RA cohorts.  
Follow-up at 1 year. 
1,349  Drug free 
remission defined 
as: 1) no current 
DMARD use, 2) 
no swollen joints 
3) Classification 
as DMARD-free 
remission by the 
patient’s 
rheumatologist. 
RA smokers were less likely to achieve sustained drug-
free remission compared to RA non-smokers (HR 0.6, 














Findings of study 
Stamp et al 
(2009), NZ 
[169] 
Observational study to determine non-
genetic factors that influence red blood 




Smoking was associated with lower red blood cell 
concentrations of MTX (r=0.5, p=0.015). 
Abhishek et 
al (2010), UK 
[170] 
Observational study to assess if 
smoking status when commencing 
anti-TNF-α treatment for RA reduces 
EULAR response criteria at 3-month 
assessment. 
 
395 EULAR response 
criteria (DAS28) 
Current smoking at commencement of anti-TNF 
treatment reduced likelihood of achieving a moderate 
response when compared with non-smokers (OR 0.2, 
95% CI 0.05-0.8). 
Rojas-
Serrano et al 
(2011), 
Mexico [153] 
Observational study to determine 
factors associated with failure to 
achieve ACR 50 response at 6 months 
in early RA. 
144  ACR50 response Smokers with RA appeared to have a worse prognosis 
in terms of DMARD response.  
The only factor associated with failure to achieve ACR 
50 was current smoking (OR 3.6, 95% CI 1.2–11.2, 
p<0.008). 
Ruiz-
Esquide et al 
(2011), Spain 
[142] 
Prospective open-label study to 
analyse the effects of cigarette 
smoking on disease activity and 
radiographic damage in early RA after 
the introduction of DMARDs;  




DAS28 DMARD response similar in smokers and non-















Findings of study 
Saevarsdottir 
et al (2011), 
Swedish 
[161] 
Cross-sectional study to determine if 
cigarette smoking influences response 






Compared with never-smokers, current smokers were 
less likely to achieve a good response at 3 months 
following the start of MTX (27% versus 36%; p=0.05) 
and at 3 months following the start of TNF inhibitors 
(29% versus 43%; p=0.03).  
Soderlin et al 
(2012),  
Sweden [171] 
Observational study to examine the 
effect of response and drug survival in 
RA patients treated with their first anti-
TNF drug.  
Follow-up at 3, 6 and 12 months. 
934 RA EULAR response 
criteria (DAS28) 
Current smoking was predictive of poor response to 
anti-TNF treatment at 3 months (OR 0.6, 95% CI 0.4–
0.9) and heavy smokers had the poorest drug survival 
(OR 0.6, 0.3-1.2).  
Vesperini et 
al (2013) , 
Italy [154] 
A prospective early arthritis cohort 
study to investigate: 
1) the initial response to treatment 
and risk of radiographic disease 
progression in current smokers, ex-
smokers, and non-smokers 
2) The influence of smoking 
cessation on arthritis outcome. 
Follow-up for 6 months. 
641 RA EULAR response 
criteria (DAS28) 
Smoking status had no influence on use of either 
DMARDs or biologic therapy in the first 12 months of 
follow-up (P>0.05). 
*HR=hazard ratio; OR=odds ratio; CI=confidence interval;  r=coefficient of correlation; MTX=methotrexate; TNF-α=tumour necrosis 
factor-alpha; DMARD=disease modifying antirheumatic drugs; DAS=Disease Activity Score; MI=myocardial infarction; EULAR=European 





2.5 Smoking Cessation  
“Giving up smoking is the easiest thing in the world. I know because I've done it 
thousands of times” Mark Twain (1835-1910) 
 
Changing entrenched smoking habits is difficult for smokers, and most smokers attempt to 
quit many times before succeeding. Surveys in the USA have consistently reported 70% of 
smokers want to quit; nearly half of these will have attempted during the previous year but 
only four to seven percent are successful [172]. Recent trends in the UK have shown that 
although fewer smokers are attempting to quit smoking each year (43% in 2007 down to 
34% in 2011/12), more smokers are making successful quitting attempts [173].  
 
The following section begins with an examination of the benefits and difficulties of 
smoking cessation. Smoking cessation is a key health goal of the NZ Government and this 
goal is described. Internationally recognised best-practice smoking cessation programme 
components are then briefly identified as this topic will be examined in specific detail in 
Chapter 5 (The Development of a Tailored Smoking Cessation Intervention for People with 
RA). The following section on smoking cessation is particularly relevant to this thesis 
because the review provided the structural design that would be utilised for the design of a 
pilot randomised controlled trial (RCT) tailored smoking cessation intervention for people 







2.5.1 Benefits and Difficulties of Smoking Cessation 
Smoking cessation is beneficial to all smokers regardless of their age or the number of 
cigarettes smoked. The immediate benefits include increased oxygen and decreased carbon 
monoxide levels in the blood, and nicotine is almost completely removed from the body 
within 24 hours [174, 175]. In the longer term, there is a reduction in risk of developing 
heart disease and some cancers [174, 175]. Even smokers who already have smoking-
related diseases can expect to gain health benefits and increase life expectancy with 
smoking cessation [176].  
  
A gain in life expectancy following smoking cessation has been demonstrated in a cohort 
study of 34,439 resident male British doctors born between 1900 and 1930 and followed 
over a 50 year period [177]. Information about their smoking habits was first obtained in 
1951 and then collected periodically, with cause-specific mortality monitored for the 
following 50 years. Up to two-thirds of lifelong smokers died from a smoking-related 
illness and half of these deaths occurred prematurely [177]. Cessation at age 30, 40, 50, or 
60 years gained respectively, an average of 10, 9, 6, or 3 years of life expectancy [177]. 
The authors predicted that cessation by age 50 years halves the risk of death associated with 
continued smoking and cessation by age 30 years avoided almost all risks [177]. Figure 2-
3 shows the survival from age 35 years for continuing cigarette smokers, ex-smokers and 
lifelong non-smokers among British male doctors born 1900-1930, with each decade 
showing percentages alive. This figure demonstrates that almost 10 years of life years may 








Figure 2-3: Mortality by percentage survival from aged 35 years for smokers, ex-smokers, 
and non-smokers 
(Adapted from [177]) 
 
Whilst there are many benefits with smoking cessation, there are short-term negative effects 
which may make cessation more difficult. Stopping smoking leads to immediate nicotine 
withdrawal symptoms, including headaches, fatigue, restlessness, anxiety, irritability, sleep 
disturbance, mood swings, sweating, dizziness, increased appetite, nausea, stomach 
cramps, and a craving for more tobacco [178]. These symptoms are most noticeable for the 
first few weeks after quitting [178]. The first two weeks have been found to be the most 
critical time in determining quitting failure rates [179]. In the short-term, smokers may find 
nicotine withdrawal symptoms worse for their well-being than any immediate or long-term 
benefits from quitting (Table 2-9). The benefits of decreasing the risk of death from CVD 































Table 2-9: Outcomes from smoking cessation  





After 20 minutes the heart rate starts to drop (from the cigarette-induced 
spike) 
The heart rate and blood pressure will have decreased to normal levels. 
Nicotine withdrawal symptoms usually start 
8 hours Nicotine starts to leave the body (nicotine levels will accumulate with 
continued smoking throughout the day and therefore will persist for 6 to 8 
hours after cessation) 
The level of oxygen in blood will start to increase 
12 hours There will be almost no nicotine remaining in the body 
24 hours The level of carbon monoxide in blood will have dropped to normal  
Risk for developing CVD or having an immediate heart attack has begun to 
diminish 
2 days Sense of taste and smell will improve as nerve endings start to regrow 
3 days Nicotine is completely out of body, therefore withdrawal symptoms will be 
at their peak 
2-3 weeks Nicotine withdrawal symptoms will have dissipated 
1-9 
months 
The immune system begins to show signs of recovery 
There will be less shortness of breath and able to exercise more easily 
Blood circulation will improve and blood will flow more easily to hands and 
feet 
The cilia in the lungs will have recovered to efficiently clean the lungs and 
airways 
1 year The risk of dying from CVD will be half that compared to when smoking 
5 years The risk of cancer of the mouth, throat and oesophagus will be half that of a 
continuing smoker 
10 years The risk of lung cancer will be less than half of a continuing smoker. 
15 years The risk of dying from any cause will be almost the same as that of a person 






2.5.2 Smoking Cessation in New Zealand 
2.5.2.1 Key Health Goals: Smoking Cessation in New Zealand  
Smoking cessation is a key goal of the NZ Health Strategy [2], which  was first published 
in 2000 and sets the platform for the Government’s action on health [182]. Progress on 
implementing the strategy is assessed annually. In NZ, tobacco control includes a large 
number of policy, service development and operational activities. The principal aims of 
these policies and activities are to reduce the uptake of smoking, increase quit rates, and 
reduce second-hand smoke exposure. Examples of public policies in NZ include the 
removal of product labelling, consistent price increases and targeted cessation programmes 
for prioritised population groups [183]. NZ was the first country to set a government 
tobacco control endgame goal: ‘Smokefree 2025’ (adopted in 2011), which has the 
principal goal of making NZ a smoke-free nation by the year 2025 [184]. 
 
In 2009, the NZ Ministry of Health’s (MOH) target ‘better help for smokers to quit’ was 
introduced to ensure all smokers are offered advice and support to quit smoking when they 
have contact with a health professional [185]. This target is part of the national performance 
measures designed to improve the performance of health services and provide a focus for 
action [186]. It was also designed as a prompt for NZ health professionals to routinely ask 
about the smoking status as a clinical ‘vital sign’, then provide brief advice and offer 
support for current smokers who want to quit [187, 188]. This policy is significant because 
there is strong evidence that brief advice is effective at prompting quit attempts and long-
term quit successes [187]. The addition of effective cessation therapies further improves 
quit rates, including NRT gum, lozenges and transdermal patches; medications such as 





face-to-face support [17]. These therapies are examined in detail in Chapter 5 because they 
provide the pharmacological and behavioural components of best practice smoking 
cessation programmes which were utilised in this thesis. 
 
In 2012/13 the ‘target’ was to ensure 95% of hospitalised smokers and 90% of patients who 
smoke and are seen by a health professional in primary care are provided with advice and 
help to quit [187]. International research has shown that having a screening system in place 
to identify the smoking status of patients can lead to a doubling of smoking abstinence 
rates, from 3.1% (no screening) to 6.4% (with screening) [189]. Meeting the target for 
hospitalised patients in the 20 District Health Boards (DHBs) in NZ has been progressing 
steadily since quarter one of 2009/10 when 18% of inpatients were given smoking cessation 
advice nationwide, to 96% in quarter four of 2012/13 [190]. The target for primary care 
patients to receive smoking cessation advice is more variable with only one of the 20 DHBs 
attaining the 90% goal, and an overall NZ DHB mean result of 65% (range 35 to 96%) 
during quarter four in 2012/13 [191].  
 
It is important to note that there are currently no similar guidelines or specific health targets 
for patients seen in the outpatient setting. The absence of guidelines or specific health 
targets for outpatients is a significant issue, as the majority of patients with chronic diseases 
such as RA are only seen as outpatients; therefore they will not be captured by general 
smoking cession initiatives within the hospital setting. This equates to a missed opportunity 
given the primary care sector has not yet reached their 90% goal of providing smoking 
cessation advice. International research on outpatient smoking rates has been limited, 
identifying a lack of progress in this area. A study in 1997 reported physicians knew the 





(with the exception of cardiology and tobacco-related visits) the smoking cessation advice 
given to outpatients was negligible [192]. Therefore, although most outpatients who were 
smoking were identified, the vast majority did not receive any smoking cessation advice. 
In a similar but more recent study, outpatient visits were followed over a 10 year period 
between 1994 and 2003. Although only a minimal increase in the identification of smokers 
was found (68% in 2003 compared to 67% in 1994), only 20% of patients were 
subsequently counselled with less than 2% of those patients using any smoking cessation 
medication [193].  
 
2.5.2.2 New Zealand Smoking Cessation Guidelines 
In 2007, the NZ Smoking Cessation Guidelines were published and structured around the 
newly adopted ‘ABC pathway for Smoking Cessation’ (Appendix 8). The ‘ABC pathway’ 
was developed by the NZ MOH and was designed to make the health sector’s approach to 
smoking cessation more systematic for all healthcare workers who have contact with 
smokers [188]. The main goal was to provide a system where all smokers are surrounded 
by a culture of support for quitting thereby generating more supported quit attempts [188]. 
These guidelines were based on evidence of best practice in smoking cessation [194] and 
were updated in 2014 [195]. Recommendations from these guidelines outline evidence-
based interventions for smoking cessation in the NZ general population, plus the following 
targeted priority population groups: young people, pregnant women, Māori and Pacific 
peoples, the hospital and preoperative environment, and those who use addiction and 
mental health services [196]. However, this means there are many long-term health 
conditions including RA that are not currently being targeted for assistance, thereby 






The NZ smoking cessation guidelines include the following key messages for healthcare 
providers [194]: 
1) Give brief advice to stop smoking to all people who smoke, regardless of whether 
they say they are ready to stop smoking or not  
2) Provide evidence-based cessation support for people who express a desire to stop 
smoking  
3) Only recommend smoking cessation treatments of proven efficacy, as identified in 
the guidelines, to people interested in stopping smoking  
 
The ‘ABC pathway’ is a brief intervention model that incorporates these messages and 
includes three key steps to help smokers quit [194]: 
1) Ask about smoking status; 
2) give Brief advice to stop smoking to all smokers 
3) provide evidence-based Cessation support for those who wish to stop smoking 
 
The principal goal of this intervention model is to generate more supported quit attempts 
more often. It is a simple and easy memory aid tool prompting all healthcare workers 







2.5.3 New Zealand Smoking Cessation Support Programmes  
The smoking cessation support programmes available in NZ are listed in Table 2-10. These 
services are provided free of charge apart from pharmacological support, which is $5 per 
course if fully subsidised (NRT, Bupropion, and Varenicline). 
 
 
Table 2-10: Smoking cessation support programmes available in NZ 
 Support Programme Support Services Offered to Smokers Reference 
Quit card Providers ‘ABC pathway’: including general practices, hospitals 
and Māori providers 
 
[197] 
Quitline Free smoking cessation services, including a helpline, 
face-to-face support, online support, text support, on-
line blogs, NRT and other tools. Reactive and 
subsequently proactive service 
 
[197] 
Aukati KaiPaipa A face-to-face support service, aimed at 
reducing smoking prevalence and consumption 





2.5.4 Best-Practice Smoking Cessation Programme Components 
The two key components of best-practice smoking cessation programmes are evidence-
based support including: 1) behavioural based support (e.g. advice and counselling); and 2) 
pharmacological based support (e.g. NRT, bupropion, varenicline). Combining both 
support options is recommended, although it is unclear which combinations are more 





than others [199]. A recent Cochrane update of systematic reviews of RCTs within the 
general population and within specific healthcare settings has, for the first time, established 
the efficacy of behavioural support over and above that of pharmacological support [200].  
 
Smoking cessation components are graded based upon strength of evidence, effect size, 
and relevance to a population’s healthcare system and graded recommendations are used 
to guide practice [201]. Table 2-11 identifies the NZ grading of recommendations for best-
practice smoking cessation interventions based on international guidelines. 
 
 
Table 2-11: Grading of smoking cessation recommendations in NZ  
(adapted from [194, 195]) 
Grade Support for recommendation Description 
A GOOD (strong) evidence Body of evidence can be trusted to guide 
practice 
B FAIR (reasonable) evidence Body of evidence can be trusted to guide 
practice in most situations 
C EXPERT OPINION only  Body of evidence provides some support for 
recommendation(s) but care should be taken 
in its application 
D INSUFFICIENT evidence Body of evidence is weak and 
recommendation must be applied with 
caution 
 GOOD PRACTICE POINT Recommended best practice based on clinical 
experience and expert opinion 
 
The NZ MOH recommends the key components of a smoking cessation programme should 
include a combination of [194]:  
 Multisession behavioural support of at least four follow-up contacts; support may 





reactive). Adding additional telephone support to face-to-face support is effective 
in situations of single counselling sessions, otherwise both are equally effective. 
 Pharmacotherapies: medications that have proven to be efficacy should be 
recommended to all nicotine dependent people. 
 
2.5.5 Efficacy of Smoking Cessation Programme Components 
This section contains a brief introduction to the efficacy of evidence-based smoking 
cessation programme components as they apply to the general population. This topic will 
be considered in depth when describing the development of a tailored smoking cessation 
intervention (Chapter 5). The standard measure of a quit rate is calculated by the number 
of individuals who received a smoking cessation treatment who subsequently quit smoking 
divided by the number of individuals who received the smoking cessation treatment in total, 
and is reported as a percentage rate [202].   
 
Unassisted quitting in the general population is low at 2 to 3% [194]. Brief advice of three 
to ten minutes from a health provider approximately doubles the unassisted quit rate [203, 
204]. The use of NRT increases the quit rate by 50-70% compared to unassisted quitting 
[205]. Increasing the number of types of NRT used can increase quitting by 20-50% over 
using a single NRT [205]. Individually tailored self-help materials in an intervention can 
increase quitting rates by 20-55% compared to brief advice [206]. Individual counselling 
and telephone counselling have been found to increase quitting rates by 25-57% and 20-






There is consistent evidence that behavioural interventions increase the likelihood of 
smoking cessation. However, while more intensive counselling can enhance smoking 
cessation rates (as compared to less intensive counselling), this strategy runs the risk having 
a more limited reach as not all smokers are interested in participating in intensive 
interventions. Therefore, choosing the intensity of behavioural interventions requires 
careful consideration as is not just a case of ‘more is better’. 
 
2.5.6 Smoking Cessation in Rheumatoid Arthritis 
The negative health effects associated with smoking in people with RA make a compelling 
case for smoking cessation. However, people with RA commonly do not recall receiving 
advice to quit smoking from healthcare providers [44, 209]. One survey from the UK 
assessing the quality of service for patients with inflammatory arthritis identified 30.9% of 
patients as current smokers, whilst less than half (48.5%) recalled being advised to stop 
smoking by their rheumatologist [44]. A more recent study in 25 countries found that less 
than one quarter of rheumatology departments had either a specific protocol or written 
advice for smoking cessation [209]. Therefore, specifically targeting smoking cessation for 
people with RA could be extremely beneficial for RA smokers.  
 
In 2002, a pilot study was undertaken to modify adverse lifestyle variables in RA, including 
smoking, unhealthy diet and excessive alcohol consumption. Participants were briefly 
advised on quitting smoking and were provided with a generic quitters pack [210]. Of the 
eight RA participants who smoked, none quit during the 11 month study period [210]. The 
impact of a RA and smoking cessation awareness campaign has previously been studied 





almost half of the people with RA questioned were ex-smokers. The study concluded that 
smokers with RA may be motivated to quit by learning that RA is a smoking-related disease 
[45]. This concept was explored in a RCT in 2013  that evaluated an educational 
intervention designed to 1) increase RA patients’ knowledge of modifiable CVD risk 
factors and 2) measure intentions to change risk factor behaviours, including stopping 
smoking, increasing exercise, healthy low-fat eating and losing weight [211]. At six months 
the intervention group had significantly higher knowledge of all CVD risk behaviours and 
had intentions to change many risk behaviours except stopping smoking [211]. This 
suggests there may be a need for interventions specifically focused on smoking cessation 
in people with RA as was developed in this thesis.  
 
The only specific smoking intervention study in patients with rheumatic disease reported 
to date evaluated a smoking cessation intervention in patients with various rheumatic 
diseases, including 55 patients with RA. The intervention consisted of brief (3-5 minutes) 
smoking cessation advice from a rheumatologist, followed by 20 minutes of verbal and 
written advice from a Rheumatology Nurse, with the offer of pharmacological support to 
patients with high nicotine dependence. Quit rates were 11.8% at three months and 15.7% 
at 12 months. In addition 29 of 152 patients (19%) had reduced their smoking by ≥50% at 
12 months [9]. These authors hypothesised that when advice emphasising specific risks for 
an illness is given by the patients’ regular physician, backed up with nurse collaboration, 
the probability of smoking cessation rate is increased [9].  This is an area that could benefit 







2.5.7 Smoking Cessation for Special Populations 
Smoking cessation interventions have traditionally been designed for smokers without 
long-term illness. Recently, targeting smoking cessation interventions to special 
populations of smokers has been suggested. Targeting in this instance refers to the process 
of designing smoking cessation programmes based on the needs and characteristics of a 
particular population [212]. Special populations of smokers have been defined as those who 
have 1) ≥10% higher smoking prevalence than the general population, 2) disproportionate 
health disparities due to tobacco use, 3) less access to smoking cessation treatments, and 4) 
few prospective smoking cessation treatment trials [8]. Smoking in RA shares the above 
characteristics defining a special population hence providing the impetus to develop a 
targeted intervention in this thesis research. 
 
In summary, this section has described efficacious and innovative smoking-cessation 
treatments (behavioural and pharmacologic) that have been developed to aid smoking 
cessation in the general population. Over the last 50 years hundreds of millions of smokers 
world-wide have stopped smoking permanently. However, it remains unclear whether these 
evidence-based smoking cessation interventions are suitable or require tailoring for the 
growing populations of individuals who live with a chronic disease such as RA. To address 
the needs of special sub-groups of smokers, smoking cessation programmes could benefit 
from addressing specific disease-related issues including physical limitations, and specific 
medical and psychosocial issues that could be targeted in a smoking cessation programme. 
Understanding the barriers to smoking cessation in the general population in addition to 
separate sub-group of smokers (including people with RA) is therefore an important aspect, 





2.6 Barriers to Smoking Cessation 
Smoking has been likened to a chronic relapsing illness [213]. Typically a smoker will 
make numerous attempts to quit, followed by periods of relapsing before they finally quit 
forever [5]. Because smokers face many obstacles when quitting smoking, it is essential to 
gain an understanding of the barriers people face during a quit attempt to enable more 
successful quitting. This section reviews barriers to smoking cessation in the general 
population, followed by identifying barriers that may be specifically relevant to individuals 
with RA. 
 
2.6.1 Demographic Barriers to Smoking Cessation 
The demographic factors in the general population, which increase or decrease smoking 
cessation success are shown in Table 2-12. Because these demographic barriers are quite 
generic, there is no reason to suggest these barriers would be any different in people with 
RA as a population. 
 
Table 2-12: Demographic factors affecting smoking cessation in the general population 
(adapted from [18, 214, 215])*  
Lower Smoking Cessation Success Higher Smoking Cessation Success 
Lower Income Higher Income 
Early age at smoking onset Older age at smoking onset 
Younger current age Older current age 
Less Education attainment Higher Educational attainment 
Non-European descent European descent 
Low BMI High BMI 
Female gender Male gender 
Single Marital Status Married Marital Status 





2.6.2 Physiological Barriers to Smoking Cessation 
Addiction and the resulting dependence on nicotine is a significant barrier to smoking 
cessation. As previously discussed (Chapter 2), nicotine activates reward pathways in the 
brain, specifically the neurotransmitter dopamine. There are many evidence-based 
pharmacotherapies that are available to aid the withdrawal process of nicotine (Table 5-1) 
and the provision of pharmacotherapies is regarded as an essential component in successful 
smoking cessation programmes [205]. Nicotine replacement therapies are widely available 
in NZ in various forms and prescriptions and NRT is heavily subsidised by the NZ Ministry 
of Health. Due to the addictive nature of nicotine, all smokers (including people with RA) 
are likely to benefit from using NRT strategies during a quitting attempt. 
 
Demographic and physiological barriers alone do not encompass all the difficulties smokers 
face in a quit attempt. The most commonly reported reason for relapsing during a quit 
smoking attempt is the desire to relieve the discomforting withdrawal effects including 
anxiety, depression, and stress as explored further in the following section. Because 
demographic and physiological barriers to smoking cessation are likely to be similar in the 
general population and people with RA, identifying other barriers to smoking cessation 
relevant in people with RA will be a key research activity in this thesis. It is anticipated that 
by identifying novel barriers in this group psychosocial and behavioural interventions could 






2.6.3 Psychosocial Barriers to Smoking Cessation 
2.6.3.1 Stress 
Elevated levels of psychological distress are known to impede smoking-cessation efforts 
[6]. Research from Quitline NZ in 2013 showed that stress was the primary reason given 
by quitters who start smoking again [216]. The study involved in depth interviews with 
people who had relapsed three months after using Quitline NZ services. The authors 
suggested relapsing was due to a smoker’s perception that smoking was a major source of 
relief from the stress caused from everyday living, such as family issues, bereavement, 
health concerns, and financial worry [216]. It is generally accepted that stress triggers 
smoking relapses [217].  
 
2.6.3.2 Anxiety 
Anxiety is known to associate with smoking dependence and to adversely affect long-term 
abstinence rates [218]. Smokers with symptoms of social anxiety often report using 
smoking as a way to cope with negative affect [219] and have been reported to show a 
tendency to experience more severe nicotine withdrawal symptoms [218]. Smoking is 
highly prevalent in individuals with anxiety disorders such as agoraphobia, and panic 
disorders although less common in generalised anxiety disorder and social phobia [218]. 
However, clinical trials do not always demonstrate anxiety as a barrier to quitting smoking, 
possibly because individuals with anxiety are less likely to enrol in smoking cessation 







Depression is overrepresented in smokers [220]. Smokers are significantly more likely to 
be diagnosed with depression than non-smokers (27% vs. 13%; p<0.001) [221].  However, 
the relationship between smoking and depression is contentious. There is some evidence 
indicating that those who experience depression use nicotine as a self-medication or coping 
strategy [222, 223]. Other literature suggests that exposure to smoking increases the 
individual’s susceptibility to depression [224]. Smoking and depression may share 
common attributes (such as environment, genetic and social) thereby increasing the risk for 
both depression and smoking [221]. It has also been noted that relapsing back to smoking 
is more likely in individuals who are depressed, and that women who smoke are considered 
at an increased risk for depressive symptoms [221].  
 
Smoking cessation has been associated with reduced stress, depression and anxiety and 
improved positive mood and quality of life compared with continuing to smoke. This 
finding has been seen equally in the general population and populations with physical or 
psychiatric conditions [225]. A meta-analysis of 26 studies that assessed the mental health 
of both ex-smokers and continuing smokers found the effect sizes for improvements in 
mental health were equal to or larger than those of antidepressant treatments for anxiety or 
mood disorders [225]. This is an important issue because although smokers may think their 
smoking is beneficial from a mental health state, a strong association between smoking and 
poor mental health has been found. In essence, smokers experience anxiety, irritability, and 
depression if they have not smoked for a while and these feelings are mitigated by smoking, 





information is relevant when considering helping people with RA who smoke develop 
alternate coping strategies away from smoking. 
 
2.6.3.4 Relapsing 
Relapsing from an attempt to quit smoking is common. Relapsing can be considered a 
barrier to smoking cessation because nearly three-quarters of smokers who quit will relapse 
within two weeks [179]. Abstinence self-efficacy, that is the confidence in one’s ability to 
abstain from smoking, has become an established predictor and possible determining factor 
of smoking cessation outcomes. The Transtheoretical Model (TTM) [226] suggests that a 
high self-efficacy is associated with successful smoking cessation, whilst the relapsing 
prevention model [227] suggests that relapses may result when a smoker is exposed to high-
risk situations such as being with other smokers. Becoming aware of individual triggers 
and then choosing to do something else to alleviate or prevent the craving, i.e. using coping 
strategies to overcome relapses, thereby increasing self-efficacy could be beneficial to 
smokers. This is the central tenet of the cognitive-behavioural model of the relapse process 







Figure 2-4: Marlatt’s cognitive behaviour model of the relapse process  
(adapted from [228]) 
 
 
2.6.4 Barriers to Smoking Cessation in Chronic Disease 
Although it is known that smoking contributes to the development of many chronic 
illnesses, little is known about the relationship between quitting smoking and chronic 
disease. While it might be expected that having a smoking-related illness may facilitate 
quitting, research has been inconsistent in this area [17]. Barriers to smoking cessation in 
chronic diseases, including RA may be more prevalent than in the general population, 
although there is no published data specifically regarding barriers to smoking cessation in 
RA. However, quitting smoking has been shown to be difficult for other long-term 
conditions such as CVD, COPD, diabetes, asthma, cancer and HIV/AIDS [6]. Identifying 
barriers to smoking cessation in chronic disease is an emerging area of research. One study 
has investigated the association between the presence of diabetes, hypertension, and/or high 





was associated with increased quitting [17]. Of  the 3,104 participants, 768 (25%) were 
current smokers and 521 (17%) were former smokers [17]. Thirty-six percent of 
participants had one chronic disease and a further 18% had multiple chronic diseases. The 
likelihood of being a former smoker did not increase as number of chronic diseases 
increased [17]. It is likely this is the same for people with RA. 
 
There are many plausible hypotheses that might explain why chronically ill smokers have 
difficulty quitting. Because individuals with chronic disease may have to perform other 
self-care behaviours, such as taking medication or following a special diet, smoking 
cessation may be viewed as an even greater burden than it is among healthy smokers [229]. 
The higher rates of depression in chronic illnesses may make quitting more difficult [230]. 
Illness often restricts smokers from activities such as sports or hobbies, thereby rendering 
smoking particularly enjoyable and reinforcing [229]. Others have observed some smokers 
find quitting easy, whereas others do not [231].  
  
However, when smokers are newly diagnosed with a chronic illness, they are confronted 
with the seriousness of their new health condition. This may prompt an emotional reaction 
that could increase motivation to change behaviour, including smoking cessation. 
‘Teachable moments’ have been described as any naturally occurring life or health events 
that increase the motivation of a person to adopt new protective health behaviours [6]. 
During these teachable moments it may be beneficial to deliver smoking-cessation 
interventions concurrent with the diagnosis and lasting throughout the initial stages of the 
medical management [6, 17]. This concept will be explored later in the thesis when any 
differences in quitting rates between newly diagnosed people with RA and those with a 





2.6.5 Barriers to Smoking Cessation in Rheumatoid Arthritis 
People with RA have described how it is difficult to focus on behaviours such as smoking 
cessation and getting regular exercise at the time of diagnosis because of ongoing pain, 
fatigue, and stress [232]. There are also the practical issues of frequent doctor visits and 
starting new medications to deal with, similar to other chronic conditions as described 
above.  
 
Stress is an important psychosocial aspect in RA. It has been noted frequently in the 
literature that people with RA have linked a stressful life-event with their disease onset 
and/or a relationship between stress and disease flares [233]. A longitudinal observational 
study in the UK found patients with RA who were under more perceived stress appeared to 
be at a greater risk of psychological comorbidity than those with lower levels of stress 
[234]. Interpreting stress levels will be an important aspect in this thesis as a result of the 
exceptional circumstances of the Canterbury earthquakes that occurred in 2010/2011 and 
the thousands of continuing aftershocks [235].  
 
Not only does living with a chronic disease lead to additional stress, but other psychological 
factors such as heightened anxiety are known to be prevalent in RA and have been 
demonstrated in a cohort of people with RA in New Zealand [236]. Anxiety occurs often 
in people with RA (21-70%) [237, 238], although there are some indications anxiety may 
be decreasing in prevalence as a result of improved treatments and the encouragement of 
physical activity in people with RA [239]. In RA, major depression is more prevalent than 





it is associated with higher levels of fatigue, work disability, pain and health service use 
but lower treatment adherence and an increased suicide risk and mortality risk [240-242].  
 
Another barrier that may be important in people with RA is a lack of awareness of the 
relationships between smoking and RA. Educating individuals about such links may be an 
important facilitator for quitting. The impact of a RA and smoking cessation awareness 
campaign has previously been studied [45]. Only one in 20 people with RA were aware of 
a link between smoking and RA and almost half of the people with RA questioned were 
ex-smokers. The study concluded that smokers with RA may be motivated to quit by 
learning that RA is a smoking-related disease [45]. 
 
2.7 Summary 
This literature review has highlighted how smoking is a significant health issue in 
individuals with RA and why smoking cessation would be particularly beneficial to this 
population of smokers. Because lifestyle changes are particularly difficult for people living 
daily with chronic diseases such as RA, it is possible that providing targeted interventions 
that address their barriers to quitting might be beneficial. However, the review highlights 
the need for further research to identify barriers to smoking cessation in RA and develop 
an intervention to aid smokers with RA to overcome these barriers, which is the overarching 
aim of this thesis. The original research in the following chapters identifies RA-specific 
barriers to smoking cessation in order to inform components for an effective RA-specific 
smoking cessation intervention. These findings are then translated into a targeted three-





was determined in a pilot study comparing the intervention to standard smoking cessation 
advice and feedback was obtained from the participants as to which aspects of the 






3 DESIGN AND METHODS 
 
3.1 Chapter Overview 
This chapter provides an overview of the design and methods utilised in the three different 
phases of research undertaken in this thesis. The chapter includes a description of the 
various qualitative and quantitative methods for data collection, the choice of which was 
determined by the nature of the research questions that needed answering. Methods for data 
analysis and establishing rigour are also described. 
 
3.2 The Nature of Research 
“A paradigm is a worldview, a general perspective, a way of breaking down the 
complexity of the real world” p37 [243] 
 
The research in this thesis is positioned within the paradigm of pragmatism, using a critical 
realism epistemology. Research within the paradigm of pragmatism is problem-centred, 
pluralistic and has a real-world orientation [244]. Pragmatism derives from the work of 
Pierce, James, Mead, and Dewey [245] and later Patton [243] and Cherryholmes [245]. 
Instead of the methods being the most important driver for a research project, the problem 
is most important driver; therefore researchers use a combination of approaches to 
understand the specific research problem. This means pragmatism is not committed to any 
one particular philosophy or method, and researchers are able to choose methods that best 





methods and different forms of data collection and analysis, which was the strategy adopted 
throughout this thesis. 
 
The critical realist epistemology is associated with Roy Bhaskar, a British sociologist, who 
introduced the concept during the 1970s [246]. The fundamental view of critical realism is 
our knowledge of reality results from social conditioning, thus cannot be understood 
independently of the social actors involved [247]. The approach recognises that social 
phenomena are intrinsically meaningful and the meaning has to be understood rather than 
measured or counted, hence there is always a hermeneutic (interpretive) element in social 
science research [246]. Rather than seek formal associations or regularities, critical realist 
research seeks substantial connections among phenomena [246].  
 
The critical realism approach to data analysis was used in two phases in this thesis: firstly, 
in the exploratory phase of research as described in Chapter 4 (Identifying the barriers to 
smoking cessation in RA) and secondly, in the evaluation phase of research in Chapter 7 
(Exploring participant attitudes to a targeted smoking cessation intervention for people with 
RA). The use of the critical realism approach enabled an amalgamation and interpretation 
of the complexity of the ‘lived’ experience of research participants; therefore the nature of 








3.3 Methodological Perspectives  
There are three strategies of inquiry in research that are used to inform the methodological 
procedures used in this thesis [244]. These strategies are quantitative, qualitative and mixed 
methodologies. Quantitative and qualitative methodologies were used in this research as a 
form of sequential mixed-methods, and are described below. 
 
3.3.1 Quantitative Inquiry 
Quantitative research is grounded in the positivism paradigm and is based on the 
assumption that the resultant data are value-free and do not change because they are being 
observed [248]. Thus, the research in this model is independent of the researcher [248]. 
Quantitative research is empirical and systematic and its use in healthcare, as in other 
spheres of research, involves the collection and interpretation of statistics using deductive 
reasoning [248, 249]. In quantitative research, theories and hypotheses are generated and 
tested with the measurement of outcomes underpinning the approaches and techniques used 
[249]. Research questions are typically specific and have a narrow focus, and the research 
process falls into four phases: 1) conceptual, 2) planning, 3) operational, and 4) 
dissemination [249]. The design of quantitative research includes specifics, which include 
variables, reliability, validity and statistics [249]. The overarching aim of quantitative 
research is to produce findings that are objective, reliable, valid and reproducible, meaning 
the research should be replicable by anyone, including the original researcher, as long as 







Quantitative research is used in healthcare to test well-specified hypotheses such as 
determining whether an intervention is efficacious or not, or finding out how much a risk-
factor predisposes an individual to a disease. With quantitative healthcare research, the 
emphasis is on causes of behaviour [250, 251]. Common approaches included in 
quantitative research methodologies are experiments, quasi-experiments and randomised 
controlled trials (RCTs) in which the data are gathered using processes such as surveys, 
structured interviews and questionnaires [249].  
 
Experiments and quasi-experiments differ in their ethical considerations [249]. A RCT is a 
type of experiment in which participants are randomly assigned to different treatment 
groups to limit bias in outcomes thus enabling statistical comparisons to be made [249]. 
Quasi-experimental designs are similar to RCTs, but participants are not randomly 
allocated to the intervention or control groups therefore participants do not have the same 
chance of being assigned to either group as would occur in randomised studies [249]. 
Quasi-experimental designs are often conducted where there are ethical or practical barriers 
to conducting a RCT [249]. Randomised controlled trials are thus regarded as more 
rigorous because there is a stronger likelihood the independent variable caused the observed 
change in the dependent variable when testing an intervention [249]. For this reason, the 
RCT design was chosen as the methodology of choice for the smoking cessation 
intervention that was developed for testing in people with RA.  
 
3.3.2 Qualitative Inquiry 
Qualitative research provides the real world ‘lived’ experience to research [243]. By 





emotions and experiential phenomena [250]. Within the paradigm of pragmatism, a 
qualitative approach is suited to investigation of a concept or phenomenon where there is 
little existing research [244]. With qualitative inquiry, the researcher seeks to establish the 
meaning of a phenomenon from the views of participants. Qualitative research is 
exploratory and is useful when the researcher does not know the important variables to 
examine [244]. Qualitative approaches allow room to be innovative and to work more 
within researcher-designed frameworks [244].  
 
3.4 Methods in Action 
This section begins by identifying the qualitative and quantitative methods used, followed 
by an explanation of rigour. The discussion here has a broad focus; the specifics of the 
methods used in each research phase in this thesis will be described in detail in the 
corresponding research chapters.  
 
3.4.1 Qualitative Methods 
In qualitative research, there are various methods of data collection including interviews, 
focus group discussions, direct observations, and text or visual analysis [243, 252]. Focus 
groups and interviews are the most common methods of data collection in qualitative 
healthcare research. The key difference between focus groups and individual interviews is 
that interviews generate data by exploring an individual’s views, beliefs, experiences and 





analysis [252]. The following section outlines and identifies their specific use and 
justification for use in the different phases of study in this thesis. 
 
3.4.1.1 Data Collection 
Focus groups 
Focus group research involves an organised discussion with a group of people (usually six 
to ten) who are asked about their views and experiences of a particular topic [253, 254]. 
The group should be small enough for all participants to share their viewpoints whilst being 
large enough to provide an adequate diversity of perceptions [254]. Groups of four to five 
participants have distinct advantages with logistics because they can easily be 
accommodated plus the group is small enough to provide the opportunity for all participants 
to share their ideas [254]. Participants are invited to attend dependent upon their meeting 
certain defined characteristics that are important to the researcher [254].  
 
A semi-structured discussion format is the norm for focus groups with the principle aim of 
allowing the discussion to develop among group members [254]. Focus groups were used 
in the exploratory phase of research for this thesis to identify specific barriers to smoking 
cessation in people with RA. It was a particularly useful method in this thesis due to the 
planning of several group meetings in Dunedin and Christchurch meaning it was flexible 
enough to allow participants to choose when to attend. This was an important consideration 
for people with RA due to their fluctuating symptoms, which can be difficult to predict and 
thus they were able to be flexible with attendance choices [255]. It was also important to 





participants a chance of attending. However, recruitment for group interviews was not 
entirely successful. Firstly, the winter weather was a consideration as many participants did 
not wish to go out when it was particularly cold and snowing. Secondly, many potential 
participants did not want to take part in group meetings. It was for these reasons that part-




There are three models of qualitative research interviews, namely: structured, semi-
structured and unstructured [252]. Structured interviews are essentially questionnaires with 
predetermined questions that have been verbally administered and they are a useful tool for 
enumerating responses from participants into pre-determined categories. In this form of 
interview, there is no scope for variations to questioning or for any follow-up probing, 
although they can involve extra lines of questions for people who give certain answers to 
initial questions. In contrast, unstructured interviews are conducted without any 
organisation and thus can be difficult to manage because they provide very little guidance 
to the interviewer or participant.  
 
Between these two extremes of structured and unstructured interviews, semi-structured 
interviews consist of several key questions that help define the subject areas to be explored 
whilst allowing for follow-up probes, including detail-oriented, elaboration, and 
clarification probes [243]. This is the most used interview format in healthcare research 
because it provides the flexibility to discover or elaborate information that is important to 





of data collection used in thematic analysis. The major benefits of semi-structured 
interviews include reliability because the same questions can be asked of all research 
participants, they provide in depth data, plus they can be used in a more informal setting as 
opposed to focus group discussions.  
 
Semi-structured qualitative data collection was used in the exploratory and evaluation 
phases of research in this thesis, including the individual interviews and focus group 
discussions. The design process and structure of the question schedules used will be 
elucidated in the relevant Chapters 4 and 7. 
 
3.4.1.2 Data Analysis  
All of the quantitative and qualitative data from the different phases of study in this thesis 
were initially entered onto the Christchurch Rheumatology and Immunology Research 
Group database and then subsequently downloaded onto an Excel spreadsheet for analysis. 
The database is password protected and is held in a secure server that is backed up daily. 
Individual study participant data is de-identified so participants are only identified by their 
study number. The database administrator is the only person able to identify participants 
by their national health identification number and this information is downloaded to a 
separate file from the study data. The analysis of the qualitative data using a Word 







Thematic analysis was used to analyse the qualitative data in this thesis. The purpose of 
thematic analysis, a widely-used qualitative data analysis method, is to identify patterns of 
meanings (themes) across a dataset to provide an answer to the research question that is 
being addressed. This form of data analysis can be applied to focus group discussions, a 
number of interviews, or even a range of texts [256]. Patterns of meaning are identified 
through a rigorous process of data familiarisation, data coding, and theme development and 
revision [256]. One of the major advantages of thematic analysis is its theoretical and 
epistemological freedom, which makes it a flexible and useful research tool [256]. It is 
particularly suited to addressing research questions related to experiences, views and 
perceptions of participants [256]. Thematic analyses can be approached in a variety of 
ways. The analytical approaches utilised in this thesis were either inductive or deductive, 
and were done semantically [257].  Each approach is described briefly in the following 
section.  
 
Inductive thematic analysis or the ‘bottom up’ way means themes or patterns identified 
from a dataset are derived from the data themselves, similar to the grounded theory 
approach [256]. In the inductive thematic analysis approach the resultant themes typically 
do not bear any resemblance to the original questions that were asked of the research 
participants, and the themes should not be steered by the researcher’s theoretical interests 
[256]. Thus, an inductive analysis is a process of coding data without trying to fit it into a 
pre-existing coding framework [256]. The resulting data is portrayed as being ‘rich’, which 
describes the notion the data collected is complex and in depth regarding the subject matter 





the data in the first phase of research where the barriers to smoking cessation in people with 
RA were identified (Chapter 4). 
 
A deductive or theory-driven (‘theoretical’) thematic analysis tends to be directed by the 
researcher’s theoretical or analytic interest in the research area, therefore it is more 
explicitly analyst driven. In contrast to an inductive thematic analysis approach, deductive 
thematic analysis tends to provide a less ‘rich’ description of the data overall, but provides 
a more detailed analysis of a pre-defined aspect of the data [256]. This method of data 
analysis was used in the evaluation phase of the research (Chapter 7), where feedback from 
the study participants was analysed according to the pre-determined themes that were 
identified in the initial exploratory phase of research (Chapter 4). 
 
Using a semantic analysis approach, the themes in a dataset are identified within the explicit 
or surface meanings of the data. This means the researcher does not interpret beyond what 
a participant has said or what data has been collected from written sources [256]. Latent 
interpretation is the opposite approach to semantic analysis where the emphasis on 
attempting to theorise the significance of the participant responses [256]. The semantic 
approach was best suited to answering the practical research questions about developing 
and evaluating the smoking cessation intervention as opposed to relating participant 
behaviours to particular theories of behaviour. Thus, the semantic approach aligns with the 






3.4.1.3 Rigour in qualitative studies 
Rigour in qualitative studies is essential. The overarching concept when considering rigour 
in qualitative methodology is ‘trustworthiness’. In Guba and Lincoln’s model of qualitative 
research, there are four components of trustworthiness: credibility, transferability, 
dependability, and confirmability [258]. Credibility is related to the trueness of the 
participant’s experiences and can be ensured by using the participant’s own words as quotes 
in qualitative studies. Transferability relates to how likely it is that study findings would be 
transferable from the study sample to the study population of interest and is can be 
evaluated by having adequate descriptions of the sample and settings [258]. Dependability 
relates to the consistency between the data and the findings. This is verified by documenting 
the processes of data collection, analysis and interpretation, and evidenced by either 
providing an audit trail or a peer review of the research [258]. Finally, using strategies to 
limit researcher bias in the research can safeguard the confirmability. Having colleagues 
check other researcher’s interpretations of data is important in this respect [258]. 
 
The rigour in the qualitative aspects of the studies in this thesis is ensured because all of 
four components of trustworthiness have been applied, as detailed in the relevant sections 
of each study. 
 
3.4.2 Quantitative Methods 
Quantitative research methods involve predetermined, instrument-based questions and tests 
so that enumeration of the resultant data is possible.  The different types of data that are 
used include performance data, observational data, medical data and census data [244]. 





differences between groups of data [244]. The quantitative methods used in this thesis 
include: 1) using a pilot study RCT approach to test the efficacy of a tailored smoking 
cessation intervention, and 2) administering standardised questionnaires for background 
information to enable comparisons to be made between the research in this thesis and other 
research on people with RA. Both are discussed below. 
 
3.4.2.1 Pilot Study Randomised Controlled Trials 
As previously described, participants in a RCT are randomly assigned to different 
experimental groups or treatments to limit bias in outcomes. Methods for allocating 
participants to different groups involve the use of random numbers generated by a computer 
program. The CONSORT (Consolidated Standards of Reporting Trials) Statement is a set 
of standard recommendations for reporting parallel-group RCTs [10]. The CONSORT 
2010 Checklist and Flow Diagram were used to illustrate recruitment and retention in the 
RCT reported in this thesis.  
 
Similar to RCTs, a pilot study RCT (referred to as pilot study in this thesis) requires explicit 
objectives and a testable hypothesis [259]. In contrast to definitive RCTs, sample size 
estimates for pilots are not derived from the estimated effect of an intervention of a 
clinically important outcome (as often the effect size is unknown at the pilot study design 
phase). However, pilot studies can be used to estimate sample sizes to power a definitive 
RCT  and provide an essential first step for exploring novel interventions [260, 261].  
 
Published guidelines for choosing sample sizes in pilot studies is limited, and recommend 





studied, with estimates between 10 to 40 participants per group suggested [262, 263]. A 
review of 24 published abstracts of comparative efficacy pilot studies using two groups of 
participants found the median number of participants to be 20.5 per group [263]. If a 
subsequent power analysis is a required outcome, then a larger sample size is required and 
30-40 participants per group has been proposed [263].  
 
Statistical analyses 
The quantitative data collected for RCT outcomes was statistically analysed with the help 
of a biostatistician using appropriate statistical analyses including 1-way analysis of 
variance (ANOVA), 2 tests or Fisher’s exact test of independence. The 1-way ANOVA is 
used to compare means from three groups or more from one variable. The χ2 test can be 
used to compare the proportion of subjects in each of two groups where there is a 
dichotomous outcome, e.g. smoking or not smoking [262]. The Fisher’s exact test of 
independence is used when two nominal variables are compared and is more accurate than 
the χ2 test when sample numbers are small [264]. 
 
Rigour in quantitative pilot studies 
In clinical research, the validity of a particular study should include reviewing the risk of 
bias in the results, which is defined as the risk of overestimating or underestimating the true 
intervention effect [265]. Sources of bias in parallel group clinical studies can be broadly 
categorised into the following features of interest: 1) selection bias resulting from the 
inadequate sequence generation process and/or allocation sequence concealment, 2) 
performance bias resulting from inadequate blinding of participants and researchers, 3) 





from incomplete outcome data being collected, 5) reporting bias resulting from selective 
outcome reporting, and 5) any other biases that do not fit into these categories [265]. 
Because the parallel group trial was the method of choice for this pilot study, the source of 
biases will be reviewed in Chapter 6. 
 
The alpha value (α) is termed the ‘type 1 error’. The alpha value is the probability of type 
1 error, which is incorrectly rejecting the null hypothesis because there appears to be a 
group difference when in ‘reality’ there is no difference between the two groups within the 
population. Setting the alpha value to 0.05 effectively means tolerating a maximum 1 in 20 
chance of making this error.  
 
The beta value (β) is termed the ‘type 2 error’. A type 2 error is when your sample leads 
you to incorrectly retain the null hypothesis because there appears to be no group difference 
when in ‘reality’ there is a difference between the two groups within the population. Setting 
the beta value to 0.20 means the researchers want at least an 80% chance of not making 
this error. This is associated with the risk of researchers drawing a false-negative 
conclusion from a RCT [266] and is referred to as statistical power. The concept of 
statistical power is positively associated with sample size, thus the power of a study 
increases with a larger sample size [267]. Higher values of power enable a higher chance 
of detecting a statistical difference between groups if one exists, or if there is no difference 
a researcher can be confident in concluding none exists [267]. A study with a low statistical 
power has a reduced chance of detecting a true effect [268]. A minimum of at least 80% 
power is considered desirable in a RCT but 95% is more common [267]. With a power of 
95%, the research statistics would represent the probability of 95 of 100 results would be 





3.4.2.2 Baseline and Follow-up Questionnaires 
In the first phase of exploratory research and during the RCT, information was gathered 
from all study participants for statistical analysis to enable comparisons of demographic, 
psychosocial, and smoking behaviours between groups, and to enable comparisons between 
other published studies. The next section details these data collection instruments and 
indicates how these measurements can be interpreted. The questionnaires detailed in the 
following section are attached in Appendix 1. 
 
Demographic Information 
Demographic information was recorded from a variety of sources including self-reporting 
by study participants (Appendix 1-a), from their medical files, and obtaining income 
statistics from their postcode. The demographic information included: 
 Self-reported age, gender, ethnicity, level of formal education, employment status, 
any history of joint replacements, and duration of RA. 
 A detailed medical history was obtained from medical records, including 
comorbidities, recent surgery, and use of medications. 
 Socio-economic status was derived from a participant’s post-code using Statistics 
NZ census data. 
 A detailed smoking history was obtained in order to calculate the number of pack-
years of smoking, which provided a continuous variable. 
 
Functional and Psychosocial Assessments 
Evaluation of anxiety, depression, stress, function and self-efficacy were undertaken using 





people with RA to be made, satisfying the concept of transferability discussed above with 
regard to the rigour of this research. The following questionnaires were used:  
 
Health Assessment Questionnaire (HAQ)  
The HAQ is a valid and reliable instrument designed to represent a model of patient-
oriented outcome assessment [269]. The HAQ is recommended by Outcome Measures in 
Rheumatology (OMERACT), and is one of the ACR core set of outcome measurements for 
clinical trials. The HAQ is currently regarded as the best scale for measuring disability 
[270]. The questionnaire is based upon the belief that an individual desires to be free of 
pain; has normal functionality, and experiencing no detrimental side effects from 
treatments [270]. The short version of the HAQ (Appendix 1-b) allows an expedited 
assessment of three of the six ACR outcome measures for RA [269]. The disability index 
assesses an individual’s level of functional ability using 20 questions in eight categories 
that involve both upper and lower extremities [271], including dressing, rising, eating, 
walking, hygiene, reach, grip and usual activities.  There are at least two sub-category 
questions for each of the eight categories. Scores for each question range from zero (no 
disability) to three (unable to carry out daily activities without assistance). The HAQ is 
calculated by using the highest sub-category score for each category, which are then 
averaged into an overall score that ranges from zero to three. Scores of 0-1 represent mild 
to moderate difficulty; 1-2 represent moderate to severe disability; and 2-3 indicate severe 
to very severe disability. Any physical aids used by an individual for dressing, rising, 








The Personal Impact Health Assessment Questionnaire (PI HAQ) 
Measuring facts about disability does not necessarily reflect their personal impact on an 
individual, thus the value a person places on having the ability to undertake a particular 
activity is important when considering the impact of disability [272, 273]. For example: if 
an individual prefers to shower and does not place a high value on being able to get into a 
bath, then the difficulty they may have with getting into a bath may have little impact on 
their value of being able to do that task [272]. This means small changes in valued highly 
activities can have a greater personal impact on an individual compared to large changes in 
activities of little personal value [272]. The PI HAQ (Appendix 1-c) is useful to place 
disability within the context of its meaning for a particular individual [272]. To enable a 
measurement of the PI HAQ, individual patient scores are used to weight their disability 
scores from the HAQ on a scale of 0 (not at all important), 1 (a little bit important), 2 (quite 
important) to 3 (very important) corresponding to the eight tasks categories. Therefore, if a 
person scored 3 in their HAQ for a particular category corresponding to a very severe 
disability, and valued the ability to be able to perform the task as very important (also 
scored 3), their PI HAQ score would be 9. If they thought it was not at all important to be 
able to undertake that task, then their score would be 0. The weighted scores for all of the 
eight categories are summed and averaged, giving an overall PI-HAQ score. 
 
The Perceived Stress Scale (PSS) 
The PSS (Appendix 1-d) was developed to measure the degree to which an individual 
appraises situations in their life as stressful and is the most widely used psychological 
instrument for measuring the perception of stress [274]. This instrument has ten questions 
that ask an individual about the frequency over the last month of how they felt or thought 





often). The scoring gives a numerical value that can be used for comparison purposes and 
involves summing the ten scores.  However, prior to summing, questions that are indicators 
of positive ways of handling stress are reverse scored (e.g. 0=4, 1=3, 2=2…) [275]. Total 
scores may range from 0 to 40, with higher scores indicative of greater perceived stress. 
The scores are interpreted as follows: 0-10 relatively stress-free; 11-20 low stress; 21-30 
medium stress; and 31-40 high stress [275, 276].  
 
The Arthritis Self-Efficacy Scale (ASES)  
The attribute of perceived self-efficacy plays a role in mediating health outcomes in people 
with RA and the ASES is a valid and reliable instrument developed to measure the self-
efficacy of people with RA [277]. For this thesis, a shortened version of the ASES using 
11 of 20 items was used (Appendix 1-e). This version contained five items related to coping 
with pain and six items related to other symptoms of RA such as mood, medication and 
fatigue. The remaining nine items related to function in RA were not included as a person’s 
function was adequately assessed in the HAQ questionnaire. Individuals self-score the 
questions on a scale from 0 to 10 corresponding to their level of certainty they can perform 
certain tasks, where higher scores indicate higher self-efficacy. Scoring involves summing 
and averaging the two categories giving two measurements of self-efficacy: 1) pain and 2) 
other symptoms.  
 
The Hospital Anxiety and Depression Scale (HADS)  
The HADS (Appendix 1-f) is a reliable self-assessment instrument for detecting states of 
anxiety and depression and to measure the level of severity of each for individuals in the 
hospital outpatients environment [278]. Fourteen questions are answered by individuals to 





to 3, with higher scores indicating a more severe state of either anxiety or depression. There 
are seven questions related to each mood state, which are summed to give a final score on 
a scale from 0 to 21 for each state. A score of 0 to 7 is regarded as being within the normal 
range; 8 to 10 indicates the possibility of anxiety or depression, and a score of 11 or higher 
indicates the probability of the state of anxiety or depression [279]. 
 
The Euroqol-5D (EQ-5D) and the EQ-Visual Analogue Scale (EQ-VAS)  
The EQ-5D (Appendix 1-g) is a standardised measure of health status developed to provide 
a simple and generic measure of health for clinical and economic appraisal that was 
introduced in 1990 [280]. It is a descriptive system comprising of five dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each 
dimension is self-scored on a scale from 1 (no problems) to 3, (extreme problems). The 
resulting five digit score provides quantitative information as a measurement of health 
outcome. There are two ways to present the EQ-5D results. Firstly, the five digit score can 
be presented as a health profile. There are 243 possible health states definable, where a 
score of 11111 indicates no problems and a score of 33333 would be the worst possible 
outcome. Secondly, the five digit score can be converted into a single summary index by 
applying a country specific weight. In the research in this thesis, the single summary index 
was used using the NZ value weights as it provided an easier score to compare individual 
outcomes for people with RA.  Country specific value sets are based on the values of their 
general population [281]. In contrast, the EQ-VAS (Appendix 1-h) is an individual-based 
score thus is not based or representative of the general population. The EQ-VAS is a self-
reported measurement of how an individual feels how good or bad their health state is on 
that particular day on a scale from 0 (worst imaginable health state) to 100 (best imaginable 





Smoking Behaviour Measurements 
The Fagerström Test for Nicotine Dependence (FTND):  
The FTND (Appendix 1-i) is an instrument for assessing the severity of nicotine 
dependence [32]. The test was designed to provide an ordinal measure of nicotine 
dependence related to smoking cigarettes [282]. The FTND has been found to predict 
smoking abstinence and is correlated with biochemical measures of nicotine dependence. 
The self-reported questionnaire contains six questions that ask current smokers to evaluate 
their: 1) quantity of cigarette consumption, 2) their compulsion to smoke, and 3) their level 
of nicotine dependence. Yes/no questions are scored from 0 (no) to 1 (yes) and answers 
with multiple choices are scored from 0 to 3. The items are summed to a score that ranges 
from 0 to 10, with a higher score indicating a greater level of nicotine dependence, as 
follows: very low (0 to 2 points); low level (3 to 4 points); medium level (5 points); high 
level (6 to 7 points); and very high level (8 to 10 points) [282]. 
 
The Smoking Self-Efficacy Questionnaire (SSEQ) 
The SSEQ (Appendix 1-j) is a questionnaire that is used to measure the confidence of 
current and former smokers to resist smoking in response to various high-risk emotional 
situations [283]. Self-efficacy is important in smoking cessation because an individual’s 
confidence in their ability to resist smoking predicts actual quitting [283]. The self-reported 
questionnaire asks a series of 12 questions: the first six questions ask how sure they would 
be able to refrain from smoking in high-risk emotional situations, and the second six 
questions ask how tempted they would be to smoke in several high-risk situations. The 
questions are answered on a five point scale from: 1 (not sure or not tempted) to 5 
(absolutely sure or extremely tempted). The scores are summed for each six items, giving 





ranging from 6 to 30. A higher score indicates a higher level of self-efficacy regarding 
smoking cessation. 
 
Smoking History Questionnaire  
The smoking questionnaire (Appendix 1-k) is used to provide information about an 
individual’s personal smoking history and their exposure to environmental tobacco smoke 
[284]. This questionnaire is useful to define the current smoking status of an individual as 
defined in Table 2-1. 
 
3.5 Summary 
In summary, this chapter has provided an overview of the design and methods utilised in 
the three different phases of research undertaken in this thesis. The research in this thesis 
is based on a pragmatic paradigm with a critical realist theoretical epistemology. Both 
qualitative and quantitative methodologies have been employed in the different phases of 
research, the choice of which was determined by the nature of the research questions that 






4 IDENTIFYING THE BARRIERS TO SMOKING CESSATION 
IN RHEUMATOID ARTHRITIS 
The original research in this chapter has been published as an article in Arthritis Care and 
Research [285]. Copyright clearance has been obtained from John Wiley and Sons via 
RightsLink on 25 June 2015: Licence Number 3656151264947.  The article in its entirety 
has been appended to this thesis (Appendix 2). As primary author of the article I was 
responsible for: assisting with planning and study design; running all of the focus groups 
and interviews; collection of all the qualitative and quantitative data; verifying all 
transcripts after they had been typed by a professional transcriptionist; subsequent data 
analysis and interpretation of the data; drafting and revising all manuscripts; submitting the 
article; responding to peer-review comments; and giving final approval of the version of 
the article to be published. My thesis supervisors were involved in the initial planning 
concept of the project; assisted with validity of the data; and all co-authors made editorial 
comments on manuscript drafts prior to the final article submission. 
 
4.1 Introduction 
The literature review in Chapter 2 identified that smoking has been recognised as the most 
important environmental risk factor identified in the development of ACPA positive RA. 
Smoking may also exert an adverse effect on RA disease activity, joint damage and 
response to therapy. Components of smoke have been shown to have an effect on 
inflammation in the synovium which reverse with smoking cessation [143]. It has also been 
suggested that remission rates of RA may be lower in smokers compared to non-smokers 





diseases, in particular CVD, COPD and osteoporosis, and identified smoking as an 
additional risk factor for these conditions. Therefore, the combination of negative health 
effects associated with smoking in people with RA makes a compelling case for smoking 
cessation. Indeed, smoking cessation is one of the EULAR recommendations for managing 
the CVD risk in RA [48].  
 
Smoking cessation interventions have traditionally been designed for smokers without 
long-term illness. However, guidelines for smoking cessation have highlighted how 
specific groups of smokers face more difficulties with quitting, particularly those with long-
term health conditions. To date, smoking cessation interventions for people with specific 
long-term diseases such as CVD, diabetes and COPD have received surprisingly little 
attention, and there has been only one arthritis smoking cessation intervention study 
published [9].  
 
We hypothesised that people with RA have specific medical and psychosocial issues that 
are not being met using traditional smoking cessation programmes. The overall aim of this 
part of the research project was to investigate disease-related issues that make smoking 
cessation difficult for people with RA. The study explored the knowledge and beliefs of 
individuals with RA in relation to smoking as it affects their condition and specific RA 






4.2.1 Study Design 
A qualitative methods study was undertaken. Participants who were current- or ex-smokers 
attended either a focus group or an individual interview and completed a set of standardised 
questionnaires.  
 
Ethical approval was given by the New Zealand Multi-Region Ethics Committee 
(MEC/11/06/061). The trial identification number was ACTRN12611001045909 and was 
prospectively registered on 5 October 2011. All participants gave written informed consent 
(Appendix 3) and were given an information sheet that detailed the study design and 
procedures, which were verbally explained (Appendix 4). Consultation with Māori was 
undertaken with the Research Manager Māori, University of Otago, Christchurch in 
December 2010 (Appendix 5). Locality approval for both Christchurch and Dunedin 
Hospitals was obtained in in 2011 
 
4.2.2 Participants 
Participants were eligible to enter the study if they were aged ≥18 years, with a diagnosis 
of RA as defined by the 2010 ACR/EULAR Criteria for RA [54]. Participants must be 
current- or ex-smokers and adhere to the requirements of the study. Participants who were 
never smokers, unable or unwilling to give written informed consent or had significant 





4.2.3 Settings and Locations 
Participants were identified from Christchurch and Dunedin Hospital Rheumatology 
outpatients, inpatients, and patient management systems. Potential participants were 
contacted by telephone and invited to participate. Those who attended were given a NZ$10 
petrol voucher or taxi vouchers to assist with travel costs. 
 
Focus group discussions were held in meeting rooms in either the Dunedin or Christchurch 
campuses of the University of Otago. Individual interviews were held at the participant’s 
private address, or at Outpatient Departments in either Dunedin or Christchurch. 
 
4.2.4 Sampling 
Convenience and stratified purposeful sampling [287] were used in order to balance gender, 
age, current smokers and ex-smokers, individuals with recent onset and long-standing 
disease, and to ensure inclusion of participants who identify as Māori, the indigenous 
people of New Zealand.  
 
4.2.5 Data Collection Measures and Verification 
The focus groups and individual interviews were all moderated by the researcher (PA). 
Focus groups and individual interviews followed a semi-structured format, where the 
discussions were guided but not limited by pre-determined questions. The participant 





schedule was assembled from a variety of sources including consultation with specialists 
in rheumatology and psychology, and the literature [36].  
 
Focus groups and individual interviews were audio-recorded and subsequently transcribed 
by a professional transcription service. Data saturation was sought based on the principle 
of theoretical saturation, when no new additional thematic material emerged from 
additional participants [256]. In practice, the number of required participants in a 
qualitative study usually becomes obvious as the study progresses when new categories, 







Table 4-1: Individual interview/focus group questions and prompts 
1. What do you know about the relationship between smoking and rheumatoid 
arthritis? (Prompts – link to symptom severity, possibility affecting how well drugs 
work, increasing the risk of heart attacks and strokes) 
2. What made you take up smoking?  
3. Did the pattern of your smoking change when you developed arthritis? 
4. What about the reasons for continuing smoking after you developed arthritis – did 
they change? 
5. What specific features about living with arthritis can make it difficult for you to stop 
smoking? (Prompts – anxiety, stress, depression, pain, sleeplessness, fatigue, living 
circumstances, cues/associations, appetite/weight, loss of ability to work/activities 
of daily living/partake in usual hobbies or pastimes) 
6. Can you tell me about any smoking cessation programmes you’ve tried? (Prompts 
– what aspects of the programme you tried worked and what did not?) 
7. Who would you turn to for smoking cessation advice? (Prompts – family, friends, 
GP, pharmacist, rheumatologist, nurse, private therapist, internet support, 
Quitline) 
8. If you have tried to quit smoking, how did you go about trying? 
9. What aspects of the way in which you tried worked and what did not? (Prompts – 
nicotine gum/lozenges/patches, ‘cold turkey’, popular books, alternative therapies, 
Smoke Stop) 
10. What advice would you give to someone with rheumatoid arthritis who was thinking 
about giving up smoking? (Prompts – could we add this into a programme? 
11. Have you ever received advice to stop smoking from your GP, Rheumatologist, 
rheumatology nurse?  








4.2.6 Analysis  
The transcribed data were thematically analysed from a critical realist epistemology as 
described in the methods Chapter 3 [246]. The analysis of participant data was carried out 
manually using Word documents to compile extracts and develop themes. The analysis was 
inductive in that the data were coded into themes evident within the focus groups and 
individual interviews without starting from a pre-existing coding frame [256]. One of the 
thesis supervisors (GJT) independently analysed the first two focus group discussions, 
which were cross-checked and referenced with the researcher (PA) to confirm the same 
themes were being discovered. Tallying of responses to major themes was used to generate 
meaning and assess the level of support from the participants that could then be explored 
in future research [289, 290]. The analysis was guided by the qualitative data with support 
from the following quantitative data. 
 
Quantitative baseline information was collected from a variety of sources. The participants’ 
duration of RA, comorbidities and use of DMARDs were extracted from hospital records 
(Appendix 6). Standardised questionnaires on demographic characteristics, health status, 
and smoking habits were used (Appendices 1a-k). Age, gender, ethnicity, level of formal 
education, and employment status were self-reported. Participants also completed the 
HAQ, PI HAQ, ASES, HADS, PSS, EQ-5D, and the EQ-VAS). A detailed smoking history 
was undertaken. Participants completed the SSEQ and the FTND (Chapter 3). Participants 
were questioned about exposure to secondary smoke in the home or at work, and whether 
they had received smoking cessation advice from a health practitioner during the past year. 
T-tests were used to test for significant differences between the current and ex-smokers 






4.3.1 Study Recruitment  
Fifty-six people with RA were invited to participate in the study. Figure 4-1 outlines the 
participant flow for the study. 
 
Whilst originally a sample size between 40 to 80 participants was estimated to be sufficient 
for focus groups, theoretical data saturation was reached after 36 participants and no new 
additional thematic material was appearing so recruitment ended.  
 
Of the 36 participants: 24 were current- and 12 ex-smokers. Nineteen participants were 
recruited from Christchurch and 17 from Dunedin. There were five group discussions (three 
in Dunedin and two in Christchurch). The focus groups averaged two to three participants 
with a mix of current- and ex-smokers. Many participants were not willing or able to 
participate in group discussions so the remainder of study involved 24 individual 
interviews. The mean average duration of the five group interviews was 60 (42-93) minutes 
and the 24 individual interviews averaged at 29 (10-65) minutes. The recruitment and data 

















Figure 4-1: Participant flow diagram for this study 
 
 
4.3.2 Baseline Characteristics of Study Participants 
4.3.2.1 Demographic and disease data of participants 
The demographic and disease details of the 36 participants are presented in Table 4-2. Mean 
age was 59 (34-77) years. The mean disease duration was 13.6 (0.5-29) years.  
  
Assessed for eligibility (n=56) 
Excluded (n=12) 
• Declined to participate (n=11) 
• Did not meet inclusion criteria (n=1)  
Did not participate (n=8) 
• Unavailable during interview phase (n=6) 
• Did not show up to focus groups (n=2) 
Participated (n=36) 
• 5 Focus Group Interviews (n=12) 
• Individual Interviews (n=24) 





Table 4-2: Demographic and disease details of participants 
Data presented as number (percentage)*  
 








Gender Female 24 (67%) 16 (67%) 8 (33%) 
  Male 12 (33%) 8 (67%) 4 (33%) 
Ethnicity NZ European 33 (92%) 22 (67%) 11 (33%) 
  Māori/PI 3 (8%) 2 (67%) 1 (33%) 
Employment  Paid  14 (42%) 12 (86%) 2 (14%) 
 Other 19 (58%) 10 (53%) 9 (47%) 
Comorbidities Osteoporosis 6 (17%) 6 (100%) 0 (0%) 
  COPD 5 (14%) 4 (80%) 1 (20%) 
  CVD 2 (6%) 2 (100%) 0 (0%) 
Joint surgery  15 (42%) 9 (60%) 6 (40%) 
Interview site Dunedin 17 (47%) 11 (65%) 6 (35%) 
  Christchurch 19 (53%) 13 (68%) 6 (32%) 
DMARDs Methotrexate 26 (72%) 17 (65%) 9 (35%) 
  Combination therapy 14 (39%) 10 (71%) 4 (29%) 
ACPA   Positive 23/27 (85%) 16/17 (94%) 7/10 (70%) 
RF  Positive 22/30 (73%) 16/21 (76%) 6/9 (67%) 
* PI=Pacific Island peoples; DMARDs=Disease-modifying anti-rheumatic drugs; 
ACPA=Anti-citrullinated protein antibodies; RF=Rheumatoid factor 
 
 
There were no significant differences between the demographics of those who participated 
in the study compared to those who did not (Table 4-3). 
 











Age (years) Mean (range) 57.4 (45-88) 59.2 (34-77) p=0.51 
Gender # Female  14 (70%) 24 (67%) p=0.80 





4.3.2.2 Smoking History of Participants 
Smoking history data of study participants are presented in Table 4-4. All except one 
participant began smoking as teenagers. All participants had smoked prior to acquiring RA 
and two-thirds were still smoking. The participants had smoked for a mean of 40 pack-
years and most smoked the equivalent of 20 cigarettes a day. The Fagerström test for 
nicotine dependency indicated the current smokers had a low to moderate dependency on 
nicotine. Nearly all of the smokers (91%) reported having received advice from a health 
practitioner to quit smoking within the last year. 
 
Table 4-4: Smoking history of participants*  







Secondary smoke at home 9 (25%) 8 (89%) 1 (11%) 
Secondary smoke at work 15 (42%) 11 (73%) 4 (27%) 
Years smoking 43 (23-61) 44 (27-61) 38 (23-53) 
Cigarettes per day N/A 14.5 (1-30) N/A 
Age at smoking initiation 16 (12-25) 17 (12-25) 15 (12-18) 
Fagerström test for nicotine 
dependency 
N/A 3.7  (0-8) N/A 




4.3.2.3 Functional Status and Psychosocial Data  
RA functional status and psychosocial data are presented in Table 4-5. There was no 
significant difference between smokers and ex-smokers in questionnaire scores for 
disability levels or impact, self-efficacy over mood or other symptoms of arthritis, nor in 
scores for anxiety, depression or stress. With respect to quality of life, EQ-5D scores were 





for ex-smokers, suggesting this group had a more positive perception of their health status. 
There were significant differences between the current smokers and ex-smokers with 
respect to smoking self-efficacy. 
 









Age (years) 59.2 (34-77) 59.5 (34-75) 58.6 (39-77) 0.80 
Disease duration (years) 13.6 (0.5-29) 12.2 (0.5-27) 16.3 (1-29) 0.18 
HAQ 1.0 (0-3.00) 1.04 (0-3.00) 1.1 (0-2.25) 0.96 
PI HAQ 2.6 (0-7.88) 2.5 (0-7.88) 2.7 (0-6.75) 0.82 
ASES pain 5.4 (1.8-8.8) 5.2 (1.8-8.8) 5.5 (3-7.8) 0.67 
ASES mood 5.6 (1.7-10.0) 5.2 (1.7-9.6) 6.2 (2.0-10.0) 0.24 
HADS anxiety 7.6 (1-17) 8.2 (1-17) 6.3 (1-12) 0.24 
HADS depression 6.2 (1-14) 6.5 (1-14) 5.6 (1-11) 0.54 
PSS 25.0 (8-36) 25.7 (12-36) 23.8 (8-36) 0.43 
EQ-5D 0.6 (0.1-1.0) 0.6 (0.1-1.0) 0.6 (0.2-1) 0.84 
EQ-VAS 63.6 (30-95) 58.9 (30-90) 71.9 (40-95) 0.02 
Smoking self-efficacy 
internal 
19.0 (6-30) 13.4 (6-30) 28.8 (25-30) <0.001 
Smoking self-efficacy 
external 
21.0 (6-30) 15.9 (6-30) 28.5 (22-30) <0.001 
* Data presented as mean (range); 
PI HAQ = Personal Impact Health Assessment Questionnaire; ASES = Arthritis Self-
Efficacy Scale; HADS = Hospital Anxiety and Depression Scale; PSS = Perceived 









4.3.3 Thematic Analysis 
By using an inductive open coding format, five key barriers to smoking cessation from the 
study participants were identified: 1) lack of suitable support for smoking cessation; 2) lack 
of education about the links between smoking and RA; 3) pain management: use of 
smoking as a distraction to pain; 4) inability to exercise due to RA; and 5) using smoking 
as a coping strategy for RA. The following section examines these five barriers in depth. 
For the purposes of validity, individual participant quotes are identified by smoking status, 
gender and age. 
 
4.3.3.1 Lack of suitable support for smoking cessation in RA 
Six of the 36 participants in this study felt unsupported due to isolation from others with 
the same illness and a further 7/36 did not know anyone else with RA.  
“I only know one other person with rheumatoid arthritis, distantly, a female a lot 
younger than me and it’s been quite interesting to hear somebody else has got 
exactly what I’ve got and yeah, knows what it’s like” [male smoker aged 38] 
 
Most of the participants had tried on numerous occasions to quit smoking. However, during 
stressful life events they felt overwhelmed and due to their isolation many had returned to 
smoking. The participants were interested in getting smoking cessation support from RA 
specific sources such as groups or websites: 
‘Well why don’t they have groups like this so that people like us can go and actually 
talk to other people with arthritis?  They used to have one years ago out …and we’d 





the most people I’ve talked to about rheumatoid arthritis in a group in my life…’ 
[male smoker aged 56] 
 
‘…one blog that I read, I thought oh well that’s someone that actually sounds like 
she’s reading my mind…I never knew that rheumatoid could be so debilitating, I 
thought…you get arthritis and it’s painful and then you get over it but I didn’t 
realise it can set you back so much so that was a bit of a shock…so talking to people 
that have the same conditions is quite useful’ [female smoker aged 50] 
 
While some participants were interested in attending group support, other participants were 
more reticent and expressed an interest in smoking cessation support in a one-on-one 
situation rather than a group: 
‘I really don’t like groups; I’m not that type of person…I’m not interested’ [female 
smoker aged 34] 
 
4.3.3.2 Lack of education about the links between smoking and RA 
Twenty-three of the 36 participants were not aware of a relationship between smoking and 
RA, and thus did not perceive this as a reason to quit: 
‘[My rheumatologist] said before that it would be a lot better for my rheumatoid if 
I wasn’t smoking but, I know loads of people that smoke who haven’t got it… so to 
me, it’s irrelevant’ [female smoker aged 34] 
 
Fifteen of 36 participants did not recall having received any advice from their medical 





‘No. It’s never been spoken about in there [hospital], when I’ve been in there…I’ve 
had my knees done 6 times…I just don’t know, it doesn’t affect me with the 
arthritis… the last time that anything was said about the smoking interfering with 
the cortisones’ [male smoker aged 72] 
 
Only 6 participants reported changes in their smoking patterns due to their RA diagnosis; 
all had increased their smoking after diagnosis. 
 
4.3.3.3  Managing their RA pain 
Twenty-two of 36 participants experienced difficulties managing pain associated with their 
arthritis. Whilst not explicitly using smoking to control their pain, they were using smoking 
as a diversion from pain, particularly during the night: 
‘I can’t sleep because of the pain, umm that will make me go back to smoking. And 
it’s just you know, the poor me thing really. I feel so sorry for myself and, and what 
can I do you know. If I can’t hold a book…I can smoke. You know smoking honestly 
does seem the only thing I can do…And you know you’re going to be awake for 
hours and hours and hours…’ [female smoker aged 69] 
 
The participants also connected a decrease in pain and a decrease in anxiety when they 
smoked: 
‘…some people might have a drink, others drink heaps of coffee and I choose to 
smoke…I probably don’t choose to smoke but yeah, smoking I’ve found that can 






However, as the ex-smoking participants revealed, this association can be overcome and 
their smoking needs can be replaced by alternative strategies: 
‘It’s the association with severe pain and the need to sit so you’re gonna sit down 
and you’re gonna grab a smoke, 'cause that’s gonna make you feel better, but then 
you find out no, you don’t need to do that, you could just sit down and rest anyway, 
it works the same’ [female ex-smoker aged 67] 
 
4.3.3.4 Inability to exercise due to RA  
Twenty-seven of 36 participants found it difficult to exercise or continue their usual 
activities (including paid employment) due to their RA: 
‘I used to do lots of tramping [hiking], I don’t do any big tramps any more…the last 
one I did was earlier this year, was just a 4 hour walk in, 4 hour walk out, no 
strenuous hill work or anything and yeah my knee blew up on the way out…’ [male 
smoker aged 38] 
 
‘I gave up work as a result; I was going from working 60 hours a week and being 
busy to basically doing nothing…’ [female smoker aged 50] 
 
Participants described being unable to use exercise or movement as a distraction from 
smoking: 
‘I’m just sitting there reading a book havin’ fag after fag after fag, 'cause you can’t 






‘It’s something to do with your hands when you don’t feel like doing anything…’ 
[female smoker aged 63] 
 
4.3.3.5  Using smoking as a coping strategy 
Smoking was or had in the past been used as a strategy for coping with life in general and 
specifically the frustration of living with RA in 33/36 individuals questioned. Some 
participants spoke emotionally about smoking, saying that quitting would be like losing a 
‘good friend’, whereas other participants saw smoking as a social behaviour and did not 
want to lose those interactions: 
‘I remember giving up once, patches and that, and I used to cry in morning. 
Honestly I did, I cried, it’s like losing your best friend’ [female smoker aged 64] 
 
Many participants mentioned that they no longer consumed alcohol due to the 
contraindications with their RA medication such as methotrexate: 
‘I haven’t had a drink since I got arthritis; I don’t drink much; I was a social 
drinker…I do find now that I don’t drink …I’m not as sociable; I know it’s wrong 
to smoke but it’s the only thing that I’ve, for me anyway that I feel, I don’t go 
anywhere, I can’t even flippin’ well have a glass of wine now, like I used to’ [male 
smoker aged 56] 
 
Participants reported that they used smoking to cope with significant negative life events 
such as the death of a close family member or marriage break-up: 
‘My marriage went to the pack, I took up smoking, I owned a dairy [shop], it 






‘I just lost my husband…so I bought a house in town and no way…was I gonna 
smoke inside, but...I don’t know… I was a bit of a mess’ [female smoker aged 67] 
 
During late 2010 and throughout 2011, Christchurch was struck by a series of severe and 
intense earthquakes, with the most powerful at magnitude 7.1 in September 2010. This was 
followed by over 13,000 aftershocks [291], including a major 6.3 magnitude aftershock in 
February 2011. Due to the intensity, acceleration and violence of ground shaking, the 
February 2011 quake was one of the strongest ever recorded in an urban environment [235], 
resulting in 185 deaths and major destruction of the city causing substantial changes to 
local social, living and working conditions. Four of 19 Christchurch participants had 
returned to smoking after the earthquakes as a way of coping with their stress:  
“…I gave up for a year and then the September earthquake, I got through that, I 
didn’t actually smoke with that one…and then the February one…yeah I just went 
for the smoke packet” [male ex-smoker aged 51] 
 
“…a few of us at work that smoked and we were all trying to give it up at the same 
time but once the earthquakes and that came, I was smoking worse than ever 







4.3.4 Participant Attitudes to Smoking Cessation Attempts 
Nearly all of the participants had made numerous attempts at quit smoking, and seven 
current smokers had previously been smoke-free for long periods of time: 
‘I’ve done it before [stopped smoking] for 12 years…I still did find it hard to do but 
I never thought I’d ever go back after 12 years’ [female smoker aged 63] 
 
The most common cessation methods used by the study participants were pharmaceutical 
based aids. Nicotine replacement therapy including patches (25/36 participants) and gum 
(13/36 participants) were the most prevalent. Just under a third of participants (11/36) had 
tried varenicline (‘Champix’). Other methods mentioned included bupropion (‘Zyban’), 
gradual reduction in smoking, acupuncture, and self-help books. Individual counselling by 
Quitline NZ, a free nationwide telephone helpline offering support for smoking cessation 
in New Zealand, was mentioned by three participants. Overall, these strategies were not 
considered effective by these participants. In particular pharmaceutical aids to quitting were 
often perceived as being inconvenient, tasting unpleasant or causing adverse effects such 
as nausea or allergic reactions: 
‘Champix …they made me feel sick… so I just stopped taking them’ [female ex-
smoker aged 53] 
 
‘I’m allergic to sticking plasters…so then they gave me chewing gum but that stuck 
to the false teeth’ [female smoker aged 67] 
 





‘I gave up and there became a few stresses with my son… thought I’d only have one 
cigarette…bought a packet and smoked the lot’ [female smoker aged 64] 
 
‘I had to give up for 7 years…my dad came over and he was smoking, I says oh 
yeah I’ll have one and just started again’ [female smoker aged 50] 
 
The ex-smokers in this study had succeeded with the same smoking cessation methods. 
One key factor which seemed to set these participants apart from the continuing smokers 
was their perception that they were ready to stop: 
‘I was just sick of the taste’ [male ex-smoker aged 53] 
 
‘I knew I didn’t want to smoke anymore’ [female ex-smoker aged 55] 
 
‘…something just clicked in my head and I just gave up’ [female ex-smoker aged 
39] 
 
Generally, these participants did not find quitting easy.  Quitting to improve the efficacy of 
their RA medication was only mentioned by one participant: 
‘…smoke free for nearly 2 years…I thought the drugs might’ve worked better than 
smoking, maybe that’s why I stopped…’ [female ex-smoker aged 70] 
 
Overall, the quitters had significantly higher internal and external smoking self-efficacy 
(p<0.001) as illustrated in Table 4-5, demonstrating their confidence in being able to resist 






4.4 Discussion  
This phase of study explored disease-related issues that hinder smoking cessation in people 
with RA. The aim was to understand RA-specific barriers to smoking cessation in order to 
inform components for an effective RA-specific smoking cessation intervention. Thematic 
analysis revealed that people with RA have specific physical and psychosocial needs 
although some of these are similar to those seen in other long-term illnesses [6, 17], such 
as: less social support; a lack of education regarding associations between illness and 
smoking; chronic pain; inability to exercise or activities; and higher rates of depression and 
anxiety. In this study cohort there were no obvious patterns of direct connections between 
the individual five themes and any specific demographic or disease factor. 
 
Smoking contributes to the disease burden in many long-term diseases including CVD, 
diabetes, COPD, and many cancers [6].  It has been argued that it is critical to evaluate 
smoking cessation for people with particular long-term illnesses to determine whether 
modifications to a cessation program should be made, based on disease-specific issues [6]. 
Smoking cessation has positive health benefits and can lead to improved disease outcomes 
in people with long-term conditions [292].  Intensive smoking cessation interventions that 
include both behavioural and pharmacological components have been demonstrated to 
improve quit rates compared to brief interventions for CVD [293] and COPD [294]. 
However, there have been few studies investigating the provision of smoking cessation 
interventions for other long-term conditions [292].  
 
Providing smoking cessation support that includes RA disease-related advice, discussion, 





beneficial for people with RA. In this study, a small proportion of participants felt 
unsupported during their attempts at smoking cessation due to isolation from others with 
the same illness. The participants were interested in getting smoking cessation support from 
RA specific sources such as groups or websites. Some of these participants were interested 
in becoming involved in support groups, whilst others were more interested in 
individualised support. Therefore, tailoring advice and support to individual people with 
RA’ needs may improve quit attempts. 
 
Whilst all the participants in this study recognised that smoking was detrimental to their 
health, most were unaware of the links between smoking and RA. Furthermore, the 
majority did not recall receiving any information from medical practitioners regarding links 
between smoking and RA. There is a need to develop appropriate educational material to 
enhance relevant lifestyle modifications in people with RA [232]. However, the main 
challenge is changing behaviour [211]. A RCT of a CVD education intervention in people 
with RA demonstrated that careful design of an education programme informed by 
qualitative stakeholder participation proved successful in increasing knowledge and 
intentions to modify adverse behaviours [211]. Whether such an approach with smoking 
cessation programmes will result in improved quit rates remains to be determined. 
  
Chronic widespread pain is a common feature of RA [295]. It has been suggested that 
individuals with chronic pain may be motivated to smoke because of a belief that smoking 
could help them cope with their pain or that quitting smoking would be more difficult 
because of their pain. There is some evidence suggesting that it is particularly difficult for 
people with chronic pain to quit smoking [296]. Although recent studies have shown that 





other studies have reported a strong association between improved  reported pain and 
smoking cessation in chronic conditions such as spinal disorders [300] and those receiving 
treatment for chronic pain [301]. In a RA smoking cessation programme pain management 
is likely to be a key barrier to cessation and as such pain management strategies should 
form an integral part of any programme. 
 
A systematic review and meta-analysis of trials that investigated the acute effects of short 
bouts of exercise on a desire to smoke found there is good evidence that physical activities 
reduce cigarette craving [302]. This review highlighted the potential of a single session of 
physical activity to reduce cravings, particularly when then cravings are high, and the 
effects are comparable and exceed the craving reduction seen with NRT use [302]. The 
general effects of exercising in RA have been shown to have specific health benefits and 
are considered to be fundamentally beneficial for all people with RA [303]. Benefits 
include lowering CVD risk; increasing body muscle mass to lessen rheumatoid cachexia; 
increasing bone mineral density; improving joint health; improving functional ability and 
psychological well-being; and reducing pain, morning stiffness, and fatigue [303]. Overall, 
exercise has not been shown to exacerbate RA disease activity [303]. Therefore, as part of 
a RA smoking cessation intervention, suitable targeted exercises should be offered. Aerobic 
and resistance exercises tailored for people with RA are likely to be of particular value. 
 
Smoking as a coping strategy was or had been used by nearly all of the study participants 
to counter their perceived frustrations of living with RA, such as their inability to do usual 
tasks, issues with pain management, and their requirement to avoid alcohol whilst taking 
DMARDs. The most commonly cited reason for smoking unrelated to RA was the use of 





natural disaster, death of a family member, and other specific individual stresses. Research 
shows that active coping skills lead to better health perceptions for people with RA [304]; 
those who do not use active coping strategies appear to be more at risk of psychological 
comorbidities [234]. Furthermore, individuals who perceive their RA to have a negative 
prognosis also report more depression, pain, morning stiffness, fatigue, and less satisfaction 
with their life [240]. Smokers with anxiety symptoms often report using smoking as a way 
of coping. Such use is associated with less success at smoking cessation [219]. The 
successful quitters in this study reported less anxiety and depression than the current 
smokers. They were significantly enabled with a sense of self-efficacy over the temptation 
to smoke. Therefore, providing individually tailored active coping strategies for living with 
RA could prove beneficial. Such strategies may include a greater awareness of their own 
personal smoking triggers, and strategies to cope with their associated RA symptoms. 
Theoretical models and contemporary research indicate that active coping leads to better 
psychological outcomes in RA [234, 240, 305].   
 
There are robust, evidence-based, effective smoking cessation interventions available that 
have been shown to reduce smoking rates in the general smoking population, and include 
medications, counselling, or a combination of both. Smokers can increase their chance of 
successful cessation by up to three times by using evidence-based medications and 
counselling compared to those who use neither [306]. Specialist individual behavioural 
support used with combination NRT has shown to have a 20% quit rate at one-year and is 
five times as effective as unaided quitting according to results from selected NHS smoking 
cessation interventions from the Smoking Toolkit Study in England [307]. Therefore, 






Unfortunately, immediate benefits from smoking cessation are seldom apparent in terms of 
health status. Former smokers with long-term illnesses have been reported to take twice as 
long to reduce their medical costs compared to those without [308]. Although recognised 
health benefits to people with RA from smoking cessation include a reduced risk of 
mortality from CVD, and improvements in bone density, these may take some years to 
realise.  
 
The main strength of this study is the use of qualitative methods. The qualitative data 
provides rich information about people with RA’ lived experience with their disease such 
as emotions, behaviours, needs, desires and personalities, which cannot be matched by 
quantitative data alone. The critical realism approach to data analysis demonstrates an 
amalgamation and interpretation of the complexity of the lived experience of the research 
participants; therefore, the nature of participants’ reality was the driving force as opposed 
to methodological or ideological predispositions. The combination of interview techniques 
and recruiting from two centres reduces the chance of homogenous bias. By interviewing 
in Christchurch and Dunedin, the effect of the Christchurch earthquakes in 2010/2011 was 
minimised. Eighty percent of individuals who were approached agreed to participate. 
Although the study was small, saturation was reached suggesting that new themes were 
unlikely to be identified with a larger sample size. Limitations of the study include the 
inability to identify specific issues for Māori due to the small sample size. There was also 
the tendency for participants to be self-selecting; hence the sample was not necessarily 
representative of all smokers with RA. It was not possible to quantify the smaller sub-
themes because there were numerous complex issues independently identified by the 







Physical limitations and disease-associated factors can adversely affect smoking cessation 
in people with RA. Smoking cessation is one of most important modifiable lifestyle factors 
in which people with RA can improve outcomes. Therefore, smoking cessation should be 
a critical aspect in the management of RA. Facilitation in areas of education, exercise, pain 
management, coping strategies, and support specifically tailored for RA may increase 
smoking cessation in RA. This study provides a valuable insight to the specific RA-related 
barriers to smoking cessation in a stratified sample of smoking and ex-smoking people with 
RA. By gaining an understanding of these specific factors from their perspectives, there is 
an opportunity to plan an effective targeted intervention that may increase the chance of 
smoking cessation. These ‘lived’ person experiences have provided the foundations for a 
smoking cessation intervention tailored for people with RA, the design of which is 






5 DEVELOPING A TAILORED SMOKING CESSATION 
INTERVENTION FOR PEOPLE WITH RHEUMATOID 
ARTHRITIS 
 
The original research in this chapter has been published in an article in Musculoskeletal 
Care [309]. Copyright clearance has been obtained from John Wiley and Sons via 
RightsLink on 25 June 2015: Licence Number 3656160336274. The article in its entirety 
has been appended to this thesis (Appendix 7). As primary author of the article I was 
responsible for: identification of the key generic components of best practice, evidence-
based, smoking cessation components for the intervention; structure and design of the 12-
week timeline for the intervention; organising and chairing the steering committee and 
presenting the findings from phase 1 of this study (identifying the barriers to smoking 
cessation in RA); organising the final structure and content for the intervention; drafting 
and revising all manuscripts; submitting the article; responding to peer-review comments; 
and giving final approval of the version of the article to be published. My thesis supervisors 
were involved in the initial planning concept of the project; and all co-authors were 
involved with the development of the resources for the intervention content and made 










The previous chapter identified five RA-specific barriers to smoking cessation: 1) people 
with RA feel isolated and unsupported when attempting smoking cessation; 2) people with 
RA are often unaware of the detrimental effects of smoking on RA and hence do not 
perceive this as a reason to quit; 3) smoking is used as a distraction from the pain associated 
with RA; 4) people with RA find it difficult to exercise and hence see themselves unable 
to use exercise as an alternative distraction from smoking; and 5) smoking is used as a 
coping mechanism for the frustrations of living with RA [285]. Therefore, smoking 
cessation strategies in RA may be more effective if they provide education and advice on 
exercise, pain management, and coping strategies.  
 
Whilst the themes identified from Chapter 4 are clear, translating these findings into a novel 
psychosocial intervention requires the development of a plan to design the structure and 
content of a novel smoking cessation intervention [310]. The aim of this chapter is to 
describe how the findings about smoking cessation needs of people with RA were translated 
into a targeted intervention that could be evaluated in a pilot study for potential use in 
clinical practice.  
 
5.2 Methods 
The steps of the intervention development process are described below in a linear fashion, 
although the process was iterative. There were two major methodological components in 





1) Identification of key generic components of existing evidence-based smoking 
cessation programmes, which were used to provide the intervention structure. 
2) Development of resources for people with RA that address the identified barriers 
for quitting smoking, which provided the intervention content.  
 
 
5.2.1 Literature Review 
A systematic literature review was carried out as an ongoing process between February to 
June 2012 in order to provide the structural design and identify key generic components of 
best practice, evidence-based, smoking cessation programmes. Sources of information 
included PubMed, OVID, Cochrane Library, Ebsco Databases and Google Scholar. The 
search was limited to smoking cessation policy and studies from 2000 onwards. The 
following terms were searched:  
 
Smoking AND Cessation AND Cochrane; Smoking AND cessation AND 
‘evidence-based’; ‘Smoking cessation’ AND USA; Smoking AND rheumatoid; 
Smoking AND cessation AND rheumatoid; Smoking AND chronic; Smoking AND 
cessation AND chronic; Smoking AND cessation AND Zealand; Smoking AND 
cessation AND ‘Ministry of Health’ AND Zealand; Smoking AND cessation AND 








The literature review focussed on two main categories of evidence:  
1) Systematic reviews and meta-analyses of RCTs to enable identification of evidence-
based smoking cessation components. The Cochrane Reviews of smoking cessation 
components were the major source of information. 
2) The most recent clinical practice guidelines on treating tobacco use and dependence 
from the World Health Organisation (WHO) European Strategy for Smoking 
Cessation Policy [311], the United Kingdom National Institute for Health and Care 
Excellence [312], the United States (USA) Department of Health and Human 
Services [189] and from the New Zealand (NZ) Ministry of Health [194, 313].   
 
5.2.2 Development of Resources for Intervention 
The intervention content was designed to address the identified barriers for quitting 
smoking in RA in the previous chapter. This process involved the development and refining 
of resources for people with RA, with modules created to address each of the five barriers. 
A steering group was convened from key stakeholders and researchers involved in the 
project with the remit of selecting and packaging the intervention content and deciding who 
would provide the necessary support. The steering group comprised of the following 
stakeholders, the researcher (PA), two consultant rheumatologists (LKS, SS), a health 
psychology researcher (GJT), and four health service providers from Arthritis NZ (the key 
support organisation for individuals with arthritis in NZ) [314]. The Arthritis NZ service 
providers included two Arthritis Educators who are the contacts for people with RA seeking 
advice and support, the Christchurch Regional Manager, and the National Service 
Development Manager. The interventions were chosen by the steering group with the 





1) Smoking cessation interventions needed to be appropriate and feasible, and based 
upon the best-practice intervention structure as identified in the literature review. 
2) Wherever possible the interventions would be based upon existing resources and 
information available from Arthritis NZ or Christchurch Hospital Department of 
Rheumatology, Immunology and Allergy. 
3) Interventions needed to fit within the existing service delivery structure of Arthritis 
NZ, which is a predominantly a telephone-based service. 
4) Appropriate education of the Arthritis Educators who were providing smoking 
cessation advice was required.  
 
Apart from the section specifically targeted to smoking cessation, the remaining resources 
and treatments used in the intervention were generically suitable for all people with RA 
regardless of their smoking status. The resources allowed for individual tailoring of the 
programme depending upon the goals and preferences of individual smokers with RA. The 
intervention structure is considered in detail in the results section following. 
 
5.3 Results 
5.3.1 Intervention Structure 
The literature review highlighted three key components for an effective smoking cessation 
intervention that are recognised internationally: 1) the optimal duration of a smoking 





behavioural based support (e.g. advice and counselling). These key components provided 
the structure for the intervention, which are as follows:  
1) The minimum standard needed to establish the outcome measure (quit smoking), 
requires smoking status to be reported at two time-points: at four weeks following 
the date smoking ceased and at three months after this quit date, with optional 
follow-up at six months and 12 months. 
2) Pharmacological support is recommended to all nicotine dependent people and 
should include medications that have proven efficacy, such as NRT. 
3) Multisession behavioural support of at least four follow-up contacts offered face-
to-face or via telephone, and weekly reminders in between. 
 
The potential interventions considered by the steering group for inclusion in the current 
intervention are listed in Table 5-1. Risk ratios (RR) have been reported in preference to 
odds ratios (OR) when available. Although both are regarded as valid, risk ratios are 
regarded to be easier to interpret than odds ratios [265]. For interventions that increase the 
chances of an event occurring, such as smoking cessation, the calculated odds ratio will be 
larger than the risk ratio, so there is a risk of overestimating the effect of the intervention 
[265]. Risk ratios describe the multiplication of the risk that occurs from an intervention, 
for example, a risk ratio of 2.0 implies that smoking cessation from an intervention is two-
fold more likely to occur than without that intervention (control group). A risk ratio of 1.0 
indicates no difference between the intervention and control group and a value <1.0 is 
indicative that smoking cessation less likely in the intervention group. The success rates 







Table 5-1: Efficacy of interventions to combat tobacco dependence in the general population  
(Based upon systematic reviews and meta-analyses from the Cochrane Collaboration [3, 200])* 
Intervention Group 
(success rate of 
treatment) 
Control Group 
(success rate of 
treatment) 





No intervention No advice  1.00 (reference)   
Brief Advice       
Brief advice to quit 
>3mins to ≤ 10mins 
(8%) 
No advice (5%) 1.76 (1.58-1.95) 26 [203, 315] 
Behavioural Interventions      
Stage-based 
counselling 
Standard advice 1.00 (0.82-1.22) 2 [316] 
Self-help materials  No materials 1.45 (1.27-1.66) 14 [206] 
Self-help materials 
(individually tailored) 
Standard advice or 
staged-based 
Counselling 










1.39 (1.24-1.57) 22 [208, 315] 
Group-based 
counselling (10%) 
Self-help (6%) 1.98 (1.06-2.46) 13 [315, 317] 
Pharmacotherapies       
Combination NRT 
(21%) 
Single NRT (16%) 1.34 (1.18-1.51) 9 [205, 315] 
NRT (17%) 
Placebo/ No NRT 
10%) 
1.60 (1.53-1.68) 117 [205, 315] 
Bupropion ‘Zyban’ 
(19%) 
Placebo (11%) 1.69 (1.53-1.85) 36 [315, 318] 




Placebo (12%) 2.27 (2.02-2.55) 14 [315, 320] 
Bupropion ‘Zyban’ & 
NRT 
Placebo 2.61 (1.65-4.12 2 [205] 
Combined behavioural and 
pharmacotherapies 




Less or  no 
behavioural support 
+ pharmacotherapy 






help/brief advice  
1.82 (1.66-2.00) 40 [199] 






Combining behavioural and pharmacological support is recommended by the Cochrane 
Collaboration since this combination can nearly double quit rates when compared with no 
intervention (RR 1.82, 95% CI 1.66-2.00) [199]. Adding behavioural support to 
pharmacological support improves efficacy when compared with pharmacological support 
alone (RR 1.16, 95% CI 1.09-1.24). However, evidence is lacking to support the superiority 
of the combination in some populations [199]. The success rate for smokers who quit 
smoking unassisted (i.e. using no pharmacotherapy or behavioural interventions) is low at 
2-3% [194, 203]. Although quitting without assistance has been successful for nearly half 
of former smokers in the USA, this is likely a reflection that effective treatments have not 
been readily available in the past [322].  
 
5.3.1.1 Behavioural Interventions 
Brief advice from a healthcare provider  
Brief advice from a healthcare provider (defined as advice from >3 to ≤10 minutes) almost 
doubles quit rates as compared to no advice (RR 1.76, 95% CI 1.58-1.95) [203]. Advice 
can either be in the form of a brief intervention (e.g. the NZ ‘ABC pathway’ - Appendix 8) 
[194, 195] or as part of a more intensive intervention such as behavioural counselling. As 
a minimum, brief advice simply means advising people to quit smoking [323]. In NZ it is 
recommended that brief advice be offered to all smokers regardless of their readiness to 
quit [194, 195]. Whilst evidence shows that brief advice delivered by physicians is the most 
effective [203], advice from other health professionals such as dentists, pharmacists, and 






Brief advice was included in the intervention in the form of the ‘ABC approach’ (Appendix 
8), which is standard practice in NZ hospitals and primary healthcare institutions.  
 
Stage-based advice 
The ‘Stages of Change’ component of the TTM has been used extensively in smoking 
cessation. This model suggests that smokers move through a series of stages before they 
are able to stop smoking [316]. Five stages of change had been identified in this model: 1) 
precontemplation where a smoker is not thinking about quitting in the next six months; 2) 
contemplation where a smoker is thinking about quitting in the next six months; 3) 
preparation where a smoker is thinking about quitting in the next month; 4) action where 
a smoker has quit successfully for six months; and 5) maintenance is the time after quitting 
for more than six months. The period of six months is arbitrary but is commonly used [326]. 
Based upon this model, it has been suggested that smokers be matched with cessation 
programmes that relate to their stage of readiness to quit. However, the findings from a 
systematic review in 2010 revealed that although stage-based interventions are better than 
no intervention, they are not better than standard advice (RR 1.0, 95% CI 0.82-1.22) and 
are less helpful than self-help material (RR 0.93, 95% CI 0.62-1.39) [316].  Based on this 
evidence, the stage-based advice strategy was not included in the current intervention. 
 
Self-help materials 
Providing standardised written self-help materials alone has only a small effect on smoking 
cessation success, although is more beneficial than no advice at all (RR 1.45, 95% CI 1.27-
1.66) [206]. The self-help materials included written, audio-visual and/or computer 





audience, but the quality of content has been found to vary widely [206]. There is evidence 
of a benefit from individually tailoring self-help materials as opposed to standardised 
materials (RR 1.36, 95% CI 1.19-1.55) although part of this benefit could be due to the 
additional assessment and contact from a healthcare provider [206]. It was agreed that 
treatment interventions addressing the individualised support needs of specific participants 
would be offered following an initial needs assessment. 
 
Person-to-person counselling 
The three key principles for smoking cessation counselling are: 1) setting a quit date; 2) 
emphasising complete abstinence; and 3) providing multi-session support [195]. 
Counselling, either individually or in a group situation, face-to-face or by telephone, has 
been demonstrated to help people stop smoking [207, 208, 317].  
 
Individual counselling (either single or multiple sessions) from a trained smoking cessation 
professional can help smokers quit (RR 1.39, 95% CI 1.24-1.57) [208], but there is 
insufficient evidence on whether more intensive counselling is more helpful [325]. There 
is no evidence showing one behaviour change model is more effective than others (e.g. 
cognitive behavioural therapy, withdrawal-orientated treatment, and/or motivational 
interviewing) [189]. 
 
The chances of quitting are doubled in group programmes (compared to self-help) where 
individuals are given the opportunity to learn smoking cessation behavioural techniques 
whilst supporting other group members (RR 1.98, 95% CI 1.60-2.46) [317]. Although 
group therapy was better than self-help and less intensive interventions, there is not enough 





counselling. Not all smokers want or can attend group sessions but they are regarded as 
helpful for those who do attend group sessions [317]. 
 
A Cochrane Collaboration systematic review found proactive telephone counselling 
(defined as those calls initiated by quit-lines to clients) was helpful (RR 1.29, 95% CI 1.20-
1.38) [207], cost effective and can have a very wide reach geographically [194]. Although 
there is limited evidence about the optimal number of calls, there is some evidence of a 
dose-response where one or two brief calls are less likely to provide a measurable benefit. 
Three or more calls increases the chances of quitting compared to a minimal intervention 
such as providing standard self-help materials, or brief advice, or compared to 
pharmacotherapy alone [207]. Evidence suggests three or more telephone calls to a patient 
increase the chances of quitting when compared with a single telephone call (RR 1.37, 95% 
CI 1.26-1.50) [207]. 
 
Regarding the length and intensity of counselling sessions, interventions of >10 minutes 
session length are more successful than no contact (OR 2.3, 95% CI 2.0-2.7) or shorter 
session length (3-10 minutes) (OR 1.6, 95% CI 1.2-2.0) [325]. There is also a strong dose-
response relationship between total contact time (i.e. the number of sessions multiplied by 
the session length) and successful treatment outcomes, but no extra benefits are seen for 
contact >90 minutes (OR 3.0, 95% CI 2.3-3.8) [325]. Four or more sessions appears to be 
particularly effective for smoking cessation (OR 1.9, 95% CI 1.6-2.2) [325].  
  
In light of the evidence above, individual counselling was offered in the current 
intervention. Although it is standard practice for Arthritis NZ to offer a predominately 





meeting would be face-to-face whenever possible to help encourage the development of a 
supportive relationship between the Arthritis Educator and the participant. If a face-to-face 
meeting was not possible, telephone support would be offered. For the current intervention 
three follow-up support telephone calls spaced at weeks one, four and eight from Arthritis 
NZ educators to aid quitting were included. 
 
5.3.1.2 Pharmacological interventions 
Smokers can be helped to quit smoking by using medications, including all types of NRT, 
antidepressants (bupropion ‘Zyban’), and nicotine receptor partial agonists (varenicline 
‘Champix’ or ‘Chantix’). These smoking cessation aids are fully-subsidised in NZ and for 
this reason are examined in the following section. 
 
Nicotine replacement therapy 
There are five different NRT products available in NZ: transdermal patches, gum, lozenges, 
mouth spray, and inhalators, of which three are currently funded by the NZ government 
(patches, gum and lozenges) [195]. Nicotine replacement therapy of any type has been 
shown to help smokers quit relative to placebo (RR 1.60, 95% CI 1.53-1.68) and can 
increase the rate of quitting by 50-70% [205]. The main mechanism of NRT is replacement 
of the nicotine that would be otherwise be obtained by smoking. Nicotine replacement 
therapy reduces the severity of nicotine withdrawal symptoms and is beneficial because it 
does not contain the harmful chemicals that are found in tobacco. It is generally used 
continually for eight to 12 weeks but can be used for longer periods [327], and is considered 
safe to use and highly cost effective. Potential side effects are more likely when NRT is 





of patch users (54%) report skin sensitivity and this is the only side-effect that has been 
reported to interfere with use [205]. NRT can be used safely by people with CVD, but for 
those who have experienced a serious CVD event in the past two weeks or have 
uncontrolled hypertension, their consulting physician should be involved in the decision to 
recommend NRT [328, 329]. Use in pregnancy carries a small potential risk to the foetus 
but is seen as having less potential risks than continued smoking in pregnancy [195]. 
 
Evidence suggests NRT is more effective in people who smoke 10 or more cigarettes a day 
[330] and higher dose NRT products are more effective than lower doses, although the 
additional benefit is small (RR 1.14, 95% CI 1.01 to 1.29) [205]. Combining two or more 
forms of NRT also increases abstinence rates by one third (RR 1.34, 95%CI 1.18-1.51) 
[205]. The efficacy of NRT appears to be independent of the intensity of any additional 
support (RR 1.14, 95% CI 0.88-1.47) [205]. There is limited evidence that NRT can be 
effectively used to help smokers reduce the number of cigarettes smoked per day (RR 1.25, 
95% CI 1.03-1.50) [205]. This strategy termed ‘cut down then quit’ approach or 
‘preloading’ can be used by smokers to help cease smoking in the long term [205, 331]. 
 
Bupropion 
Bupropion is an atypical antidepressant that reduces nicotine withdrawal severity. It is 
thought to act through its ability to inhibit the neuronal reuptake of noradrenaline and 
dopamine [332]. It may also work by improving depressed mood [319]. It is a funded stop-
smoking medication in NZ and is cost-effective to use [195]. It is taken for seven weeks, 
and is only available by prescription due to known contraindications (e.g. if the person has 
a history of seizures; current or past eating disorders) and drug interactions (e.g. 





is as effective as NRT and more effective than placebo (RR 1.69, 95%CI 1.53-1.85) [319]. 




Varenicline was specifically developed as a smoking cessation medication and is an 
analogue of crytisine [333]. Although Varenicline is a nicotinic acetylcholine receptor 
partial agonist, it also possesses antagonist properties, and some combination of these 
actions is involved in the mechanism of Varenicline as a smoking cessation aid [333]. It is 
thought that Varenicline competes with nicotine for the same receptor sites in the brain, 
thereby reducing both nicotine withdrawal severity and the rewarding properties of nicotine 
to the individual [333].  
 
Varenicline is very effective compared to placebo (RR 2.27, 95% CI 2.02-2.55) and is more 
effective than NRT (OR 1.57, 95% CI 1.29-1.91) or bupropion (RR 1.52, 95% CI 1.22-
1.88) in the general population [319]. Because of its nicotine antagonist properties, it is not 
recommended to be used in conjunction with NRT [325]. In NZ, varenicline is funded 
subject to Special Authority criteria for patients, who must have completed two trials of 
NRT or one trial of bupropion prior to its use. It is available only by prescription for 12 
weeks [195]. Post-marketing surveillance has raised some concerns about possible links 
between varenicline and serious CVD adverse events, although this association has since 
been questioned due to less than optimal methodology [334]. A recent meta-analysis of 22 
RCTs did not find any significant increase in the risk serious CVD adverse events from 
using Varenicline [334], thus the USA Food and Drug Administration have stated the 






Bupropion and varenicline must be prescribed by a registered medical practitioner, but 
NRT can be prescribed by any health professional in NZ who has received the basic ABC 
pathway approach for smoking cessation training and registration [188]. For this reason 
NRT in the form of patches, gum or lozenges, was chosen as the form of NRT to be offered 
in the current intervention.  
 
5.3.1.3 Combination Therapy Support 
Clinical trials have supported combining behavioural support and pharmacological therapy 
[199]. However, there is currently no direct estimate of the benefits expected from 
combining these two types of treatment [199]. Combining behavioural support with 
pharmacotherapy significantly aids cessation by just over 80% as compared to a smoker 
who is not utilising either (RR 1.82, 95% CI 1.66 to 2.00) [199]. Increasing the amount of 
behavioural support interventions as an adjunct to pharmacotherapy minimally increased 
the chances of sustained smoking cessation by about 10 to 25% (RR 1.16, 95% CI 1.09-
1.24) compared to pharmacotherapy alone. Although a small effect, this is still regarded as 
important [321].  
 
Overall, the provision of combined behavioural and pharmacological support increases the 
success of people trying to quit smoking. This suggests that both types of smoking cessation 
aids should be used concurrently. Therefore, a combined therapy support approach was 






5.3.1.4 Timing of interventions 
Condensing behavioural support into the first two weeks of smoking cessation is known as 
front-loading [179]. Front-loading the treatments in a smoking cessation programme could 
be beneficial because approximately 60-70% of smokers who quit will relapse by two 
weeks post-cessation [179]. Those who can remain abstinent for longer than two weeks 
have a 50% higher likelihood of remaining abstinent at one year post-cessation [179]. 
Although this is an area that requires further research, front-loading treatments has been 
suggested to be a promising treatment model.  
 
The steering group therefore agreed that front-loading patient contact would be included in 
the current intervention. We planned the intervention to include an initial baseline needs 
assessment at week 0, followed by continuing support at weeks one, four and eight with 
generic emails sent at weekly intervals for 12 weeks with support, advice and tips for 
quitting. 
 
5.3.1.5 Length of intervention 
In accordance with international recommendations for smoking cessation programmes the 
optimum duration for the RA specific intervention was set at three months [202, 313, 336]. 
Figure 5-1 demonstrates the format for the 3-month smoking intervention designed for 







Figure 5-1: Timeline of the 3-month smoking cessation intervention for people with RA 
 
 
5.3.2 Content of the Targeted Smoking Cessation Intervention  
In order to address the five smoking cessation barriers in RA identified in the previous 
chapter [285], the steering group agreed upon the following intervention strategies for a 
tailored intervention in smoking cessation for people with RA.  
 
5.3.2.1 Support 
Lack of support was identified as a major barrier to smoking cessation in RA. Individuals 
feel unsupported in smoking cessation attempts and isolated from other people with RA 






1) An initial needs assessment by telephone or face-to-face with an Arthritis NZ 
Educator to identify individual barriers to smoking cessation and offer 
individualised support based on participant preferences.  
2) Three follow-up contacts by telephone or face-to-face and continued counselling 
from Arthritis NZ to address barriers to quitting. 
3) Generic weekly smoking cessation tips to be sent for 12 weeks (Appendix 9 and 
10). 
4) A support webpage where all support material could be accessed. 
5) Smoking Cessation education course for the Educators: NZ Heart Foundation Stop 
Smoking Practitioner Training Course [337]. 
 
5.3.2.2 Education about the links between smoking and RA 
As identified in Chapter 4, people with RA who participated in the qualitative study were 
aware of the general health risks associated with smoking, but many were not aware of 
specific relationships between smoking and RA. Those people with RA did not readily 
identify a link between the severity of their RA and their smoking [285]. Consequently, it 
was agreed that the novel intervention would include a single-page leaflet designed by the 
Steering Group outlining the association between adverse outcomes and smoking in RA. 
This leaflet included information on the risks of increased disease activity, reduced efficacy 
of RA medications, and the potential for more joint damage in those who smoke (Appendix 
11). This leaflet also highlighted the additional risk posed by smoking in terms of CVD and 
osteoporosis: comorbid conditions which are more common in RA than the general 






5.3.2.3 Pain Management 
Chronic widespread pain is a common feature of RA [338]. Participants in the qualitative 
study suggested that they used smoking as a distraction from the pain associated with RA 
[285]. Individuals with chronic pain may be motivated to smoke because of a belief that 
smoking could help them cope with their pain or that quitting smoking would be more 
difficult because of their pain, although recent studies refute this [297-299]. Therefore, pain 
management strategies formed an integral part of this intervention. Arthritis Educators are 
knowledgeable in discussing pain management issues, and hence the following 
interventions would be offered (Appendix 12):  
4) Arthritis NZ ‘Managing your Pain’ booklet.  
5) Advice on specific strategies for basic pain relief such as complementary therapies 
and taking medications as advised. 
6) Advice on pacing, managing fatigue, and sleep hygiene. 
7) Referral to rheumatologist or their GP for pain management if required. 
 
5.3.2.4 Exercise 
The people with RA in the qualitative study found it difficult to exercise due to joint pain 
and had a perception that exercise may worsen their arthritis. As a result many felt that they 
could not undertake exercise as an alternative distraction to smoking [285]. However, there 
is good evidence that physical activities not only reduce cigarette cravings [302] but have 
additional health benefits in RA [303]. Importantly, exercise has not been shown to 
exacerbate disease activity in RA [303]. The steering group agreed that the following 
exercise resources should be made available for the intervention, and participants were 





1) A booklet with specific strengthening hand exercises (produced by the 
pharmaceutical company Abbott) (Appendix 13-a and-b). 
2) A booklet on ‘general exercises for RA’ (also produced by Abbott) (Appendix 13-
c).  
3) A booklet called ‘Arthritis: exercises to keep you moving (produced by Arthritis 
NZ) (Appendix 13-d). 
4) A DVD presenting home-based exercise (produced by Arthritis NZ). 
5) A handout on local community exercise resources (with details of places, dates and 
time schedule) (Appendix 13-e).   
6) A handout on local hydrotherapy classes available locally (Appendix 13-f).  
7) Referral to a physiotherapist or occupational therapist. 
8) A pedometer. 
 
5.3.2.5 Coping  
In the qualitative study, smokers with RA reported that smoking helped them to cope with 
the frustrations of living with RA. Therefore, support for individuals to develop alternative 
coping mechanisms were seen as a key component of any intervention [285]. Research 
shows that active coping skills lead to better health perceptions for people with RA [304]; 
those who do not use active coping strategies appear to be more at risk of psychological 
comorbidities [234]. Smokers with anxiety symptoms often report using smoking as a way 
of coping [285]. Using smoking to cope with negative health perceptions is detrimental to 
successful smoking cessation [219], whereas high coping effectiveness leads to better 





triggers for smoking and providing alternative self-management strategies may assist with 
smoking cessation. The steering committee recommended the following interventions:  
1) A smoking triggers diary to enable participants to identify their smoking triggers 
(Appendix 14). 
2) A discussion with the Arthritis Educators of goals and self-management to change 
coping strategies away from smoking.  
 
The following Table 5-2 outlines the key aspects of this smoking cessation intervention. 







Table 5-2: Details of targeted interventions for smoking cessation intervention in RA 
Theme Intervention 
1. Education Handout: ‘The link between smoking and RA’ 
2. Exercises Abbott Handout: ‘Hand exercises for RA’  
 Abbott Handout: ‘General exercises for RA’ 
 Arthritis NZ Booklet ‘Exercises to keep you moving’  
 Arthritis NZ DVD: home based exercise ‘Keep moving’  
 
Handout: ‘Community exercise classes for RA’ (times, dates and 
locations) 
 Handout: ‘Hydrotherapy classes’ (times, dates and location) 
 Physiotherapist or Occupational Therapist referral 
 Pedometer 
3. Pain Arthritis NZ Booklet: ‘Managing Your Pain’ Booklet 
4. Support Advice from Arthritis Educator: Managing Pain / Keep a Pain Diary 
 Advice from Arthritis Educator: Complementary therapies 
 Advice from Arthritis Educator: Managing Medications 
 Advice from Arthritis Educator: Pacing 
 Advice from Arthritis Educator: Managing fatigue 
 Advice from Arthritis Educator: Disturbed Sleep 
 Referral to GP (to revise analgesia) 
 12 Weekly Smoking Cessation Advice Emails (from Quitline NZ) 
 Support Website: ‘Smoking Cessation and RA’ 
5. Coping Handout: One week diary for ‘Identifying smoking triggers’ 
 Advice from Arthritis Educator: Goals and Self-management 
 Discuss available support (social, psychological and physical) 







Table 5-3: Contacts and content for the smoking cessation intervention for people with RA 
Timeline Intervention Group 
Week 0 (i) General information  
 (ii) ABC pathway for smoking cessation intervention 
 (iii) Standard intervention pack given and explained 
 (iv) Needs assessment with Arthritis NZ Educator (1st contact) 
  Contact details 
  Assessment: Main concerns with RA 
  How is RA affecting daily activities? 
  How do they manage their RA? 
  
Intervention Checklist - information discussed and tailored to 
study participant 
  1. Education (Handout) 
  2. Exercises (Handouts) 
  3. Pain management 
  4. Coping Strategies 
  5. Available support 
  Use of NRT documented 
Week 1 Follow-up contact with Arthritis NZ Educator (2nd contact) 
  General well-being since intervention 
  Review of interventions requested and/or used/useful 
  Review of current smoking status 
 Email reminder: ‘Smoking and your body’ 
Week 2 Email reminder: ‘Stress, feeling down and cravings’ 
Week 3 Email reminder: ‘Money benefits’ 
Week 4 Follow-up contact with Arthritis NZ Educator (3rd contact) 
  General well-being since intervention 
  Review of interventions requested and/or used/useful 
  Review of current smoking status 
 Email reminder: ‘Social Situations’ 
Week 5 Email reminder: ‘Weight gain’ 
Week 6 Email reminder: ‘The smoking addiction’ 
Week 7 Email reminder: ‘Health benefits’ 
Week 8 Follow-up contact with Arthritis NZ Educator (4thcontact) 
  General well-being since intervention 
  Review of interventions requested and/or used/useful 
  Review of current smoking 
 Email reminder: ‘Nicotine patches, gum and lozenges’ 
Week 9 Email reminder: ‘Why get help?’ 
Week 10 Email reminder: ‘Setbacks and trying to quit again’ 
Week 11 Email reminder: ‘Quit success stories’ 







This chapter describes how the findings about smoking cessation needs of people with RA 
from a qualitative study were translated into a targeted intervention. This process will 
enable researchers and rheumatology practitioners to replicate the process and/or make use 
of the intervention that was devised. This novel intervention adds to the current state of 
knowledge regarding smoking cessation in special populations, and provides the 
opportunity to evaluate the benefit and efficacy of a targeted smoking cessation 
intervention for people with RA.  
 
Nicotine dependence can be regarded as a chronic condition that often requires repeated 
interventions and multiple attempts before successful cessation, particularly for people with 
RA [209]. The best evidence identified by Cochrane Systematic Reviews has established 
that smokers in the general population using a combination of evidence-based treatments 
which includes pharmacotherapy and behavioural support have almost three times of the 
rate of quitting when compared with those who use neither [3, 200, 306]. Smoking cessation 
is one of most important modifiable lifestyle factors for people with RA. Quitting can 
improve health outcomes; therefore smoking cessation should be a key goal in the 
management of RA. This process of designing a pragmatic tailored smoking cessation 
intervention for people with RA made use of evidence from the general population and 
addressed previously identified barriers for quitting smoking by matching intervention 
components that aimed to impart skills necessary for self-management of RA and thus 







This research builds on previous research on smoking cessation in RA, which has either 
focused on multiple health interventions for people with RA, including but not limited to 
smoking cessation, or tailored smoking cessation interventions in multiple rheumatic 
conditions (Chapter 2). The more intensive smoking cessation intervention as outlined in 
this chapter may improve quit rates over and above that observed in previous studies. 
 
A healthcare intervention is considered complex if it includes a number of separate and 
interacting components that are important to the proper functioning of the intervention.  
The Medical Research Council’s framework for complex interventions to improve health 
provides guidance for developing and evaluating pragmatic RCT interventions with 
multiple and complex outcomes [339]. This framework recognises it is often difficult to 
identify which particular ingredient of a complex intervention is the most effective [339]. 
Developing a smoking cessation intervention for people with RA is an example of a 
complex intervention due to the interacting components within the experimental and 
control interventions (smoking cessation advice); the difficulty of the behaviour required 
by those receiving the intervention and controls (smoking cessation in both groups); and 
the flexibility or tailoring of the intervention that was required.  
 
The strengths of this intervention’s development process were the ability to package the 
resources to be relevant for the individuals with RA depending upon their perceived support 
and educational needs. Therefore the participants could choose any of the intervention 
suggestions depending on their needs and goals. The active engagement of individuals with 
their own health care decisions has been shown to improve their health status (patient-





smoking cessation treatments enables the trial outcome regarding smoking cessation to be 
internationally comparable to other RCTs.  
 
The process that was followed has limitations. Only two Arthritis Educators were involved 
in development of the intervention. Involving more Educators, and their international 
counterparts, would be beneficial in future research developing an international consensus 
on recommendations for smoking cessation interventions for people with RA. The 
intervention content was also bound by the support services available from Arthritis NZ, 
although this reflects pragmatic delivery of a complex intervention. Many of the difficulties 
of complex interventions are related to the difficulty of standardising the design and 
delivery of the interventions; local context sensitivity; the difficulty of applying the 
experimental methodology to general service delivery; and the length and complexity of 
linking the intervention with the chosen outcome [342]. 
 
5.5 Conclusion 
The smoking cessation intervention for people with RA that was developed is grounded in 
previous research, informed by patient opinion, and incorporates successful methodologies 
and evidence-based smoking cessation intervention components used in recent RA, arthritis 
or rheumatology studies of health, lifestyle and smoking interventions. In contrast to 
previous studies in this field, this intervention is focused solely on smoking cessation 
support for people with RA and offers a more comprehensive and intensive support whilst 
allowing for the individualisation of the support package based on the support needs and 





cessation barriers in people with RA by empowering individuals with problem-solving 
strategies, which may lead to improvements in life expectancy through addressing barriers 
to smoking cessation in RA. This approach, if successful, also enables an immediate 
translation into clinical practice, which could be rolled out internationally within existing 
arthritis service frameworks. A pilot study was undertaken to evaluate the efficacy of this 






6 RANDOMISED CONTROLLED TRIAL:  PILOT STUDY OF A 
RHEUMATOID ARTHRITIS SPECIFIC SMOKING 
CESSATION PROGRAMME IN COLLABORATION WITH 
ARTHRITIS NZ 
 
The original research in this chapter was presented as a poster at the 2014 ACR/ARHP 
Annual Meeting in Boston, MA during November 2014. The published abstract [343] is 
included in Appendix 15. 
 
6.1 Introduction 
Recently, targeted and tailored smoking cessation programmes have been suggested for 
special populations of smokers, such as people with RA, recognising there are specific 
barriers that make smoking cessation more difficult for some groups of smokers [212]. 
Targeting smoking cessation programmes to particular populations of smokers enables 
specific medical and psychosocial issues to be addressed that are not being met using 
traditional programmes. Tailoring of programmes enables the individual needs of smokers 
to be accommodated depending upon their particular disease-related issues. Therefore, the 
next step in the research process was to test the efficacy of this tailored intervention outlined 
in the preceding chapter in a pilot study. This chapter describes and discusses the outcome 








The primary aim of this pilot study was to determine whether a targeted 3-month smoking 
cessation intervention programme for people with RA increases smoking cessation rates at 
6 months compared to standard smoking cessation advice. 
 
6.3 Methods 
6.3.1 Study Design 
The study design was a randomised parallel group RCT.  Current smokers with RA were 
recruited. Participants were randomised on a 1:1 ratio into the control or the intervention 
arms of the study. All participants were given the current standard of care for smoking 
cessation at Christchurch Hospital, the ‘ABC pathway’ (Appendix 8). Those randomised 
to the intervention arm received additional advice, education and support from Arthritis NZ 
Educators, based on the needs of people with RA as identified in the qualitative study 
(Chapter 4) with the intervention design described in Chapter 5. Recruitment and data 
collection were conducted between November 2012 and March 2014. 
 
Ethical approval was given by the New Zealand Multi-Region Ethics Committee 
(12/STH/28). All participants gave written informed consent. The trial identification 







6.3.2 Study Timeline 
The 6 month trial timeline for the study is shown in Figure 6-1. 
 
 
Figure 6-1: Pilot study timeline 
 
 
 ABC: The control arm received the current local standard of care (‘ABC pathway’) 
and structured follow-up interviews with me (the researcher) at three and six 
months.  
 ABC+: The intervention arm received the same current local standard of care 
(‘ABC pathway’) and follow-up interviews PLUS additional targeted advice from 
trained Arthritis NZ Educators for three months, with regular contact face-to-face 
or by telephone, and weekly email contact, as described in the previous chapter. 
Advice was tailored to participants’ specific needs from a range of intervention 





previously identified key barriers. These participants also undertook structured 
follow-up interviews with me (the researcher) at three and six months. 
 
6.3.3 Study Intervention Timeline 
The smoking cessation intervention continued over three months, as follows: 
Week 0:  Informed consent and baseline data collection with researcher 
 Current local standard of care for smoking cessation: ‘ABC pathway’ 
programme administered by rheumatology specialist nurse 
 Initial face-to face meeting with Arthritis NZ Educators to determine 
relevant interventions (needs assessment) 
Week 1, 4 & 8: Telephone intervention follow-up from Arthritis NZ Educators 
Week 1-12: Email reminders and tips based on Quitline NZ 
 
The schematic showing the timeline of the 3-month smoking cessation intervention is 




6.3.4.1 Eligibility Criteria 
Participants were eligible to enter the study if they were aged ≥18 years, with a diagnosis 
of RA as defined by the 2010 ACR/EULAR Criteria for RA [54]. Participants must be 





were unable or unwilling to give written informed consent or had significant serious 
medical illness or serious mental health issues were excluded. 
 
6.3.4.2 Settings and locations 
Participants were identified from Christchurch Hospital Rheumatology outpatients, 
inpatients, and patient management systems. Advertising was also undertaken in the local 
newspaper (The Christchurch Press) and on public noticeboards throughout Christchurch 




6.3.5 Study Outcomes 
6.3.5.1 Primary outcome measure  
The primary outcome measure was self-reported smoking abstinence at six month’s post-
randomisation into the study.  
  
A participant was recorded as having quit smoking based on: 
a) Participant self-report of smoking abstinence, measured in days from their identified 
quit date with no subsequent smoking. This measurement is continuous abstinence. 
b) The recalled smoking status at 6 months post-randomisation was used for participants 






6.3.5.2 Secondary outcome measures  
There were two secondary outcome measures: 
1) Reduction in cigarette consumption at six months. This was defined as the 
difference between the baseline daily smoking rate and 6-month daily smoking rate.  
2) Identification of the aspects of the intervention that were accepted by each 
participant. In addition, feedback was sought from participants about what aspects 
of the programme they felt were most helpful. 
 
Smoking status for secondary outcomes was assessed in four categories in relation to 
behaviour over the last 4 weeks: no smoking; reduced consumption from normal; five or 
fewer cigarettes over the past month, and no change [313].  
 
 
6.3.6 Sample Size 
A biostatistician was consulted to determine a suitable sample size to test the feasibility of 
this intervention. A cohort of 40 participants was considered to be an appropriate sample 




The random allocation sequence for 48 potential participants was generated by a 
biostatistician using an Excel spreadsheet in six blocks times eight allocations. This meant 





allocations, therefore improving the chance of an even allocation of participants regardless 
of the endpoint size of the study.  
 
Implementation of randomisation was divided into two sections: 
1. Enrolment, informed consent (Appendix 17), general study information sheet 
(Appendix 18), and baseline questionnaires (Appendices 1a-k) were undertaken by 
the researcher for all participants.  
2. The ‘ABC pathway’ (Appendix 8) was provided by one of two rheumatology 
specialist nurses trained to deliver the ‘ABC pathway’ to all participants. The 
rheumatology specialist nurse opened the uniquely numbered sealed opaque 
envelope which contained the randomisation allocation: control or intervention. The 
standard intervention pack was given to intervention participants. 
 
Until opening the sealed randomisation envelope, the nurse and participant were blinded to 
the randomisation allocation. The researcher remained blinded to participant allocation 
until the 3-month follow-up interview with all study participants. 
 
6.3.8 Needs Assessment Visit  
After completion of the randomisation process, the rheumatology specialist nurse notified 
the Arthritis NZ Educators of the participants contact details. The intervention participants 
were provided with a standard intervention information pack because the needs assessment 
meeting with the Educators could feasibly be by telephone. This also enabled the 
participants to be familiar with the material prior to the needs assessment. The standard 





between smoking and RA, a pain management booklet for RA (Appendix 12), two RA 
specific exercise handouts (Appendices 13-b and 13-c), and a smoking triggers diary 
(Appendix 14).  
 
One of two Arthritis NZ Educators subsequently contacted each participant to organise a 
needs assessment meeting that would be undertaken within the same week as randomisation 
into the study. The needs assessment meeting included a discussion to assist the participants 
to set a quit date, to identify their own perceived barriers to quitting smoking, and to decide 
which intervention components would be most suitable to meet their individual goals and 
preferences. Both of the Educators undertook a two-day intensive smoking cessation 
provider course as offered by the NZ Heart Foundation. The needs assessment checklist 
was developed in consultation with Arthritis NZ (Appendix 19).  
 
6.3.9 Data Collection Measures and Verification  
Quantitative baseline and follow-up data was collected from all study participants 
immediately following informed consent in week 0, and at the two follow up interviews at 
three and six months. The information was collected from a variety of sources. A 
participant’s duration of RA, comorbidities and use of DMARDs were extracted from 
hospital records. Age, gender, ethnicity, level of formal education, employment status, any 
joint surgery, and smoking history were self-reported. Standardised questionnaires on 
demographic characteristics, health status, and smoking habits were used. Participants 
completed the HAQ, the PI HAQ, the ASES, the HAD, the PSS, the EQ-5D, the EQ-VAS, 
the SSEQ, a smoking history questionnaire, and the FTND. The methods Chapter 3, 






The data from the intervention contacts (needs assessment meeting at Week 0 and contacts 
at Weeks 1, 4 and 8) were recorded onto participant contact sheets by the Arthritis NZ 
Educators (Appendix 20). The needs assessment data included each participant’s RA 
management and smoking cessation concerns. Identification of which intervention 
components were accepted by each participant was recorded, as was their current smoking 
status and use of NRT. Written summaries were also completed regarding ongoing advice 
and support discussions. Feedback was sought from participants about what aspects of the 
programme were most useful during the 3- and 6-month follow-up interviews with the 
researcher (Appendix 21).  
 
6.3.10 Statistical Methods Analysis 
Quantitative data was analysed using SPSS software. Between group comparisons for 
primary (smoking cessation at 6 months) and secondary outcomes (sustained reduction in 
smoking at 6 months) were undertaken, together with baseline and follow-up 
demographics, disease and psychosocial factors associated with smoking cessation.  
Statistical analysis employed 1-way analysis of variance (ANOVA), 2 tests or Fisher’s 
exact test of independence. An intention-to-treat (ITT) approach was utilised, in which data 









The next section outlines the results from the quantitative aspects of this pilot study.  The 
qualitative aspects of the study are explored in Chapter 7, which involve a closer look at 
the motivations, beliefs and individual experiences of study participants. 
 
6.4.2 CONSORT Schematic of Study 
The participant flow for the pilot study using the CONSORT flow diagram schematic is 


















97 Assessed for eligibility 
58 Excluded (60%) 
23 Not smoking (24%) 
23 Declined to participate (24%) 
5   Unable to Contact (5%) 
7   No contact after information 
sent (7%) 
19 Analysed (Baseline)  
11 Analysed (3 month follow-up)  
16 Analysed (6 month follow-up) 
0 Excluded from analysis 
 
3 Withdrew from follow-up 
16 Completed follow-up 
 
 
19 Allocated to ABC+ (3 month 
Intervention) 
19  Received allocated ABC+ (100%) 
0 Did not receive allocated ABC+ 
0 Did not complete allocated ABC+ 
0 Withdrew from follow-up  
20 Completed follow-up 
20 Allocated to ABC (Control) 
20 Received allocated ABC (100%) 
0 Did not receive allocated ABC  
19 Analysed (Baseline)  
15 Analysed (3 month follow-up) 
19 Analysed (6 month follow-up) 
1 Excluded from analysis: did 




39 Randomised (40%) 
Enrolment 
 






6.4.3 Study Recruitment 
Thirty-nine participants were enrolled in the study. Recruitment was undertaken between 
26 November 2012 and 20 September 2013 (10 months). The recruitment process took 
longer than initially anticipated. In the first week of the study, seven participants were 
recruited and by the end of the fourth month half of the participants had been recruited. By 
the end of May 2013 there were 32 participants in the study. However, recruitment became 
increasingly difficult and by the end of September 2013 with only a further seven 
participants were added.  A decision was made to stop recruiting at 39 participants so as to 
not delay the end of the study. As described in the CONSORT diagram above, one 
participant who identified as having RA was subsequently found not to have RA, but 
another rheumatic condition, giving a final number as 38 participants. The following Figure 
6-3 demonstrates the trend in recruitment throughout the recruiting phase showing the drop-
off in recruitment after May 2013. 
 
  


























6.4.4 Baseline Characteristics of Study Participants 
The baseline demographics for this study are described in Table 6-1.    
 
Table 6-1: Baseline demographic characteristics of participants 








Age  Years 56.0 (12.1) 57.0 (11.9) 56.5 (11.8) 
Disease Duration  Years 8.2 (10.1) 7.2 (6.3) 7.7 (8.4) 
Education (years) Years 12.2 (1.9) 11.3 (1.0) 11.7 (1.5) 
Socio-economic deprivation 5.2 (2.8) 5.0 (2.9) 5.47 (2.7) 
Gender Female 12 (63%) 9 (47%) 21 (55%) 
  Male 7 (37%) 10 (53%) 17 (45%) 
Ethnicity 
NZ 
European 17 (90%) 17 (90%) 34 (88%) 
  NZ Māori 2 (10%) 0 (0%) 2 (6%) 
  Other 0 (0%) 2 (10%) 2 (6%) 
Employment Full-time  11 (58%) 8 (42%) 19 (50%) 
  Part-time  2 (11%) 2 (11%) 4 (11%) 
 Not working 6 (32%) 9 (47%) 15 (39%) 
ACPA Positive 18 (95%) 16 (84%) 34 (90%) 
RF Positive 17 (90%) 13 (68%) 30 (79%) 
DMARDs Methotrexate 15 (79%) 12 (63%) 27 (71%) 
Comorbidities CVD 2 (11%) 2(11%) 4 (11%) 
  COPD 2 (11%) 1 (5%) 3 (8%) 
  Osteoporosis 4 (21%) 3 (16%) 7 (18%) 
Previous Joint Surgery 3 (16%) 1 (5%) 4 (11%) 
*ACPA= anti-cyclic citrullinated peptide antibody; RF=rheumatoid factor; DMARDs= 
disease-modifying anti-rheumatic drugs; CVD=cardiovascular disease defined as 








Baseline questionnaires show the intervention and usual care groups to be similar in their 
baseline demographic and disease-related characteristics.  
 
The baseline functional and psychosocial characteristics for participants in this pilot study 
are shown in Table 6-2.  
 
Table 6-2: Baseline functional and psychosocial data of participants  








HAQ 1.0 (0.8) 0.6 (0.6) 0.8 (0.7) 
EQ VAS 69.4 (17.3) 74.8 (19.5) 72.1 (18.4) 
EQ-5D 0.6 (0.2) 0.7 (0.2) 0.7 (0.2) 
PI HAQ 2.6 (2.0) 2.1 (2.0) 2.3 (2.0) 
ASES Pain 5.9 (1.7) 6.7 (2.1) 6.3 (2.0) 
ASES Mood 7.0 (2.1) 7.5 (2.1) 7.2 (2.1) 
HADS Anxiety 6.4 (3.7) 7.1 (3.9) 6.7 (3.8) 
HADS Depression 4.1 (3.1) 5.0 (3.3) 4.5 (3.2) 
PSS 22.7 (8.7) 20.6 (8.4) 21.7 (8.5) 
Smoking self-efficacy internal 13.5 (6.1) 12.5 (6.4) 13.0 (6.2) 
Smoking self-efficacy external 13.6 (5.2) 14.1 (6.1) 13.8 (5.6) 
*HAQ=health assessment questionnaire; PI HAQ= personal impact HAQ; ASES= arthritis self-
efficacy scale; HADS= hospital anxiety and depression scale; PSS=perceived stress scale; EQ 
VAS= Euroqol visual analogue scale; EQ-5D=Euroqol-5D; 
 
 
The responses from the questionnaires demonstrated no statistical differences between the 
intervention and control group participants with regard to psychosocial data including 





scores for anxiety, depression or stress. The EQ-VAS scores were similar, suggesting both 
groups had a positive perception of their health status. The lack of difference in smoking 
self-efficacy demonstrates the similarities in these study groups with regard to their ability 
to refrain from smoking. 
 
The self-reported baseline smoking history of participants is outlined in Table 6-3.  Both 
study groups were similar in their smoking history. The Fagerström test indicated the 
participants had moderate dependency on nicotine. The measure of the average time to first 
cigarette indicated participants in both study groups smoked within 31 to 60 minutes of 
waking (mean 1.9, 95% CI 1.6-2.2) indicating a ‘low’ dependent phenotype of smoker 
[344]. Nearly all of the participants (90%) reported having received advice from a health 
practitioner to quit smoking within the last year. A daily smoking rate averaging at 16.5 
cigarettes suggests a moderate dependence on nicotine. 
 
Table 6-3: Baseline smoking history of participants 








Number of cigarettes per day 16.6 (8.2) 16.4 (6.9) 16.5 (7.5) 
Smoking history (years) 40.6 (12.2) 41.7 (12.0) 41.2 (12.0) 
Fagerström Nicotine Dependence 4.0 (1.6) 4.0 (2.2) 4.0 (1.9) 
Time to first cigarette 1.9 (0.9) 1.9 (1.1) 1.9 (1.0) 
Pack Years of Smoking 38.1 (27.3) 37.4 (18.5) 37.8 (22.9) 
Exposed to indoor tobacco smoke at home 4 (21%) 8 (42%) 12 (32%) 
Advice from Health Professional to quit 
smoking during the previous year 







6.4.5 Study Participant Follow-up Contacts 
Three intervention participants withdrew from follow-up, two at three months and one at 
six months, although these participants did complete the intervention visits. All three 
participants stated they no longer wished to quit smoking.  At the 3-month follow-up 
interview 26 of 36 study participants were interviewed. The remaining ten participants were 
not able to be contacted within one month after their respective 3-month follow-up date so 
they were not contacted again until six months post-randomisation. Thirty-five participants 
were interviewed for the 6-month follow-up interview. Of these, 17 of 35 study participants 
were not able to be contacted within one month of six months post-randomisation, and the 
mean delay for the 6-month follow-up contact was 64 days. This delay was unavoidable 
because most of the participants were not willing to make a special visit to the hospital for 
follow-up; therefore the interviews were either timed to correspond with the participant’s 
next outpatient visit, or were interviewed by telephone at a time convenient to each 
participant if their next out-patient appointment was not within three months.  
 
Participants who were interviewed by telephone for the 3-month follow-up were mailed the 
demographic, psycho-socio and smoking history questionnaires for completion and return 
by mail (return postage was included). This was unsuccessful as a strategy as only one 
participant returned a completed questionnaire. This strategy was abandoned and only those 
participants who attended face-to-face follow-up interviews with the researcher completed 
the questionnaires. In total, the questionnaires were answered by 20 participants at the 3-
month follow-up and 15 participants at 6-month follow-up. There was no difference in the 






6.4.6 Primary Outcomes 
The primary outcome for the study found smoking cessation rates at six months for 
intervention arm was five of 19 participants (26%) and the control arm was four of 19 
participants (21%). The difference in quit rates between the intervention and control groups 
was not statistically different (p=0.70). Risk ratio is one method to assess an effect size for 
categorical measures of two treatment groups in a RCT [345]. The risk ratio for this pilot 
study was RR 1.25 (95% CI 0.40-3.96). The number needed to treat (NNT) is another 
method used to assess an effect size, and for this study the NNT was 20. This value is the 
estimated number of patients who need to be treated with the intervention for one additional 
patient to quit smoking compared to the control group. [346].  
 
For both arms of the study, the quit rates were high compared to general smoking cessation 
rates for interventions. The three intervention participants who were withdrew from follow-
up were included in the quit rate calculation as smokers, which produces a more 
conservative estimate of quit rates. This is referred to as an ITT analysis. An ITT is a 
method of analysis in RCT in which all participants are included in analysis regardless of 
whether or not they completed or received the treatment [347]. 
 
The continuous abstinence rates revealed the amount of time (in continuous days) during 
the study a participant had ceased smoking, and is calculated at the endpoint of the study 
(six months following randomisation). Figure 6-4 shows that six of nine study participants 
who quit smoking had quit within the first week of the study. Of the remaining three 





interview and two control group participants had quit smoking during the last two weeks 
of the study. These results suggest that the intervention participants were more likely to 
have quit smoking during the intervention phase of the study, whereas the control group 
participants were more variable in the timing of their quitting. 
 
 




6.4.7 Secondary Outcomes 
The sustained reduction in smoking rates at six months was calculated as the difference 
between the baseline number of cigarettes smoked daily and the number smoked at six 
months (Table 6-4). There was no statistically significant difference between the smoking 
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Table 6-4: Secondary pilot study outcomes 
Data presented as mean (SD) or % 
Secondary Study Outcome Intervention Control Overall P value 
Baseline (No. of cigarettes per day) 16.6 (8.2) 16.4 (7.0) 16.5 (7.5) 0.92 
6 months (No. of cigarettes per day) 9.9 (10.7) 8.6 (6.7) 9.3 (8.8) 0.67 
Sustained reduction smoking  
(6 months) 




The number of smokers in each group that 1) quit, 2) had ≥50% reduction in daily smoking, 
or 3) had <50% reduction in daily smoking is shown in Figure 6-5.  The overall reduction 
in percent of daily smoking rates was similar for both groups, and ranged from 20 to 96% 
for those participants who cut down their daily smoking rates; this equated to a 60% mean 
reduction in daily smoking for intervention participants and 57% mean reduction for 
control group participants. The absolute total reduction in daily smoking for both groups 


































6.4.8 Factors Predicting Quitting in the Study 
The preceding sections identified that there were no statistically significant differences 
between the intervention and control arms in this study with regard to the primary outcome 
(quitting smoking at six months) and secondary outcome (sustained reduction in smoking 
at six months). The next section examines if there were any factors that predicted smoking 
cessation in the study participants. 
 
6.4.8.1 Disease duration and smoking cessation in RA 
There was no statistically significant difference in RA disease duration between the 
individuals who quit smoking and those who did not. This result is demonstrated in Table 
6-5.  
 
Table 6-5: Disease duration in those who quit and those who did not 
 Smoking Status at 6 months ≤2 years RA >2 years RA Total P value 
Quit  3 6 9  0.74 
Non-quit  8 21 29    
Total  11 27 38  
 
 
6.4.8.2 Use of NRT  
All study participants were asked by the researcher to recall their NRT use during the two 
follow-up interviews. Twenty-six of 35 participants (74%) who were interviewed used 





(89%) than non-quitters (69%) but this result was not statistically significant, as 
demonstrated in Table 6-6. 
  
Table 6-6: Use of NRT vs number quit smoking 
Smoking Status at 6 months Intervention Control Used NRT P value 
Quit (n=9) 4 4 8  0.60 
Non-quit (n=26) 7 11 18   
 
 
6.4.8.3 Advice by a health professional to quit smoking 
Thirty-four of 38 participants had been advised by a health professional to quit smoking 
during the year prior to enrolment in this pilot study. There was no statistically significantly 
difference between the participants who quit and those who did not with respect to previous 
advice about quitting, as shown in Table 6-7. 
 
Table 6-7: Advised by a health professional to quit smoking during the last 12 months vs number 
quit smoking 
Smoking Status at 6 months Yes No Total P value 
Quit  8 1 9 0.95 
Non-quit  26 3 29  
 
 
6.4.8.4 Other factors associated with smoking cessation  
Table 6-8 identifies baseline demographic, disease and psychosocial factors associated with 
smoking cessation. This table demonstrates that successful quitters showed a tendency 
towards having a greater number of years in education beyond high school and had smoked 
less across their lifetime but these findings were not significant. No other demographic, 






Table 6-8: Baseline demographics, disease and psychosocial factors associated with smoking 
cessation 
All data are presented as mean (SD)* 







(n=38) P value 
Education (years) 12.6 (1.9) 11.5 (1.3) 11.7 (1.5) 0.06 
Cumulative pack-
years of smoking 
(years) 
25.6 (10.4) 41.7 (24.5) 37.8 (22.9) 0.07 
Current age (years) 55.2 (12.3) 56.9 (11.8) 56.5 (11.8) 0.72 
Socio-economic 
deprivation 
5.0 (3.3) 5.3 (2.6) 5.2 (2.8) 0.77 
ASES pain 6.9 (2.2) 6.2 (2.0) 6.3 (2.0) 0.36 
ASES mood 7.5 (2.0) 7.2 (2.1) 7.2 (2.1) 0.62 
HADS anxiety 6.7 (3.4) 6.7 (4.0) 6.7 (3.8) 0.97 
HADS depression 3.7 (1.9) 4.8 (3.5) 4.5 (3.2) 0.36 
PSS stress 19.0 (7.5) 22.5 (8.8) 21.7 (8.5) 0.29 
HAQ 0.6 (0.4) 0.9 (0.8) 0.8 (0.7) 0.26 
PI HAQ 2.0 (1.4) 2.5 (2.2) 2.3 (2.0) 0.52 
EQ VAS 76.3 (15.6) 70.8 (19.2) 72.1 (18.4) 0.44 
EQ-5D 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.31 
Smoking self-efficacy 
internal 
12.7 (6.0) 13.1 (6.4) 13.0 (6.2) 0.85 
Smoking self-efficacy 
external 
14.3 (3.5) 13.7 (6.2) 13.8 (5.6) 0.77 
Fagerström Nicotine 
Dependence 
3.8 (1.6) 4.3 (1.9) 4.0 (1.9) 0.72 
*Abbreviations: ASES, Arthritis Self-Efficacy Scale; HADS, Hospital Anxiety and 
Depression Scale; PSS, Perceived Stress Scale; HAQ, Health Assessment 
Questionnaire; PI-HAQ, Personal Impact Health Assessment Questionnaire; EQ-VAS, 








This chapter describes the outcomes from a pilot study designed to test the efficacy of a 
tailored smoking cessation intervention targeted for people with RA. The study did not find 
any statistically significant differences between quit rates at 6 months (p=0.70) or in 
sustained reduction in smoking rates (p=0.67). As no difference was observed in quitting 
rates between participants with less than two years RA disease duration compared to those 
with a longer disease duration (p=0.74), there was no evidence of a ‘teachable moment’ [6] 
in early diagnosis that might facilitate smoking cessation in people with RA. There were 
no statistically significant demographic, disease-related or psychosocial factors associated 
with smoking cessation in the study population, although people with fewer years of 
education (p=0.06) or longer history of smoking (p=0.07) were less likely to quit and may 
require particular cessation support. However, the findings from this study are clinically 
relevant due to the high number of smokers who were able to quit smoking and the high 
amount of sustained reduced smoking during the six month study period. The absolute 
reduction in number of cigarettes smoked by the study participants as a group equated to 
276 less cigarettes every day, or over 100,000 cigarettes on an annual basis.  
 
By comparing the quit rates from other studies of similar intervention intensity and/or 
similar study populations, it is apparent both arms of this smoking cessation intervention 
achieved a high quitting rate. Intensive clinical smoking cessation programmes provided 
by the NHS for the general population in the UK entail regular meetings (group or one-to-
one) with a trained adviser using structured, withdrawal-oriented behavioural therapy 
combined with smoking cessation medications such as NRT, bupropion or varenicline 





overview of the treatment of over two million smokers in a clinical setting. A systematic 
review in 2010 found intensive NHS treatments for smoking cessation resulted in 15% 
abstinence at one year [348]. Although the length of follow-up differs from the current 
study (one year versus six months), it is recognised smokers are most likely to relapse in 
the first six months following treatment rather than the second six months [349]. 
 
Despite the evidence that smoking increases the impact of many chronic diseases, including 
RA, the little research that has examined smoking cessation in chronic disease has primarily 
been focused on lung cancer, stroke and CVD [17]. The only study published to date of a 
smoking intervention designed specifically for patients with rheumatic diseases was a 
prospective study with an educational intervention in a single hospital in Spain. Quit rates 
of 11.8% at three months and 15.7% at 12 months respectively were reported, compared to 
previously recorded unassisted quitting rates of 4.6% over the past five years in the same 
patient population [9]. One hundred and fifty-two patients with rheumatic disease received 
verbal and written advice from a rheumatologist: the advice lasted from three to five 
minutes and was designed to be given at the end of regular medical visits. The advice 
included general benefits of quitting smoking, in addition to advice describing potential 
benefits in reduced CVD risks and specific advice involving the development of rheumatic 
diseases from smoking [9]. This advice session was followed by a more intensive session 
of 20 minutes of verbal and written advice from a rheumatology nurse, designed to detect 
individual barriers for not quitting. Personalised motivational advice of the best way to quit 
smoking was then provided. An offer of pharmacological support (varenicline) to patients 
with high nicotine dependence was given following their standard practice but NRT was 
not offered. Follow-up consisted of a telephone call in the third month from the 





study by Naranjo et al (11.8% at three months and 15.7% at 12 months) were similar to the 
NHS studies of intense general population smoking interventions. Interestingly, only nine 
percent of the study participants patients used varenicline, which included 12% of quitters 
(three of 24) [9]. Quit rates in that study may have been higher if pharmacological support 
was more widely used.  
 
However, the context of that study means it is difficult to compare their findings to this 
pilot study. In NZ, the use of NRT is widespread because it is an essential component of 
the ‘ABC pathway’ and its efficacy as a pharmacological smoking cessation aid has been 
firmly established (Table 5.1). Thus, if NRT had been routinely offered in the Spanish 
study, they could have expected higher quit rates than were observed. In this study, being 
able to attribute the educational component to the quitting rates seen is not possible due to 
the highly complex nature of the intervention and the use of NRT. In addition to this, by 
including other rheumatic diseases in the participant pool, the results are not directly 
comparable to smoking cessation in RA. 
 
In this pilot study, there was no difference between participants who quit smoking and those 
who did not with regard to their level of education (p=0.06), although this may have been 
a sample size issue. This finding differs to smoking cessation studies undertaken in the 
general population where demographic barriers to quitting smoking include less 
educational attainment (Table 2-12) [215, 350]. A USA study in 2005 examined the 
association between educational level and smoking status in a community-based sample of 
employed adults [350]. They found the prevalence of current-smoking was nearly three 
times higher in adults with less than high school diploma compared to those with a college 





with a college degree compared to having less than a high school diploma (60% versus 
29%). In NZ, the equivalent of a college degree would be a university degree and less than 
high school diploma would be leaving high school with no or level one NCEA 
qualifications. A causal link between smoking and lower educational attainment has been 
established in a study of 1445 participants in the USA that found pack-years of smoking 
was higher in individuals who did not complete a high school education (RR 1.6, 95% CI 
1.3-1.9) [215]. These individuals were also less likely to attempt to quit smoking (OR 0.3, 
95% CI 0.2-0.6) [215]. Thus, the lower level of education in the study participants who did 
not quit in the pilot study, which averaged at one year less high school education (11.5 non-
quitters versus 12.6 years quitters) might have had a small effect on quitting rates. Another 
USA study found that for individuals born between 1937 and 1956, one year of college 
education decreases smoking prevalence by 3.8% and increases smoking cessation by 5% 
[351]. In that study, an advanced education is theorised to raise awareness about the 
damaging effects of smoking.  
 
In this study, there was no statistical difference found regarding participants who had a 
longer history of smoking and their likelihood to quit (p=0.07), although this finding may 
have been due to the small sample size. This finding also differs from smoking cessation 
studies where the number of cigarettes smoked per day has been shown to effect smoking 
cessation behaviour, where those who smoke a higher number of cigarettes are less likely 
to quit smoking [352, 353]. Either way, a lower educational attainment and a higher rate of 







Measuring a sustained reduction in daily smoking was the secondary outcome from this 
pilot study. The positive benefit of ≥50% reduction of smoking on established CVD risk 
factors has been recognised for many years [354]. An open study in 2001 in Sweden 
measured the effects on blood based CVD risk factors of eight weeks of reduced smoking 
prior to a quit smoking attempt at nine weeks. They found the eight weeks of smoking 
reduction resulted in clinically significant improvements in established CVD risk factors 
including high-density/low-density lipoprotein ratio [354]. Therefore, the sustained 
reduction in smoking in this pilot study can be regarded as helpful for people with RA given 
their elevated CVD risk factors associated with RA and smoking. 
 
The smoking cessation intervention in this study was designed to utilise a combination of 
internationally recognised best-practice evidence-based smoking cessation treatments to 
maximise quitting probabilities for participants, whilst at the same time allowing for 
tailoring of intervention components to meet the needs of individual RA participants. The 
Cochrane Collaboration systematic reviews have established the most efficacious smoking 
cessation treatments include a combination of pharmacotherapy and behavioural 
interventions, which can demonstrate a quitting rate of 60-100% higher than brief advice 
alone [199]. The intervention in this study incorporated a large proportion of the 
recommendations for evidence-based smoking cessation treatments. The lack of significant 
difference between the intervention and control groups in primary outcome quit rates in 
this study could be the result of several factors. This lack of difference may have been due 
to unintentional biases being introduced into the trial. Randomised controlled trials are 
designed to anticipate, detect, quantify, and control bias as much as possible but it is not 







Biases in behavioural intervention studies can occur because participants who agree to take 
part in studies may be more motivated to achieve the study outcome as opposed to those 
who refuse. This is termed ‘participation effects’ [356]. A review of literature that 
examined patients’ reasons for participation in clinical trials was undertaken in 2002 by the 
Emergency Care Research Institute [356]. Information was gathered from 14 studies of 
2,189 patients who provided reasons for participating in a trial, in addition to 6,498 patients 
who declined to participate. Potential health benefits from participating (45%), physician 
influence (27%), and the potential to benefit others (18%) were the main reasons for 
participating [356]. Reasons for not participating in studies included inconvenience (25%), 
concern over experimentation (20%), potential lack of benefit (19%) and physician 
influence (19%) [356]. Thus, in the study presented in this chapter, the participants who 
agreed to take part may have had a higher motivation for quitting smoking regardless of 
their study allocation. It is equally possible the 30 people (Figure 6.2) who declined to 
participate in this study did so because they had no intention or desire to quit smoking.  
 
A further possibility of bias in this pilot study that added to the increased quit rates of the 
control group could have been occurred during the information (Appendix 18) and consent 
process for all study participants because the relationships between smoking and RA was 
discussed. This information could have acted as an unpredicted educational intervention 
thereby providing extra motivation for control group participants to quit. The Spanish study 
of smoking cessation in rheumatic diseases described above demonstrated a two-threefold 
increase in baseline smoking cessation that could have been due in part to the brief disease-
specific educational component that was added to the initial consultation with a 






Although these factors probably played a part in this study, another source of the high 
quitting rate of participants in the control group was the use of NRT as a common treatment. 
The success of using NRT to help smokers quit has led to its use being recommended as 
first-line treatment in many international clinical guidelines, including the ‘ABC pathway’ 
for smoking cessation in NZ [205]. In addition to NRT, the ‘ABC pathway’ also 
incorporated brief advice, which independently increases the changes of quitting smoking 
by nearly double again. Thus, the primary outcome quit rates of 21% in the control group 
in this pilot study were a reflection of the success of the ‘usual care’ treatment of using 
NRT in combination with brief advice.  
 
The Cochrane Collaboration has reviewed behavioural smoking cessation interventions 
used as an adjunct to pharmacological treatments [321] to ascertain whether an increase in 
quitting rates over and above the pharmacological interventions rate is seen. In total, 38 
randomised or quasi-randomised smoking cessation studies where evaluated. All but two 
of these studies provided behavioural support in four or more sessions, and 27 studies used 
NRT as the control treatment [321]. In that review, the mean quit rate in the control groups 
after pooling studies was 21%. This is very similar to that of the control group in this study, 
although the review did include all types of pharmacotherapy including varenicline and 
bupropion, which have higher quit rate success (Table 5.1). The median quit rate for adding 
behavioural interventions to pharmacological treatments in that review was 24% (95% CI 
23-26%), which was slightly less than this study (26% quit rate). Thus, the difference in 
primary outcome quit rates in the study presented in this chapter was within the range 
expected. Specifically, the recommendations from the Cochrane Collaboration state that 





statistically and clinically significant outcome, particularly for interventions that have four 
or more support contacts [321]. 
 
6.5.1 Strengths and Limitations 
Randomised controlled studies are considered the ‘gold standard’ for evaluation health care 
interventions [357]. The key advantages of using a pilot study are the ability to predict the 
feasibility and operational acceptability of an intervention and they are cost-effective to run 
[260]. There were few exclusion criteria for entry into this study, thus minimising 
population choice bias [355]. The random allocation of study participants to the different 
arms of the study decreased the potential of allocation bias [355]. The strengths of this pilot 
study were the development of a focused research question, using allocation concealment, 
use of blinding, and the use of the ITT analysis. Continuous abstinence rates as the primary 
endpoint enable this pilot study to be compared to similar studies. There was also a high 
retention of participants: none of the 19 intervention participants withdrew from the 
intervention and only three of 38 participants withdrew from follow-up.  
 
The study had several limitations. Pilot studies by their design are underpowered to 
adequately detect reliable measureable estimates of benefits or harms [260]. However, the 
sample size in this pilot study was adequate based on the published guidelines as outlined 
in Chapter 3. Additionally, self-reporting of smoking status rather than using a formal test 
of smoking cessation (e.g. measuring serum cotinine) and self-reporting of quit dates can 
be a source of error due to recall bias [358]. The delay in some six month follow-up 
interviews with the researcher could have been a source of recall bias error as the 





bias would have also evident with participant’s recollections of recognising the specific 
interventions that were provided during the first week of the study. Selection bias was 
evident in this study because 30 of 97 individuals declined to participate (Figure 6-2). It is 
most likely these individuals did not want to quit smoking thus did not see any benefit to 
enter the study.  
 
6.6 Conclusion 
This pilot study evaluated the efficacy of an individually tailored smoking cessation 
programme in people with RA. Although, this was no more effective than usual care, the 
smoking cessation rate was high compared to previous smoking cessation studies [9, 348]. 
The lack of added benefit of the tailored intervention suggests brief advice plus 
pharmacotherapy is the best practice supporting people with RA who wish to quit smoking. 
People with RA with fewer years of education or longer history of smoking may require 
particular cessation support.  
 
In order to explore whether this targeted smoking cessation programme had benefits not 
readily identified in the quantitative outcomes of the pilot during this study, detailed follow-
up interviews were undertaken at three and six months post-randomisation. The results of 






7 EXPLORING PARTICIPANT ATTITUDES TO A TARGETED 
SMOKING CESSATION PROGRAMME FOR PEOPLE WITH 
RA 
7.1 Chapter Overview 
The previous chapter presented the quantitative findings from the pilot study designed to 
evaluate the efficacy of an individual tailored smoking cessation programme in people with 
RA. Despite no significant difference in the primary outcome of smoking cessation rates 
between intervention and control group participants, the study did result in a high quitting 
rate among participants in both groups. In view of this, an evaluation of the implications 
for future practice and research exploring the acceptability and feasibility of the smoking 
cessation programme from the participants’ perspective is warranted. This chapter provides 
an in depth exploration and analysis of qualitative secondary outcomes of the pilot study 
as described below.  
 
7.2 Aims and Objectives of Exploratory Research 
The aim of the exploratory research phase of the pilot study was to seek feedback from 
participants about which aspects of the intervention were most useful. The analysis is 
presented in the following order to answer that research aim: 
1) Did the study intervention overcome barriers to smoking cessation in people with RA? 
a) Exploration of perceived barriers to smoking cessation in the intervention 
participants. 
b) Identification of intervention components accepted by each participant. 





d)  Analysing whether the intervention components were successful in facilitation of 
smoking cessation.  
2) What other factors facilitated or impeded smoking cessation in people with RA? 




7.3.1 Study Design 
This study design was a qualitative study adjunct to the pilot study of the RA specific 
smoking cessation programme in collaboration with Arthritis NZ (Chapter 6).  
 
 
7.3.2 Data Collection Measures and Verification 
7.3.2.1 Interviews 
The two sources of information for the qualitative evaluative analysis included: 1) the notes 
documented by the Arthritis NZ Educators at the four contacts with the intervention 
participants, and 2) the notes documented from the two follow-up interviews between the 
researcher and the participants in both intervention and control groups at three and six 
months post-randomisation. The interviews followed a combined structured and semi-
structured format, were undertaken on a one-to-one basis, and the interview notes were 






The initial needs assessment meeting occurred between the Arthritis NZ Educator and each 
intervention participant during week 0 of the programme (Appendix 19). Participants were 
asked questions regarding their main concerns with their RA, how their RA affected their 
daily activities, and how they managed their disease. A structured checklist of all the 
intervention components offered and accepted was completed by the Educator. This 
checklist also enabled discussion points to be noted for referencing and referring back to 
during the three subsequent intervention contacts at weeks 1, 4 and 8. Nicotine replacement 
therapy use was recorded at each intervention contact.  
 
The checklist for the following three intervention contacts between the Educator and 
participant was a variation on the initial needs assessment question-schedule (Appendix 
20). The participants were asked open-ended questions to: 1) establish how they have been 
since the last contact, and 2) encourage an open discussion about how they had used the 
intervention components they had chosen. This format not only allowed for documenting 
the expected large variations in responses from individual participants, but also allowed for 
an accurate recording of the interventions offered, accepted, and subsequent usage by each 
participant. 
 
The two follow-up interviews at three and six months (Appendix 21) with the researcher 
(PA) were conducted in person unless this was inconvenient to the participants. The 
preferred location was the Outpatients Department of Christchurch Hospital or by 
telephone if the participants were not able or willing to attend a follow-up meeting. The 
interview questions were structured and closed-ended to enable tallying of responses to the 
previously identified themes/barriers (described in Chapter 4). Each closed-ended question 





more detail, whilst still allowing for any new emergent themes to be identified. The 
interview schedule had both generic and separate question areas for intervention and 
control group participants, which included the following subject areas:  
 
Generic interview questions for all study participants 
 Did you change your smoking behaviour over the last 3 months? How? Why? When? 
 Did you use smoking cessation medications over last 3 months? Which? How useful?  
 Did you access other smoking cessation services? Which? Why? How useful? 
 Smokers: Are you planning to quit? When? 
 Smokers: How could you improve your ability to quit smoking? 
 
Interview questions for intervention participants about success of the intervention  
 Which intervention components were accepted? How useful?  
 Any suggestions to improve intervention? 
 
7.3.2.2 Data Analysis 
The data were analysed in three stages, as follows: 
 
1. Data Cleaning 
The data were screened and simplified to identify suitable qualitative data fields to analyse. 
The screening method involved sorting the data into the most relevant and data-rich fields 
that addressed the aims of the study. These fields subsequently become the data source for 





2. Deductive Categories 
Data was thematically analysed using a deductive analysis format (Chapter 3). This form 
of analysis enabled an evaluation of the aspects of the intervention or the study as a whole 
that were feasible, acceptable and overcame the participants’ barriers to smoking cessation 
to be undertaken. The rationale was to: 1) ascertain if the five previously identified barriers 
to smoking cessation were addressed for each of the individuals in the intervention arm of 
the study, and 2) identify which components of the intervention and overall study were 
useful (i.e. feasible and acceptable). For each participant in the intervention arm the notes 
from their four intervention contacts and two follow-up visits were reviewed on a case-by-
case basis. The control group participants had their two follow-up visit notes reviewed, 
looking for similar themes if they were apparent. Analysis of the intervention participants 
will be presented first to establish the resident themes. In total, the data were coded into 
nine deductive categories for each study participant, as listed below:  
 
Deductive categories:  
1) Support: lack of suitable support for smoking cessation in RA. 
2) Education: lack of knowledge of the links between RA and smoking. 
3) Pain Management: use of smoking as a distraction to pain. 
4) Exercise: inability to exercise due to RA. 
5) Coping Strategies: smoking used as a coping strategy for RA. 
 
Other research questions  
6) Intervention group participant feedback to identify if there were any novel themes in 






7) Participant feedback from all study participants to identify any novel themes in the pilot 
study as an entity that had not been previously identified in the exploratory phase of the 
study.  
8) All study participant attitudes to their particular study results. 
9) Relationships to Canterbury earthquakes. 
 
3. Tallying of Responses 
The decision as to whether the intervention components overcame the five identified 
barriers to smoking cessation was made using the data from the intervention participants. 
The more formal method of structured questions was used for data collection thus enabling 
participant responses to be tallied for analysis. For example, under the theme of education: 
the number of participants who made a reference to the handout that outlined the 
connections between RA and smoking was tallied. Participant quotes sourced from the 
records written by the Educators the researcher were also analysed because they provided 
a rich source of information to understand more clearly the context of their responses. Any 
novel themes not captured in the original exploratory research were inductively analysed 
using thematic analysis as described in Chapter 3. Tallying of the control group participant 
data for the same nine individual and global themes was also undertaken using the same 
analysis method, with the purpose of assessing if they were able to overcome their own 
barriers to smoking cessation. 
 
To confirm that there was consistency in discovered themes (internal validity), one of the 
thesis supervisors (GJT) independently analysed two intervention participants’ data sheets, 





Having colleagues check other researcher’s interpretations of data is important in with 
regard to rigour in qualitative studies, and this is referred to as confirmability (Chapter 3). 
 
7.4 Results 
7.4.1 Did the Study Intervention Overcome Barriers to Smoking 
Cessation in People with RA? 
7.4.1.1  Identification of Participants’ Barriers to Smoking Cessation 
The needs assessment was the first meeting between individual intervention participants 
and an Arthritis Educator from Arthritis NZ so participants could identify any difficulties 
they experienced with controlling their RA, and to decide which resources and treatments 
from the intervention component package would assist them to quit smoking. Apart from 
the components specifically targeted to smoking cessation, the remaining resources and 
treatments used in the intervention were suitable for all people with RA, regardless of their 
smoking status.  
 
Although 19 participants were enrolled into the intervention arm of the study and received 
the standard intervention pack and ‘ABC pathway’, only 18 participants undertook the 
needs assessment, since one participant was difficult to contact and the Arthritis NZ 
Educator was unable to book an appointment. However, this participant did receive the 
standard intervention pack handed out by the rheumatology specialist nurse at the study 






The next section classifies and quantifies the intervention participants’ barriers to smoking 




There were limited comments from the participants regarding support and isolation.  Whilst 
only three participants mentioned they had a good support network of friends and family, 
isolation from others was not mentioned as problematic by the participants. Participants 
were asked by the Educator about their support network, but support with regard to past 
smoking cessation attempts was not discussed in the needs assessment. 
 
2. Education 
As part of the information and consent process for the study, all participants (including 
control group participants) were informed of the relationship between RA and smoking, 
which was discussed prior to giving consent to enter the study (Appendix 18). While the 
majority of participants were not aware of the deleterious relationships specifically between 
smoking and RA, they were very aware of the negative health effects from their smoking 
habit. Their specific responses to the links between RA and smoking were not detailed at 
the time but were discussed with the researcher. This meant this intervention component 
was discussed with all study participants and essentially became included in the ‘usual care’ 






3. Pain Management 
Pain and swelling in joints was identified as a concern by 16/18 of the intervention 
participants, which led to difficulties with low mood, sleep disturbances and stress. The 
associated joint pain and swelling had an adverse effect on the day-to-day activities and 
hobbies of these participants, which affected movement and mobility, e.g.  
 “Pain in hands, shoulders and feet – makes working [heavy lifting] harder” 
(SRA024, male aged 58 years) 
 
“Don’t fix cars anymore due to dropping things…hands and sensation changes” 
(SRA032, male aged 61 years) 
 
“[RA] slows me down in everything I do” (SRA033, female aged 65 years) 
 
Low mood, sleep disturbances, fatigue and stress as a result of RA pain and limited mobility 
were commonly stated (7/18 participants):  
“Feeling down at times at not being able to do what she used to” (SRA028, female 
aged 31 years) 
 
“Stressed out that RA is back after a 6-year remission” (SRA037, female aged 43 
years) 
 
However, 12/18 felt their RA pain was well controlled by medication and a further three 
participants were currently having their medications altered to help control their RA: 







Two participants reported they were able to use physical activity in association with 
medication as a mechanism of controlling their RA:  
“RA controlled by medication, heat, rest, gentle exercise and hobbies such as 
reading, gardening & music” (SRA006, female aged 56 years) 
 
However, most of the remaining participants (12/18) mentioned they had difficulty with 
daily living and exercise due to restricted movement from swollen and/or painful joints:  
“Some difficulty with daily life due to aching wrists and knees…limit distance I can 
walk” (SRA019, female aged 61 years) 
 
 “Not able to work, can’t lift or hold things” (SRA016, female aged 47 years) 
 
In addition to RA, four participants had serious comorbidities including COPD, stroke, 
diabetes and cancer. These comorbid conditions were viewed by these participants as 
having a greater effect on their daily lives than RA at the time: 
“RA least of her [health] troubles” (SRA021, female aged 68 years) 
 
Only one participant felt that their RA was not affecting their daily activities in any way. 
 
5. Coping 
Overall, five participants specifically revealed that they use smoking to cope with their RA, 
principally to cope with their pain, but also as a mechanism for coping with RA in general: 
“Reluctant to be on ibuprofen, so have a cigarette when in pain” (SRA004, male 






“Having a cigarette takes her mind off pain” (SRA003, female aged 64 years) 
 
7.4.1.2 Intervention Components Accepted by Participants  
The number and percentage of participants who accepted specific intervention components 
are identified in Table 7-1. All of the participants were offered exactly the same 
components and were encouraged by the Arthritis NZ Educator to choose the components 
that were most appropriate for their own needs and requirements. The standard intervention 
pack components (Appendices 11, 12, 13b-c and 14) provided to each participant are 
identified in bold. The table below reflects interventions accepted by all 19 participants, 
because all of the participants were provided with the standard intervention pack during 
randomisation. The information in Table 7-1 demonstrates the support and advice 
components of the tailored intervention were the most accepted optional intervention 
components. The exercise components were less accepted. No participants were referred to 






Table 7-1: Number and percentage of participants who accepted intervention components  
Theme Intervention Number (%) 
Support & advice  Managing Pain / Keep a Pain Diary 12 (63) 
 Complementary therapies 6 (32) 
 Managing Medications 10 (53) 
 Pacing 14 (74) 
 Managing fatigue 16 (84) 
 Disturbed Sleep 16 (84) 
 Referral to GP (to revise analgesia) 0 (0) 
 12 Weekly Smoking Cessation Advice Emails  16 (84) 
 Support Website: ‘Smoking Cessation and RA’ 19 (100)# 
Education Handout: ‘The link between smoking and RA’ 19 (100)# 
Pain Arthritis NZ: ‘Managing Your Pain’ Booklet 19 (100)# 
Exercise ‘Hand exercises for RA’ handout 19 (100)# 
 ‘General exercises for RA’ handout 19 (100)# 
 ‘Exercises to keep you moving’ booklet 5 (26) 
 ‘Keep moving’ DVD 6 (32) 
 ‘Community exercise classes for RA’ handout 4 (21) 
 ‘Hydrotherapy classes’ handout 5 (26) 
 Physiotherapist or Occupational Therapist referral 3(16) 
 Pedometer 10 (53) 
Coping  Handout: 1 week diary for ‘Identifying smoking 
triggers’ 
19 (100)# 
 Advice from AE: Goals and Self-management 18 (95) 
 Discuss available support (social, psychological and 
physical) 
18 (95) 
 Use of NRT documented and discussed 18 (95) 
*NZ=New Zealand; AE=Arthritis Educator; NRT=nicotine replacement therapy 





7.4.1.3 Identification of the Usefulness of Intervention Components 
This section analyses the usefulness of the intervention components as informed by the 
participants who had accepted each component. To verify whether the components were 
ultimately useful in helping people with RA give up smoking, the study outcome quit status 
of the participants who found the components useful is described. 
 
The intervention components found most useful by participants are identified in green in 
Figure 7-1 and are ranked from most to least accepted (in red). Because NRT was a shared 

















































































































1. Support and Advice Intervention Components 
a) Arthritis Educator Support and Advice  
It was recognised in the exploratory research and design phase of this research that some 
participants may have different needs for support and advice. Therefore, support was 
individualised for each participant and their support choices were monitored by the 
Arthritis NZ Educators at subsequent contacts throughout the intervention. The following 
topics were discussed: 
1) Pain management and encouraging participants to keep a diary to identify when 
they had pain. 
2) Complementary therapies.  
3) Managing medications.  
4) Using pacing to cope with their energy levels.  
5) Managing their fatigue. 
6) Disturbed sleep. 
7) Referral to their general practitioner to revise analgesia if appropriate.  
 
Although participants were asked whether they received support and advice for each of the 
identified issues, for the purposes of the following analysis all support and advice 
components were combined into one category rather than being added up across each 
component. This was necessary because individual participants were not able to identify 
each support or advice component separately in the two follow-up interviews at three and 
six months. Overall, the support and advice received by the participants was found to be 
useful by 11/16 of the participants (the three participants who were withdrew from follow-
up were not included in this analysis). Of these 11 participants, three subsequently quit 





end of the 6-month follow-up period. Their comments were very positive and suggested 
that the support and advice offered from the Arthritis Educators was valued and 
appreciated: 
 “Absolutely, definitely helpful and really liked the educator” (SRA009, female 
aged 47 years, no change, 3 months post-randomisation) 
 
 “…was disappointed that tonight was our last phone call” (SRA024, male aged 58 
years, reduced, 8 weeks post-randomisation) 
 
“…thought the face-to-face support worked really well for her” (SRA037, female 
aged 43 years, quit, 6 months post-randomisation) 
 
One participant did not find the support and advice useful and felt they did not require this 
type of intervention to accomplish their goal: 
“…received phone calls, emails and information; didn’t find them helpful as was 
very motivated to quit smoking” (SRA023, female aged 62 years, quit, 6-months 
post-randomisation) 
 
b)  Weekly emails “Pip’s Smoking Cessation Tips” 
Twelve weekly emails based on Quitline NZ smoking cessation tips were sent to the 
participants who supplied an email address (16/19). Topics were varied (Appendix 10) and 
included, e.g. how smoking affects your body, cravings and mood, addiction, and the use 
and effects of NRT. The exact order of sending the 12 emails was not crucial, thus the 






Twelve participants commented upon the usefulness of weekly support emails.  Of these, 
six participants found the emails useful, although some tips were thought to be more useful 
than others depending upon the interests and knowledge of the participants: 
“Is printing out weekly emails so she can read at her leisure” (SRA021, female 
aged 68 years, reduced, week 1 post-randomisation) 
 
“Was emailed the tips and would look at them – some were good” (SRA024, male 
aged 58 years, reduced, 6 months post-randomisation) 
 
Of six the participants who found the emails useful, one subsequently quit smoking, three 
reduced and two did not change their smoking at six months post-intervention.  
 
Two participants did not find the emails useful: one participant did not read the emails and 
one participant felt they were already familiar with the information supplied in the emails. 
Of the remaining four participants: one participant did not supply a valid email address and 
three participants did not have access to emails or the internet: 
“Didn’t have a private email at the time and didn’t receive the emails at work – 




c)  Support Website 
The support website was designed as a reference tool that provided links to other smoking 





Arthritis NZ, and links to the intervention handouts and weekly emailed smoking cessation 












The address for the website was only available to intervention participants and was referred 
to in each weekly email tip that was sent to the intervention participants, in addition to 
being detailed on the Education Handout. The website was hosted on the University of 
Otago Arthritis theme site. Initially, the support website was intended to be linked to the 
Arthritis NZ website, but this was not possible due to administrative compliance issues. 
The support website was used by the participants but less than anticipated. Access data is 
presented below. 
 
The website received most views on the homepage, and very few participants followed 
through to view associated links or pages. Figure 7-3 illustrates the number of page-views 
were steady throughout the study, averaging at 21.8 views per three-month period (range 
17-27). The mean time spent on each page view was 2.4 minutes per view (range 0.44 to 




































Figure 7-4: Support webpage: mean time on page per view 
 
2. Educational Intervention Component 
The educational handout was designed to explain the links between RA and smoking.  All 
19 in the intervention arm received the education handout, and nine participants provided 
feedback on usefulness of the information. This lack of feedback may be a recall issue as 
many participants did not remember receiving the handout, although several were familiar 
with the information contained in the handout when asked during interviews.  
 
Six participants found the handout on smoking and RA to be useful:  
“Motivated to give up this time especially after reading effects of smoking on RA” 


























“We did discuss this and [participant] found this a major motivating factor for 
giving up smoking” (SRA028, female aged 31 years, quit, week 0 post-
randomisation) 
 
Of the six participants who found this information useful, three subsequently quit smoking 
during the intervention, two participants reduced their daily smoking, and one did not 
change their smoking behaviour.   
 
3. Management of Pain Intervention Component 
The Arthritis NZ booklet ‘Managing your Pain’ was provided to each participant as part of 
the standard intervention pack. Two participants reported that they had no recollection of 
receiving this booklet. None of the other 14 participants specifically referred to the 
usefulness of this booklet per-se in the 3- or 6-month follow-up interviews, although 12 
participants were given support and advice regarding pain management by the Arthritis NZ 
Educators. No participants were referred to their GP to revise their analgesia, suggesting 
the participants felt their pain management was satisfactory. This view was supported by 
the needs assessment in week 0 that indicated the participants felt their RA pain was either 
already controlled by medication or were currently in the process of having their 
medications altered by their RA specialist. 
 
4. Exercise Intervention Components 
This intervention offered a variety of components that were designed to provide 
information about exercises that were appropriate for people with RA, including handouts 





and hydrotherapy classes, and a pedometer was offered to each participant as a motivational 
tool.  
 
Apart from the two handouts in the standard pack given to all intervention participants, the 
other exercise components were accepted by less than half of the participants; the 
pedometer was accepted by 10 participants; the other components were accepted less. Three 
participants were already receiving physiotherapy or other exercise classes to aid with joint 
movement, and seven other participants felt they were active enough with their daily 
activities, including work or sports and hobbies. However, some participants did report they 
had increased the amount of exercise they undertook as a result of the intervention, even if 
this had no effect on their smoking outcomes:  
“Since the intervention, she has been walking a lot more – plus she now has a puppy 
so more motivation to walk – goes walking for about an hour three times a week” 
(SRA009, female aged 47 years, no change, 3 months post-randomisation) 
 
a)  Pedometer 
Five participants commented upon the usefulness of the pedometer: three found the 
pedometer useful, although these participants did not use their pedometer more than a 
couple of times during the intervention period. The other two participants did not find the 
pedometer useful. Of the three participants who found the pedometer useful, two reduced 
their daily smoking and one did not change their smoking.  
“Pedometer good when feeling fit and healthy, but not during flare-ups” (SRA003, 






Of the two participants who did not find the pedometer useful, one did not use it although 
did quit smoking during the study. The other participant had unsuccessfully attempted use 
if their pedometer: 
“Pedometer not useful…firstly, I didn’t know how to use it – no instructions given, 
secondly, batteries were flat – keeps forgetting to get new battery when she goes 
shopping…” (SRA009, female aged 47 years, no change, 3 months post-
randomisation) 
 
b) Exercise Handouts and Booklet 
Two RA specific exercise handouts were provided in the standard intervention pack: hand 
exercises and gentle full-body exercises (Appendices 13b and 13c). Four of the participants 
found these handouts useful and two did not. The hand exercise handout received the most 
positive feedback:  
“Yes, has used the Abbot hand exercises…now able to make a fist, fingers follow 
each other in the right direction and able to write better” (SRA006, female aged 56 
years, reduced, week 1 post-randomisation) 
 
[Hand exercises] “Useful until hands get sore…need to keep moving, good to keep 
fingers moving” (SRA020, male aged 41 years, reduced, 3 months post-
randomisation) 
 






“Doesn’t do the exercises because get enough exercise at work – does lots of 
climbing and walking” (SRA024, male aged 58 years, reduced, 6 months post-
randomisation) 
 
The availability of an Arthritis NZ exercise booklet by order form was discussed with the 
participants and five participants were interested, although none followed through with 
purchasing a copy.  
 
c) Home-based exercise DVD 
Although six participants indicated an interest in the home-based exercise DVD, it was not 
purchased by any of the participants in this intervention. It was not commented upon by 
any participants. 
 
d) Hydrotherapy and Community Exercise Classes handouts 
The community exercise and hydrotherapy classes (Appendices 13e and 13f) were not 
undertaken by any of the participants. Many of the participants had indicated either they 
were not interested in community exercise classes or the classes were not local enough. For 
those participants who were in employment, the timing of the classes during work hours 
was not convenient. The hydrotherapy pool was closed on the 21 February 2013 for 
earthquake repairs so this intervention was unavailable during this study, although some 






5. Coping strategies 
As described in Chapter 5, the smoking triggers diary enabled participants to identify the 
situations when they are most likely to smoke. The diary (Appendix 14) had three columns: 
in the first column the participants recorded the times of the day when they usually smoke 
and what they are doing that causes a craving to smoke, e.g. a cigarette with a cup of coffee 
at 7.00am; the second column records their feelings at the time of smoking, e.g. stressed or 
angry; and in the third column the participant is encouraged to come up with an alternative 
activity to take their mind off smoking during the craving, e.g. go for a walk or have a drink 
of water. 
 
The triggers diary was commented upon by 12 participants; being able to identify what 
triggered their own smoking was found useful by 9/12 of these participants. The triggers 
included emotional triggers such as stress, smoking as a habit related to certain activities, 
or smoking to fill in time and to overcome boredom: 
“Boredom is still an issue with smoking. [Participant] has identified this as a 
trigger to smoking” (SRA031, male aged 38 years, reduced, week 1 post-
randomisation) 
 
“It was emotional triggers that had her reaching for a cigarette” (SRA003, female 
aged 64 years, reduced, week 8 post-randomisation) 
 
As noted in the needs assessment, participants also identified smoking to cope with pain, 
although this was not mentioned in association with the triggers diary. Four of nine 





daily smoking, and the remaining participant had not changed their smoking by the end of 
the 6-month follow up period.  
 
Of the three participants who did not find the diary useful, one did not remember receiving 
the diary and the other two decided not to use it, although both of these participants had 
reduced their daily smoking at the end of the study: 
“Don't remember receiving this” (SRA009, female aged 47 years, no change, 3 
months post-randomisation) 
 
7.4.1.4 Success of Interventions in Facilitation of Smoking Cessation 
The following Figure 7-5 summarises the smoking status at six months post-randomisation 
of the participants who found the various individual intervention components useful. 
 
 








































This figure demonstrates the components that were most useful to the participants who 
accepted and used them were: the Arthritis NZ Educator support and advice, the smoking 
triggers diary, the educational handout, and the email support. These components might 
have had a positive effect facilitating the quitting (primary outcome) or sustained reduction 
in daily smoking at six months (secondary study outcome) of intervention participants. 
 
 
7.4.2 What Other Factors Facilitated or Impeded Smoking Cessation in 
People with RA? 
A potential risk in any study intervention is the possibility of unidentified mediators or 
difficulties being discovered during the analysis phase that may have independently 
facilitated or impeded the study outcomes. The next section begins by examining responses 
from intervention participants to establish whether there were any barriers that were not 
captured by the intervention components that could have affected smoking cessation rates. 
The emphasis of the analysis then changes to include all study participants, to see if there 
were any common facilitators or barriers that could have augmented or impeded smoking 
cessation for all participants in the study. Nicotine replacement therapy, the use of other 
community smoking cessation programmes, and effects from the Canterbury earthquakes 
are considered. 
 
7.4.2.1 Novel Barriers to Smoking Cessation 
Three intervention participants identified other health-related barriers that might have had 





of the study. One of these participants (SRA019) was identified as having multiple novel 
barriers including comorbid ill health and other extreme personal life stresses: 
“Toes removed in Jan 2014…not in a good mental state [death of a family 
member]…house flooded” (SRA019, female aged 61 years, no change) 
 
A further two participants were experiencing ill-health from comorbid conditions that had 
a larger effect on their daily lives other than RA:  
“[Participant] has had a very difficult six weeks, and is unable to even hold a cup 
of tea or a pen” (SRA003, female aged 64 years, reduced) 
 
7.4.2.2 Common Study Factors Facilitating or Impeding Quitting  
1. Nicotine Replacement Therapy 
Nicotine replacement therapy was offered to all participants as ‘usual care’ regardless of 
their randomisation status. The usefulness of NRT was commented on by 19/19 
intervention and 18/19 control group participants at various time-points during the study.  
In total NRT was used by 14 intervention and 15 control group participants, equating to 







Table 7-2: Use of NRT in the pilot study* 
Use of NRT Intervention Control 
Yes 14 15 
No 5 3 
Unknown 0 1 
Quit using NRT 4 4 
Non-quit using NRT 10 11 
*This table differs from Table 6-7 because the NRT use by the three participants who 
were withdrew from follow-up had been recorded by the Educators 
 
 
Although the study participants had varying opinions regarding NRT, the experiences 
between the intervention and control groups were similar; the patches were found to be 
more useful initially; the gum and/or lozenges were used long-term for whenever they felt 
a craving:  
“[Participant] hasn’t had a cigarette since starting the patches. Both herself and 
her partner have given up smoking” (SRA028, female aged 31 years, quit, 
intervention arm) 
 
“Still using the gum quite a bit; Initially, I used the patches for 2 months until I got 
a reaction to the adhesive, then I stopped” (SRA037, female aged 43 years, quit, 
intervention arm) 
 
“Found the patches were great…didn’t envisage that the patches would have 
worked so well…will still use patches when completely given up for a while just to 







Others mentioned a dislike for the gum and lozenges: 
“…gum makes me dry retch”, tried patches but stopped, cut down smoking, parent 
in hospital, cold & cranky & sore [winter]” (SRA020, male aged 41 years, reduced, 
intervention arm) 
 
“Used the gum and lozenges; Lozenges tasted like cardboard…tried patches and 
gave up smoking for 4 days but found they didn’t work” (SRA001, male aged 63 
years, no change, control arm) 
 
The participants who did not find the NRT useful mentioned side effects to the patches 
such as skin sensitivity and sleep disturbances: 
“…got nightmares from using patches, and when I took them off at night, I stopped 
getting any effect from them so I stopped using them” (SRA004, male aged 56 years, 
quit, intervention arm) 
 
One participant, having initially tried to quit using NRT and had side effects, had been 
prescribed varenicline (Champix) by his GP. As previously described, participants were 
permitted to use other smoking cessation aids in this study. Unfortunately, varenicline also 
caused side effects for this particular participant: 
“Tried using Champix for 3 and half weeks…couldn’t eat and another side effect 
was developing a great fear of water…had to have time off work” (SRA018, male 
aged 58 years, reduced, control arm) 
 
Not filling their NRT prescriptions was commonly mentioned (8/37 participants). Some 





“NRT script not filled yet as [participant] not ready to give up smoking” (SRA009, 
female aged 47 years, no change, intervention arm) 
 
“Not interested in using NRT…don’t like it…doesn’t want more medication” 
(SRA033, female aged 65 years, no change, intervention arm) 
 
Overall, there was no difference between the intervention and control group participants 
with regard to the use and success of NRT in the study. However, it appeared that those 
who were more successful in quitting or reducing their smoking rate in either study arm 
had used NRT during the study (Figure 7-6). Nearly all of those who quit during the study 
had used NRT (8/9), as had 13/16 participants who reduced their smoking rate. Not using 
NRT or not finding it useful was more common for those who showed no change in their 
smoking status during the trial. 
 
 










































2. Use of Other Community Smoking Cessation Programmes 
One intervention participant and two control group participants used Quitline NZ services 
during the study period. The intervention participant who used Quitline as an adjunct to 
their intervention did quit smoking but the two control group participants were still smoking 
at the end of the study. One further participant joined a smoking cessation community group 
near the time of the 6-month follow-up; subsequently this participant quit smoking, but this 
did not occur during the study follow-up period. Compared to the intervention participants, 
slightly more control group participants utilised other smoking cessation services (two in 
control arm compared to one in intervention arm), but these numbers were too low to 
suggest a difference.   
 
3. Canterbury Earthquakes 
The Canterbury earthquakes during 2011-2012 and the thousands of aftershocks [359] were 
mentioned by three intervention participants and one control group participant as having a 
continuing and major effect on their stress levels, and consequently affecting their ability 
to contemplate quitting smoking. One intervention participant had housing issues after the 
earthquake with the effect of seeking alternative accommodation proving very stressful to 
him personally and for his family, while his house was repaired. All three of these 
participants did not change their smoking status during the study:  
“Smoking because land/house shakes because of road-works/repairs – feel nervous 
– repairs for at least one month longer” (SRA010, female aged 77 years, no change, 






“…the earthquakes and the stress around that time was her trigger to take up 
smoking again – not being able to answer questions to [her] children about the 
earthquakes and whether they would happen again/for how long..” (SRA009, 
female aged 47 years, no change, intervention arm)  
 
Only one control group participant mentioned the stressful effect of the earthquakes on 
their well-being during the study, mainly due to “lots of niggles about repair work” to their 
house. This participant was initially reticent about taking part in the study and had delayed 
their randomisation until their house repairs had been completed, but subsequently was able 
to quit smoking between the 3-month and 6-month follow-up interview. This delayed entry 
into the study may have had a positive effect on the outcome for this participant as their 
major life-stress factor had been reduced due to their house repairs. The effects from the 
earthquakes were not mentioned by any other participants.  
 
In summary, three intervention participants had other health-related conditions that may 
have impeded their ability to contemplate quitting smoking. The common study factors 
affected each study group equally: NRT facilitated both the primary outcome (quitting) and 
the secondary outcome (reducing smoking rates); too few participants used other smoking 
cessation programmes to make a decision regarding facilitation of quitting. The 
earthquakes were identified by three participants as impacting on their stress levels and 






7.4.3 Participant Attitudes to their Smoking at Study Completion 
7.4.3.1 Intervention Participants 
The 16 intervention participants who completed the six month follow-up were asked how 
they felt about their smoking status outcomes. The major theme evident was the participants 
had become more conscious of their smoking and 14/16 participants had developed coping 
strategies to control their smoking even if they had not quit. These coping strategies 
included controlling, cutting-down and delaying their smoking. This was particularly 
evident with the seven participants who had reduced their daily smoking rates during the 
study:  
“Goes and does something else when she has the urge to smoke… goes for a walk, 
cleans out a drawer, tidy something up” (SRA016, female aged 47 years, reduced) 
 
“Uses a rubber band around wrist and ‘pings’ it” (SRA027, male aged 71 years, 
reduced) 
 
“Rolls 5 cigarettes a day, but breaks off the top third of each one before smoking” 
(SRA24, male aged 58 years, reduced) 
 
Financial benefits of quitting or cutting down were important to three participants. Health 
benefits were mentioned by seven participants, although these were focused on overall 
health, rather than their RA specifically: 
“Has noticed [her] complexion has improved and taste improved” (SRA016, 






“Starting to exercise more now…feels healthier and can inhale deeper…has been 
told that the whites in her eyes are brighter” (SRA028, female aged 31 years, quit) 
 
Four participants were already planning their next quit attempt: 
“Going to try Champix…has filled prescription already and is ready to make 
another attempt in the next month” (SRA016, female aged 47 years, reduced) 
 
“Going to try and quit smoking this weekend” (SRA024, male aged 58 years, 
reduced) 
 
The five participants who quit smoking during the study felt very positive about their 
quitting, and strong motivation to quit was the overarching theme evident: 
 “Was very motivated to quit; found it easy to quit” (SRA023, female aged 62 years, 
quit) 
 
“Empowering to be able to give up smoking” (SRA037, female aged 43 years, quit) 
 
However, being in the right “headspace” to quit or having a desire to quit was a dominant 
theme for eight of 14 who did not quit: 
“Still smoking and not able to stop at the moment…one day I will, when the time is 
right” (SRA019, female aged 61 years, no change) 
 






Additional life stresses in addition to their RA was particularly relevant for some of these 
participants, and giving up smoking at this time was seen as a considerable additional stress: 
“Currently, is sorting out other issues rather than quitting smoking…can only do 
one thing at a time, she has given up drinking alcohol, which she thought was more 
harmful to her family, whereas smoking is only harmful to her” (SRA009, female 
aged 47 years, no change) 
 
“Will look at quitting smoking when it is a less stressful time at work” (SRA031, 
male aged 38, reduced) 
 
One participant, who was withdrew from follow-up at 6 months, admitted he did not want 
to give up smoking (when interviewed at three months), although he did acknowledge that 
he “should” give up smoking:  
 “Was trying to give up…particularly with heart issue last year…had a lot of 
enthusiasm, but now don’t want to give up smoking” (SRA011, male aged 51 years, 
no change, withdrew from follow-up) 
7.4.3.2 Control Group Participants 
The 19 control group participants were also asked how they felt about their smoking status 
at the end of the study. Their comments were positive and reflected the progress they felt 
they had made independently including: controlling, cutting down, and delaying their 
smoking (10 participants); financial savings (three participants); health benefits (10 
participants); and their high motivation to attempt another quit attempt (eight participants). 





feel she had made any changes, and her smoking is still the “first thing she does at the start 
of the day”. 
 
When commenting upon controlling their smoking, the main themes identified by 10 
participants included: they were smoking later in the day; smoking less at night time; and 
not taking cigarettes out with them to social occasions. Similar to the intervention 
participants, the overarching theme was they had gained more power over when they chose 
to smoke, even if they had not changed their amount of daily smoking during the study:  
“Recently had a weekend away and hardly smoked at all – can leave it for several 
hours” (SRA013, female aged 76 years, no change) 
 
“…down from 25 a day to 3 a day: Smokes one in morning, one at lunch time, and 
one mid-afternoon” (SRA018, male aged 58 years, reduced) 
 
Health benefits were mentioned by 10 control group participants where they commented 
they felt better physically and/or mentally at the end of the study period. Although this was 
particularly evident with the four participants who quit during the study, it was also 
apparent from many of the other participants as well. Weight gain was mentioned positively 
by one participant as they had lost weight while on RA medications: 
“Is eating better and more – has put on 5 kg, which is a good thing as he was losing 
weight – he had lost 13kg from RA medications” (SRA018, male aged 58 years, 
reduced) 
 
Improved general health (physical and mental) was mentioned by participants, but again, 





“He feels better and finds his arthritis is not as bad – joints still quite stiff but not 
as bad as it was prior to giving up smoking” (SRA002, male aged 48 years, quit) 
 
“Big change: for a couple of weeks at the beginning, was coughing up phlegm from 
lungs, but not coughing now” (SRA008, male aged 62 years, quit) 
 
“Feel a lot better – not physically but mentally” (SRA017, female aged 47 years, 
no change) 
 
Generally, similar to the intervention participants, the control group participants were quite 
motivated to try another quit attempt:  
“Will shortly get hold of one of these electronic cigarettes by buying on-line and 
will give up tobacco slowly” (SRA026, male aged 40 years, no change) 
 
“Expects to be completely off smoking in a couple of weeks” (SRA029, male aged 
65 years, reduced) 
 
Only one participant disclosed they did not put any effort into the study: 
“Didn’t really put any effort into the trial but always thinking about giving up” 
(SRA017, male aged 48 years, no change) 
 
Although three participants found positive financial benefits from smoking less or quitting, 
generally this was not reported as a motivating factor in this study: 
“…have an amount of money each week to spend on entertainment and smoking 





did recently, and have over $500 still in the account…money not spent on 
cigarettes” (SRA002, male aged 48 years, quit) 
 
Eleven of 19 control group participants had independently developed their own coping 
strategies to in an attempt to regulate their daily smoking. Seven of these 11 participants 
developed strategies focused on substituting their smoking with other activities including 
psychological strategies: 
“Devised a mental picture of how to give up smoking” (SRA002, male aged 48 
years, quit) 
 
“Never worried about smoking before entering into the trial, but now thinks about 
it more” (SRA007, male aged 65 years, reduced)   
 
“…has one packet of cigarettes locked away in the boot of his car so he can’t get 
them, but doesn’t stress as he knows he has some” (SRA018, male aged 58 years, 
reduced) 
 
Nine of 11 participants used physical activities to take their mind off smoking, including 
swimming, household chores, walking dogs, hobbies, and drinking water: 
“If she needs a cigarette between the hour, she will put it off by doing other 
activities such as dishes or take the dog for a walk” (SRA034, female aged 65 years, 
no change) 
 
“Plays soccer…is a process of keeping herself distracted” (SRA015, female aged 






“Try to keep busy – the more she does, the less she smokes…keep moving, which is 
important with arthritis” (SRA005, female aged 30 years, no change) 
 
One participant mentioned they were spending more time with family members since they 
had reduced their smoking, and four participants controlled the places they let themselves 
smoke:  
“…will only smoke pipes at home outside on the porch – if he goes out, he doesn’t 
take pipe out with him” (SRA038, male aged 73 years, reduced) 
 
“Getting out in his boat and pottering around – smoke-free boat, can go out on the 
boat for long days and not smoke” (SRA018, male aged 58 years, reduced) 
 
Similar to the intervention participants, stress was impeding their ability to quit for seven 
of 13 control group participants:  
“Trying to deal with a lot at once at the moment so not ready” (SRA005, no change) 
 
“Waiting to get normality back into life before giving up” (SRA007, male, reduced) 
 
“Stress factor is the main reason he continues to smoke” (SRA029, reduced) 
 
In summary, this section has presented and examined the study participants’ attitudes to 
their smoking status at the end of the study.  Interestingly, their attitudes and outcomes 
were very similar in the intervention and control arms, and the control group participants 





behaviours. Their outcomes demonstrated that study participants were either very 
motivated to give up during the study or else they felt they did not have the desire to quit 
at that time and this was regardless to receiving extra support from the intervention. 
 
7.5 Discussion 
This chapter provided an in depth exploration and analysis of the qualitative secondary 
outcomes from the pilot study and provided detailed information concerning the 
experiences of the study participants. The aim of the research was to evaluate which aspects 
of the intervention were most useful to the study participants. To achieve this aim, feedback 
was sought from participants at pre-determined time points, namely the four intervention 
contacts with the Arthritis NZ Educator (intervention participants), and the two follow-up 
interviews at three and six months with the researcher (all study participants).  
 
The use of a deductive thematic analysis method revealed the tailored intervention 
components had addressed the five previously identified barriers to smoking cessation in 
RA. Analysis of the individual needs assessments established each participant had 
identified their concerns with RA, which as expected, varied considerably between 
individuals. However, as a trend, the participants in this study recognised they used 
smoking to cope with their RA, particularly as a diversion to RA associated pain. Pain and 
swelling in joints was a predominate concern of the participants as a group, which 
ultimately affected their day-to-day activities by restricting movement and mobility. Some 
participants experienced difficulties with low mood, sleep disturbances, fatigue and stress 





the relationships between RA and smoking, which was observed during the information 
and consent process of the study. The only novel barriers apparent from using an inductive 
thematic analysis method were comorbid ill health and extreme personal life stresses. These 
barriers only affected three participants but may have impeded their smoking cessation 
attempts during the study timeframe. 
 
The range of intervention components used in this study had been selected by a steering 
group of stakeholders including researchers, rheumatologists, and arthritis service 
providers (Chapter 5), with modules created to address the previously identified barriers to 
smoking cessation in RA (Chapter 4). Some of the intervention components were provided 
as a standard intervention (Table 7-1), while others were optional. There was only one 
component not utilised in the intervention, which was the option of referral to the 
participant’s GP to revise their analgesia; this was not unexpected since participants had 
identified they felt their pain management was either under control or they were currently 
having their pain medications altered.  
 
The most accepted and useful intervention component was the individually tailored support 
and advice from the Arthritis NZ Educators. This component included support and advice 
on managing pain, medications, fatigue, disturbed sleep, and how to pace activities to 
manage RA. Overall, the Educators support was a key component and was fundamental to 
this intervention. The participants particularly enjoyed the one-to-one support from the 
Educators and appreciated this aspect of the study. This finding was corroborated using 
supplementary information from the Educator’s exit interviews (Appendix 22) [360], 






The next most accepted and useful intervention components were predominately focused 
on facilitating smoking cessation, and included the use of a smoking triggers diary and 
smoking cessation advice that was emailed weekly over the period of 12 weeks. Both the 
triggers diary and the email tips were focused on participants recognising their triggers for 
smoking and providing alternative self-management strategies that may aid smoking 
cessation. Participants needed to have access to the internet to receive the weekly emails, 
and for some participants, this was not possible.  
 
The educational handout that explained the links between smoking and RA was particularly 
useful to some intervention participants principally, with three of the five quitters 
specifically mentioning being motivated to quit from learning this information. Other 
participants may have believed the information was given too late for them, as they already 
had developed RA. This type of resistance was noted by the Educators [360]. A study in 
2013 evaluated patient education to address CVD aspects in RA and demonstrated 
educating patients about their personal risk did significantly increase their knowledge about 
disease related factors long-term [211]. However, in that study, smoking behaviours were 
recognised as more difficult to change than other behaviours such as increasing exercise 
and eating a healthy diet [211]. Difficulty in changing smoking behaviours is most likely 
related to the physiologically addictive behaviour of nicotine [16], in addition to the social 
and emotional aspects of smoking where smokers often habitually reach for cigarettes when 
bored, angry, or stressed [31]. 
 
As has been stated earlier in this thesis (Chapter 4), physical activity is not only beneficial 
in RA for health reasons [303], there is also good evidence that short bouts of exercise can 





barriers to physical activity compared to the general population due to perceptions that 
exercise makes their arthritis worse with respect to pain and fatigue. This issue has also 
been explored in a review of literature on perceived barriers, facilitators and benefits of 
physical activity in RA [361]. That review suggested there were no differences in barriers 
between those who exercise and those who do not, but differences in how people with RA 
negotiate and overcome those barriers were found to influence exercise behaviour [361]. 
Individuals with a higher self-efficacy were found to be more physically active and have a 
higher attendance at exercise programmes regardless of their barriers [361]. Education 
about exercise programmes in RA is recognised as important but a RCT exploring different 
ways of providing educational information found changing RA patient’s intention to 
increase their physical activity was more easily achieved than changing their actual 
behaviours [211]. However, a recent study has found increased physical activity on high-
fatigue days may be beneficial to people with RA’ mood in everyday life [362]. Thus, 
physical activity and exercise programmes may be more beneficial if they promote the 
development of coping strategies to overcome perceived barriers to exercise in addition to 
providing physical activity opportunities [361]. 
 
In the current study, the intervention participants did not find the exercise components of 
the intervention useful. This may have been due to the extra monetary cost for some of the 
components such as the exercise DVD, the booklet, and the community classes, or they had 
been simply overlooked. It could also have been as a result of the high number of 
intervention participants in full-time or part-time employment (69%) because the classes 
were held during traditional work hours. It is also possible the participants were not keen 
on group classes or were managing to meet their exercise needs by other means. The 





occupational therapy from other health service providers, so that need had already been 
met. Providing exercise options at times more suited to those who work may have been 
more helpful to the participants. The pedometer was initially found appealing by some of 
the participants, but it was not subsequently used for any length of time. However, other 
participants mentioned that they had taken up other forms of physical activity such as 
swimming, walking their dog, and going to the gym as a result of being motivated from 
taking part in the study intervention. Physical employment also provided adequate physical 
activity for some participants. Thus, the participants who increased their physical activity 
may have had a higher self-efficacy with regard to changing their exercise behaviours, 
rather than the exercises being inconvenient. 
 
In summary, within the intervention arm, the Educator support and advice were identified 
as the most accepted and useful to the intervention participants in this study. In addition, 
there were common factors in the study had either facilitated or impeded smoking cessation 
for all the study participants in both study arms. These factors included use of NRT, the use 
of other community smoking cessation programmes, and the stress from the Canterbury 
earthquakes and the resulting aftershocks. The next section explores these issues, as they 
may provide reasons as to why the study outcomes of quitting and reducing smoking were 
similar for both arms of the study. 
 
Nicotine replacement therapy acts by replacing the nicotine that have would be provided 
by smoking, and research has demonstrated the use of NRT can increase quitting rates by 
50-70% [205]. The intervention and control group participants had similar experiences of 
NRT that was offered as part of the usual care ‘ABC pathway’. Nearly all of the study 





attempt to use NRT during the study. The participants who quit or reduced their smoking 
rate during the study had done so with the assistance of NRT. Therefore, it was a successful 
shared treatment facilitator for smoking cessation in this study.  
 
The use of other community smoking cessation programmes was not widespread by study 
participants. The use of other programmes was encouraged as part of the usual care ‘ABC 
pathway’ and all of the participants received handouts with other programme contact 
details, including Quitline-NZ and Aukati KaiPaipa. Therefore, there was insufficient 
information from this study to comment upon their usefulness, although they might have 
had a positive influence on quitting for two participants, one who quit smoking during the 
study and one who quit after the study ended.  
 
The Canterbury earthquakes were a specific and substantial barrier for some participants, 
although these participants were in a minority in the study as a whole. One participant 
delaying entry into the study that was negatively affected by the earthquakes exemplifies 
how extreme personal life stressors can affect smoking cessation outcomes, because this 
participant was able to quit smoking once that stress had been resolved. Local research that 
studied changes in smoking prevalence following the Canterbury earthquakes interviewed 
1,001 participants in a high flow pedestrian area in Christchurch. That study reported one 
quarter of ex-smokers had resumed smoking and one third of smokers had increased their 
smoking rate as a result of their stress from the earthquakes [235]. This relapsing was found 
to be consistent with other studies where stress was found to be a trigger for increased 






The earthquakes also had an effect on the study regarding the availability of the 
hydrotherapy exercise component as it was closed for repairs for nearly all of the 
intervention timeframe. This component may have been popular with the intervention 
participants if it was available; an opinion that was confirmed by the Educators in their 
exit-interviews [360]. Hydrotherapy has been found to useful for reducing pain and 
improving the health status of people with RA in the short-term [365] so this was a missed 
opportunity for the quarter of participants who indicated a desire to use this component. 
 
The participants’ attitudes to smoking and strategies for quitting were similar in both the 
intervention and control group participants. The similarities in their quitting strategies 
could have explained the lack of difference between the study outcomes. Whilst the 
intervention participants were given extra support and advice to assist with quit smoking 
attempts, the control group participants independently developed their own strategies, 
which were often similar, particularly with respect to their attempts to gain control of their 
smoking. Overall, participants were either very motivated to give up during the study or 
else they felt they lacked, or did not have, the desire to quit at that time as shown by similar 
comments from participants in both study arms. Therefore, there was an element of the 
participants needing to be ready and determined to quit smoking. The Arthritis NZ 
Educators [360] observed some intervention participants were ready to quit (based upon 
Prochaska’s ‘stages of change’ model of smoking cessation [366]), so made sure they 
provided support that included self-management skills. The Educators also recognised 
other participants were resistant to quitting smoking and surmised this was due to their 






The findings regarding motivations to quit smoking in this study fit well with the findings 
from a small-scale qualitative research project undertaken by the Quit Group in 2005 [367]. 
That study explored quitting motivations and barriers in 16 smokers with the goal of 
providing information for future media and communication smoking cessation campaigns 
in NZ [367]. Smokers who were assessed to be in contemplation and preparation stages (as 
defined in the ‘stages of change’ theory) [226] were interviewed in depth to ascertain their 
motivations to quit. A ‘tipping point’ was argued where smokers are motivated to quit 
smoking when the benefits of smoking are outweighed by the benefits of quitting smoking. 
Their findings suggested that every individual has a unique ‘tipping point’, which will 
change over time and can occur at any time [367]. They suggested there is a residual belief 
in smokers that willpower is the key to quitting and there is still a strong perception amongst 




In conclusion, this chapter provided an in depth exploration of the qualitative secondary 
outcomes of the pilot study by analysing the detailed information concerning the 
experiences of the study participants. The analysis demonstrated the support and advice 
from the Educators was the key component in the intervention that was most valued by the 
participants. Components that successfully contributed to smoking cessation included a 
smoking triggers diary and emailed generic smoking cessation advice, both commented on 
by participants as being helpful. There were common factors to both intervention and 





NRT, the use of other community smoking cessation programmes, and the stress from the 
Canterbury earthquakes. Control participants had independently developed their own 








8 GENERAL DISCUSSION  
 
8.1 Overview of Thesis Research Findings 
The purpose of this thesis was to identify specific barriers to smoking cessation in people 
with RA and then develop an intervention to assist smokers with RA to overcome these 
barriers. The literature review identified a significant body of research demonstrating a link 
between smoking and the onset of RA. There is also increasing evidence to suggest that 
smoking impacts outcomes in RA both in terms of poorer responses to treatment, and 
increasing risk of comorbid conditions such as CVD, COPD and osteoporosis. Smoking 
cessation is one of the ten EULAR evidence-based recommendations for managing the 
CVD risk in people with RA [48]. Smoking cessation is also a recommendation of the ACR 
guidelines for the prevention of glucocorticoid-induced osteoporosis because the fracture 
risk in people with RA may be increased in current smokers [49]. 
 
Thus, smoking is a key risk factor and contributor to morbidity and mortality in people with 
RA. Although smoking prevalence is higher in people with RA compared to the general 
population [137-140], best practice, evidence-based, smoking cessation interventions have 
traditionally been designed for smokers without long-term medical conditions. However, 
there has been very little research on smoking cessation and RA and to date only one RCT 
of brief smoking cessation advice for rheumatology outpatients has been published [9]. 
Therefore, the literature review confirmed there was a need for a targeted smoking 






In the first phase of study, five disease-related barriers to smoking cessation in RA were 
identified: 1) lack of support; 2) lack of knowledge of the relationship between smoking 
and RA; 3) RA associated pain; 4) difficulty with exercise, and 5) smoking was used to 
cope with the frustrations of living with RA. Overall, this first phase established that people 
with RA have particular physical limitations and disease-associated factors that make 
quitting smoking challenging. Based on these findings a novel tailored smoking cessation 
intervention targeted for people with RA was developed in collaboration with Arthritis NZ.  
 
In the final phase a pilot study demonstrated no difference in quit rates between those who 
received the novel targeted smoking cessation intervention in conjunction with ‘ABC 
pathway’ brief advice and NRT and those who only received the ABC. Despite this lack of 
benefit the intervention was well received. The number and timing of counselling sessions 
received, the way support was offered (by telephone or face to face), the location where 
sessions took place, the speed of progress in quitting or reducing smoking, and additional 
tailored support (e.g. education about smoking and RA, exercise opportunities, coping 
strategies, pain management, support for smoking cessation) all contributed to the delivery 
of an empowering and client-centred intervention that was valued by the participants. 
Interestingly, the control group participants had independently developed their own 
strategies to control their smoking. These strategies were similar to the intervention 
participants who had received intensive support from the Educators.  
 
Of particular importance it is apparent from this research that the current standard of care 
for smoking cessation, the ‘ABC pathway’, which includes NRT and brief advice is 






8.2 Discussion of Findings 
For healthcare providers including individual practitioners and organisations such as New 
Zealand’s district health boards, this research demonstrates that the best practice, evidence-
based, smoking cessation pharmacological aids, such as NRT and brief behavioural advice 
as included in the ‘ABC pathway’ are an effective tool for smoking cessation in RA. It is 
most likely to be applicable to other chronic diseases, particularly if specific disease-related 
information regarding the relationship between an individual’s disease and smoking is 
offered in parallel. Whilst most of the general public is aware of the connections between 
smoking and lung cancer [368, 369], there are many other chronic diseases that are directly 
affected by smoking such as diabetes [370, 371], MS [372, 373] and Crohn’s disease [374, 
375] in addition to RA. The Cochrane Collaboration have concluded that although the 
benefit of adding behavioural to pharmacological support is small, it is a statistically and 
clinically significant outcome, particularly for interventions that have four or more support 
contacts. However, increasing the number and amount of behavioural and pharmacological 
interventions does not result in equivalent increases in abstinence [321].  
 
The ‘Stages of Change’ component of the TTM has been used extensively in smoking 
cessation. The basic principle of the TTM, as outlined by Prochaska and colleagues, is that 
smokers are in five different stages of readiness to quit, and smoking cessation 
interventions should be individualised and personalised based on the stage of readiness a 
smoker has to quitting [326]. But there is juxtaposition between the Cochrane Collaboration 
reviews and the viewpoint of Prochaska. The Cochrane reviews are focused on efficacy in 
clinical trials with no consideration for the impact on the overall population smoking rates. 





populations [376]. Impact is defined as the participation rate multiplied by efficacy. Thus 
if a smoking cessation intervention has a 30% abstinence rate but only 5% participation, it 
has an impact of 1.5%, whereas an alternative intervention that generates 20% abstinence 
but has 75% participation has a much higher impact of 15%. The tenet of this argument is 
that because less than 8% of daily smokers in the USA are in the preparation stage and 
prepared to quit within the next month, evidence-based smoking cessation programmes are 
not having an impact on the other 92% of the smoking population [376].  
 
The difference of viewpoints between the Cochrane reviews and Prochaska as discussed 
above is interesting. Increasing smoking cessation rates using successful interventions is 
the primary outcome goal of any smoking cessation programme. However, population 
smoking cessation rates have not increased measurably in the USA in any population group 
since the early 1990’s although tobacco control policies and smoking cessation 
programmes have increased dramatically [376]. Research from the USA based on 
responses from 39,000 smokers has shown that although varenicline is very effective in 
smoking cessation, it’s use has merely displaced NRT and bupropion [377]. Quitting rates 
in the USA have remained relatively stable with only a slight increase from 4.5% in 2003 
to 4.7% in 2010-11 [377]. Quitters were defined as the amount of smokers who had quit 
for at least three months over the last 12 months [377]. Thus, there appears to be a limit to 
increased quitting rates from using traditional smoking cessation treatments, and a more 
novel approach may be required in the future to increase quitting rates. Hence, it has been 
suggested that more effective smoking programmes are more likely to emerge from new 






In NZ, the quitting smoking rates as reported in the 2012/3 NZ Health Survey had increased 
from 8% (2006/7) to 11% (2012/3) in the general population [378], although those quit 
rates had remained steady from 2006 to 2009 [379]. Successful quitters were defined as 
having quit smoking between a month and a year from when they participated in the health 
survey and remained quit [378]. Nicotine replacement therapy was used by 25% of quitters 
in 2012/3, which was an increase from 20%, in 2009 [378, 379]. Varenicline and bupropion 
were used by 18% of quitters in 2012/13 [378], but bupropion was used rarely in 2006 
(<7%) and varenicline was not yet available [377, 380]. The ‘ABC pathway’ was reported 
to have been offered to 48% of current smokers from their GP during 2012/13 [378] and 
was not available in 2006, although some form of quit advice was received by 26% of 
smokers from their GP [380]. While it is difficult to compare the NZ quit rates with the 
USA quit rates due to differences in time frames and outcome measurements, the USA has 
seen a decrease in smoking prevalence from a steady 21% during 2004-2009 to 17.8% in 
2013 [381]. Therefore, the emerging emphasis of targeted smoking cessation programmes, 
as evident by recent reviews from the Cochrane Tobacco Addiction Group may be having 
an impact on the USA quit rates 2009 onwards [382]. 
 
When evaluating healthcare research it is prudent to go beyond purely reporting results and 
to take a step back to consider the rigour of the research in ways that fit the research 
methodologies that were used [258, 383]. The lack of observed differences in the quitting 
rates and reduction in daily smoking rates in this pilot study were surprising given the level 
of intensity of the designed intervention and the high level acceptability of the intervention 






A pilot study can give valuable insights into the efficacy of a behavioural or 
pharmacological intervention even if they cannot provide definitive support for specific 
therapeutic claims [260]; hence this method was chosen to address the research problem in 
this thesis. However, the small sample sizes typically seen in clinical pilot studies (and 38 
people with RA in this study specifically) mean the likelihood of observing statistically 
significant differences is low [260]. The effect size of a study is an important driver in 
clinical decision making regardless of whether the difference is statistically significant or 
not [357]. The NNT for the pilot study was 20, which shows the small effect size of the 
intervention. Another notion is they could have independently been ready to quit smoking 
before they entered the study, meaning the study was opportune in timing. The RR was 
1.25 (95% CI 0.40-3.95) giving a small positive non-significant effect size of 25%, which 
is interpreted as the probability of quitting smoking was one quarter larger from the 
intervention (ABC+) compared to the control treatment (ABC). This result was similar to 
the Cochrane systematic review of 38 RCTs (15,506 participants) that added behavioural 
interventions as adjuncts to pharmacotherapy (principally NRT) finding a small but 
statistically significant benefit from more intensive support (RR 1.16, 95% CI 1.09-1.24) 
[321]. Thus, the effect from the intervention in the pilot study fit well with other smoking 
cessation clinical trials in the general population with similar intervention structure and 
content.  
 
Effect sizes can be used to calculate sample sizes required for future studies [384]. A sample 
size calculation for a full RCT using the pilot study primary smoking cessation outcomes 
gives an indication of the number of participants required to show a statistically significant 
difference between the intervention and the control arms of the study. The sample size 





intervention using 95% power would be 3472 participants (1736 participants per study 
arm). If a lower power was desirable, then a somewhat smaller sample would be required: 
e.g. 80% power would require a sample size of 2100 participants, and 90% power would 
require 2800. Overall, the requirement for participant numbers for a full RCT is high, 
reflecting the small effect that was detected between the intervention and control groups in 
the pilot study. As discussed, this is most likely due to the use of the highly efficacious 
NRT in both arms of the study. Given the costs of such a large study, undertaking a full 
RCT would not be financially judicious at the public health level given the high success 
and efficacy of the ‘ABC pathway’ and the small effect size of the intervention. 
 
Biases in behavioural intervention studies can occur from participation effects with 
participants having extra motivation for quitting regardless of their study allocation [385]. 
As outlined in Chapter 6, research has suggested that it is likely that individuals who 
volunteer to participate in a research study may be more motivated to change than those 
who do not volunteer [385]. This suggests the pilot study findings may only be 
generalisable to highly motivated individuals and not to individuals that do not have any 
motivation to change [385]. This potential for this type of bias is virtually ubiquitous in 
clinical outcome research and there has been no agreed upon solution for this bias [385]. 
The participants in the study in this research were volunteers who were interested in either 
helping identify barriers to quitting smoking in RA, or were people with RA who smoked 
who wanted to attempt to quit. The control group participants may have been highly 
motivated to quit because of these reasons. Those who chose not to participate may not 






Study design alone is not an adequate marker of the evidence of quality in a public health 
intervention evaluation [383]. Public health interventions, such as the novel smoking 
cessation intervention described in this pilot study, tend to be complex, pragmatic, and 
context dependent which make it difficult to use traditional evaluation methods [386]. The 
smoking cessation intervention for people with RA that was developed for this pilot study 
was an example of a complex intervention due to the interacting components within the 
experimental and control group interventions (smoking cessation advice); the difficulty of 
the behaviour required by those receiving the intervention and controls (smoking cessation 
in both groups); and the flexibility or tailoring of the intervention that was required. 
Interpretation of the final outcome result should be applied in this context. 
 
The evidence of effectiveness for complex interventions must be comprehensive enough to 
encompass the appropriate level of complexity [383]. It may not be feasible to judge the 
quality of a complex intervention using the well-established criteria designed to appraise 
large clinical RCTs because there are many aspects of evidence that will not covered [383]. 
For example: it may not be possible to distinguish between the reliability of the evaluation 
process in detecting the success or failure of the intervention and the success or failure of 
the intervention itself [383]. This is because proper interpretation of evidence depends upon 
descriptive information on the intervention and its context being available, so that the 
transferability of the evidence can be determined [383]. This is currently an area of 
contention. The development of clearly defined standards for evidence around population-
level interventions, including the need for contextual information, is a current area of 
research for several stakeholders in the evaluation and systematic review fields, including 
the Cochrane Collaboration, and the Centers for Disease Control and Prevention’s 





the best way to determine a causal relationship between an intervention and its predefined 
outcomes [383]. Overall, it is important to recognise in a pilot study that there are many 
issues surrounding rigour of the result, and the outcome from the study for this pilot study 
could have been affected from any one of these, or a combination.  
 
8.2.1 Strengths and Limitations  
The strengths of this research in this thesis included the key role of the Arthritis NZ 
Educators, and the support network from Arthritis NZ. The Educators are experienced in 
providing support and advice to people with RA, and the pilot study intervention was 
designed to fit within their existing service delivery structure, and was based where possible 
upon existing resources and information from Arthritis NZ. The wide range of intervention 
components available and offered to participants was a key strength of intervention because 
of the ability to tailor to each participant, whilst providing facilitators for both the 
management of RA and smoking cessation. The limitations of the thesis study are 
encompassed in aspects of rigour of the exploratory research and pilot study phases as 
discussed in Chapters 4 and 6. 
 
8.3 Implications for Future Research 
This thesis has important implications for future research on the treatment for smoking 
cessation in people with RA. In particular, the findings highlight the strategies that can be 
focused on for improving smoking cessation rates in people with RA. Promoting health 





improving health status whilst reducing health care costs at the individual and population 
level [387].  
 
There is the possibility that the educational component from the intervention had a larger 
effect than was recognised, therefore disease-related information given in addition to brief 
advice may be beneficial. Thus, for future studies, re-piloting the smoking intervention 
using the key education component should be undertaken. There is considerable evidence 
demonstrating education the causal link with health behaviours [351]. An Organisation for 
Economic Co-operation and Development (OECD) symposium in 2006 examined the 
effects of education on health and reported there was robust evidence that confirmed 
appropriately designed and delivered education interventions have the potential to change 
both health beliefs and behaviours, including substantial evidence that education can 
change smoking behaviours [351]. The educational handout in the pilot study was well 
received by the intervention participants and may have aided in their smoking cessation 
attempts. It is a simple aid that could be used in clinical practice when individuals are newly 
diagnosed or when smoking cessation is being discussed and could be offered by 
Rheumatologists, Nurse Practitioners and/or psychologists where available in the 
outpatient setting. It is likely this type of intervention would take approximately five 
minutes extra time to a medical appointment, and may prove to be cost and time efficient.  
 
Further studies might examine whether particular help with smoking cessation should be 
offered to RA smokers with a lower educational attainment and those with a larger pack 
year smoking history because these participants seemed to be the least likely to quit during 
the pilot study. Although these two findings were non-significant in the pilot study from 





smoking cessation in the general population [215, 350]. People with RA who smoke are 
likely to have similar barriers to quitting. Referral to Arthritis support agencies, such as 
Arthritis NZ may be the most practical route for RA smokers who require extra assistance 
with quitting because these organisations already provide advice and support specifically 
targeted to people with RA. The intervention components used in the pilot study were 
largely based upon existing resources and information from Arthritis NZ and fitted within 
their existing service delivery structure, which is a predominantly telephone-based service. 
 
Future research that followed the study participants long-term who managed to quit 
smoking would be valuable to ascertain if they experience any changes in RA disease 




The novel intervention developed for this research was grounded in previous research, was 
informed by patient opinion, provided support and advice from Arthritis NZ, and 
incorporated evidence-based smoking cessation treatments. The methods used in the 
different phases of research in this thesis give strength to the findings. Both quantitative 
and qualitative methodologies were utilised depending upon the nature of the research 
question and the particular outcome sought. Qualitative methodologies were used in the 
exploratory and evaluative phases enabling the participants the opportunity to share their 
lived experience and difficulties of RA and smoking cessation. As is usual practice in 





the efficacy of this smoking intervention to be tested in a rigorous manner. This research 
adds to knowledge by providing feedback from both intervention and control group 
participants on a comprehensive intervention specifically targeted to people with RA, 
which resulted in a high quitting rate among all participants. 
 
The tailored smoking cessation intervention for people with RA had no significant impact 
on quit rates, suggesting the ‘ABC pathway’ is currently the best practice for supporting 
people with RA who wish to quit smoking. Adding a disease-specific educational 
component that outlines the relationship between RA and smoking may be beneficial. 
Because smoking has a direct and significant impact on RA, particularly the risk of 
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Appendix 1: Baseline and Follow-up Questionnaires 
 
a) Standard Baseline and Follow-up Demographic Questions 
 




Study Number  
 
This questionnaire includes information not available from blood tests or 
any source other than you. Please try to answer each question even if you 
do not think it is related to you at this time. There are no right or wrong 
answers. Thank you. 
 
1. What is your current AGE?     _______ years 
 
 
2. Are you        Male   OR   Female 
 
 





















Smoking Cessation in Rheumatoid Arthritis 
Ko tēhea momo tāngata e whai 
pānga atu ana koe?  Tohua te katoa o 









 tētahi atu (pērā i 
TATIMANA, HAPANĪHI, 
TOKELAU). Tuhia mai: 
 
Which ethnic group do you belong 
to? 
Mark the space or spaces which apply 
to you. 
 NZ European 
 Māori 
 Samoan 





 Other (such as DUTCH, 






















6. Have you had any joint surgery?  YES  /  NO 
 

























8. At this time are you?  (Please circle all that apply) 
 
 Are you in paid employment / self-employed?  
 
 Are you working full time / part time? 
 
 Are you in physical / manual or non-physical employment? 
 
 Are you retired? 
 
 Are you a home maker full time or student 
 
 Are you unemployed? 
 
 Are you not working because of ill health / disability? 
 
Other (describe) ________________________________ 
 
 
9. What is your CURRENT OCCUPATION? (If you are not working what 





10. How many YEARS OF EDUCATION have you completed? 
 
Please circle the NUMBER OF YEARS AT SCHOOL, COLLEGE, 
UNIVERSITY etc. 
 
 3  4  5  6  7  8  9  10  11 (5th form)  12  13 (7th form)  14  15  16  17  18  19  20 
 
 
11. Smoking history 
  
Have you ever smoked? 
  
  No 
 










13. Do you smoke now? 
  
   YES 
  







b) The Health Assessment Questionnaire (HAQ) 
 
For the items below, please tick the ONE response which best describes 












1. DRESSING AND 
 GROOMING 
 Are you able to: 
 - Dress yourself,  
  including tying 
  shoelaces and 
  doing buttons? 
 




































 Are you able to: 
 - Stand up from an 
  Armless straight chair? 
 






















 Are you able to: 
 - Cut your meat? 
 
 - Lift a full cup or glass 
  to your mouth? 
 
 - Open a new carton of  






























 Are you able to: 
 - Walk outdoors on  
  flat ground? 
 






















Please tick any aids and devices that 




 Walking frame 
 Crutches 
 Wheelchair 
 Special or built-up chair 
 Devices used for dressing  
  (button hook, zipper pull,  
   long handled shoe horn etc.) 
 Built-up or special utensils 
 Other (please specify) 
  .............................................  
Please tick any categories for which 
you usually need help from another 
person: 
 




Please tick any aids or devices that you 
usually use for any of these activities: 
 
 Raised toilet seat 
 Bath seat 
 Jar opener  
  (for jars previously opened) 
 Bath rail 
 Long handled appliances for reach 
 Other (please specify) 
  .............................................  
Please tick any categories for which you 




 Gripping and opening things 








For the items below, again please tick the ONE response which best 














 Are you able to: 
 - Wash and dry your  
  entire body? 
 
   - Take a bath? 
 
































 Are you able to: 
 - Reach and get down a 
  5lb object (e.g. a bag of 
  potatoes) from just 
  above your head? 
 
 - Bend down to pick up 
  clothing from the  






























 Are you able to: 
 - Open car doors? 
 
 - Open jars which have 
  been previously opened? 
 































 Are you able to: 
 - Run errands and shop? 
 
 - Get in and out of a car? 
 
 - Do chores such as 
  Vacuuming housework 




































c) The Personal Impact HAQ (PI HAQ) 
 
These questions ask about how important it is to you to be able to do 
different things.  You might feel it is not important that you do the 
gardening yourself – it could be done by someone else.  On the other hand 
you might feel that it is important to do the gardening yourself – even 
though it could be done by someone else.  How important is it to you this 
week to be able to do the following things yourself? 
 
 Not at all 
important 
 








1. Carry out tasks involved in 
dressing and grooming, 
including tying shoelaces, 
doing buttons, and 











2. Carry out the sort of tasks 
that involve getting up 









3. Carry out the tasks 










4. Walk, including flat 










5. Carry out the tasks 
involved in personal 
hygiene, including using 










6. Carry out the sort of tasks 
that involve reaching up 









7. Carry out the sort of tasks 
that involve gripping 









8. Carry out general activities 
such as light gardening, 













d) The Perceived Stress Scale (PSS) 
 
The next few questions ask about your feelings and thoughts during the 
LAST MONTH. Answer each question fairly quickly using the rating 
scale below:   
 
 
 0 ------------- 1 ----------- 2 ---------- 3 ----------- 4 
 never  almost never  sometimes  fairly often  very often 
  
In the last month, how often have you… 
a) Been upset because of something that happened unexpectedly? ……….0  1  2  3  4 
b) Felt that you were unable to control the important things in your life? 0  1  2  3  4 
c) Felt nervous and “stressed”?.......................................................................0  1  2  3  4 
d) Dealt successfully with irritating life hassles?...........................................0  1  2  3  4 
e) Felt that you were effectively coping  
  with important changes occurring in your life?....................................... 0  1  2  3  4 
f) Felt confident about your ability to handle your personal problems?.....0  1  2  3  4 
g) Felt that things were not going your way?..................................................0  1  2  3  4 
h) Found that you could not cope with all the things that you had to do?...0  1  2  3  4 
i) Been able to control irritations in your life?...............................................0  1  2  3  4 
j) Felt that you were on top of things?...........................................................0  1  2  3  4 
k) Been angered because of things  
   that happened that were outside of your control?................................... 0  1  2  3  4 
 
l) Found yourself thinking about things that you have to accomplish?......0  1  2  3  4 
12. Been able to control the way you spend your time?.................................0  1  2  3  4 
13. Felt difficulties were  





e) The Arthritis Self-Efficacy Scale (ASES) 
 
In the following questions we would like to know how your arthritis 
symptoms affect you. For each of the questions, please circle the ONE 
number which corresponds to your certainty that you can now perform 
the following tasks: 
 
1. How certain are you that you can decrease your pain quite a bit? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
2. How certain are you that you can continue most of your daily activities? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
3. How certain are you that you can keep arthritis pain from interfering with 
your sleep? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
4. How certain are you that you can make a small-to-moderate reduction in 
your arthritis pain by using methods other than taking extra medication? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
5. How certain are you that you can make a large reduction in your arthritis 
pain by using methods other than taking extra medication? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
6. How certain are you that you can control your fatigue? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
7. How certain are you that you can regulate your activity so as to be active 
without aggravating your arthritis? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
8. How certain are you that you can do something to help yourself feel better 





 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
9. As compared to other people with arthritis like yours, how certain are you 
that you can manage arthritis pain during your daily activities? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
10. How certain are you that you can manage your arthritis symptoms so that 
you can take pleasure from the things that you enjoy doing? 
 Very uncertain 1    2    3    4    5     6    7    8    9    10 very certain 
 
11. How certain are you that you can deal with the frustration of arthritis? 




























i) The Fagerström Test for Nicotine Dependence (FTND) 
 
For current smokers, for the items below, please tick the ONE response 





1. How soon after you wake up do you smoke 






Within 5 minutes 
6-30 minutes 
31-60 minutes 
After 60 minutes 
2. Do you find it difficult to refrain from 
smoking in places where it is forbidden, 






















10 or less 
11 – 20 
21 – 30 
31 or more 
5. Do you smoke more frequently during the 
first hours after waking than during the 






6. Do you smoke if you are so ill that you are 










j) The Smoking Self-Efficacy Questionnaire (SSEQ) 
 
The following are some situations in which certain people might be 
tempted to smoke. Please indicate by placing a tick in the box whether 
you are sure that you could REFRAIN from smoking in each situation 






Fairly sure Absolutely 
sure 
When I am nervous      
When I feel 
depressed 
     
When I am angry      
When I feel very 
anxious 
     
When I want to think 
about a difficult 
problem 
     
When I feel the urge 
to smoke 
     
 
The following are some situations in which certain people might be 
tempted to smoke. Please indicate by placing a tick in the box how much 
you are TEMPTED to smoke in each situation 










When having a drink 
with friends      
When celebrating 
something      
When drinking beer 
wine or other spirits      
When I am with 
smokers      
After a meal 
     
When having tea or 





k) Smoking History 
SMK1 Have you smoked at least 100 cigarettes, cigars or pipefuls in your lifetime? 
1=Yes 
2=No (Go to question SMK8) 
3 = Uncertain (Go to question SMK8) 
 
 
SMK2 Have you ever smoked daily (= almost every day for at least one year)? 
1= Yes  
2= No (Go to question SMK8) 




SMK3 Do you now smoke? 
1= Yes, daily (Go to question SMK5) 
2= Yes, occasionally  
3 = Not at all  
 
SMK4 When did you stop smoking daily? (If you have quit smoking several times,  
give the time when you last stopped smoking daily?) 
1= Today or yesterday 
2= 2 days - 6 days ago 
3= 1 week - less than 1 month ago 
4= 1 month - less than 1 year ago 
5= 1 - 5 years ago 
6 = More than 5 years ago  
 
SMK5 On average, how many times do you smoke per day (= number of cigarettes, 
cigars, pipefuls of tobacco etc.)? 
 
SMK6 Which of the products do you frequently smoke?  
Manufactured cigarettes (1=yes, 2=no) 
Self-rolled cigarettes      (1=yes, 2=no) 
Pipe                                 (1=yes, 2=no) 
Cigars                              (1=yes, 2=no)  
 
 
SMK7 Have you during the past year (12 months) been advised by a health  
professional to stop smoking? 
1 = Yes 
2 = No 
3 = I have not smoked during the past 12 months 
 
SMK8 Are you exposed to indoor tobacco smoke at home? 
1 = Yes 
2 = No 
 
SMK9 About how many hours per day are you exposed to indoor tobacco smoke  
at your workplace? 
1 = I do not work outside the home 
2 = Almost never 
3 = Less than one hour a day 
4 = 1-5 hours a day 








Appendix 2: Original Article: Identifying Barriers to Smoking 






















































Appendix 3: Consent Form for Phase 1 Exploratory Study 
 
CONSENT TO PARTICIPATE IN 
Smoking cessation in rheumatoid arthritis 
 
REQUEST FOR INTERPRETER 
 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 





Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko 
kupu 
E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki 
na gagana o na motu o te Pahefika 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
 
I have read the Information Sheet dated October 2012 and have had the study fully 
explained to me in a language that I understand.  
I have also had the opportunity for full discussion with one of the investigators, a person 




 Taking part in this study is voluntary (my choice). I may withdraw from the study at any 
time and this will in no way affect my continuing health care. 
 My participation in this study is confidential and no material which could identify me will 
be used in any reports on this study. 
 I know who to contact if I have any questions about the study. 
 I will receive a copy of this Consent Form and the Information Sheet. 
 This study has received ethical approval from the Multiregional Ethics Committee. 
 I wish to receive a copy of the results.     YES / NO 





 I consent to the use of my data for future  related studies, which have been given ethical 
approval from a New Zealand Accredited Ethics Committee  YES/NO 
 I consent to being contacted in the future for follow-up studies  YES/NO 
 
 
I …………………………………………. (Full name) hereby consent to take part in this 
study. 
 
Signature: ………………………………………………                  Date:    /    /   . 
Project explained by………………………………………… 
Signature ……………………………………………… 
Signature of investigator: ………………………………………….  Date:    /    /   . 
Christchurch 
Ms Pip Aimer Phone (03) 364-0496 (work) or 021-048-3885 
Assis Prof Lisa Stamp Phone (03) 364-0953 (work)  
Dunedin 
Dr Simon Stebbings Phone (03) 474-0999 ext. 8504 (work) 
Dr Gareth Treharne Phone (03) 479-7630 (work)  
Arthritis New Zealand 





Appendix 4: Information Sheet for Phase 1 Study 
 
 
Smoking cessation in rheumatoid arthritis 
INFORMATION SHEET 
Investigators 
Prof Lisa Stamp, Rheumatologist, Christchurch Hospital 
Dr Simon Stebbings, Rheumatologist, Dunedin Hospital 
Dr Gareth Treharne, Psychologist, University of Otago 
 
You are invited to participate in a study looking at smoking cessation in patients with 
rheumatoid arthritis. Recent evidence has shown that smoking has a number of effects on 
rheumatoid arthritis. Smoking can increase the risk of developing RA, it can make 
rheumatoid arthritis more severe and it can make rheumatoid arthritis more difficult to treat, 
In addition, smoking is a recognized risk factor for heart disease, which is significantly 
increased in patients with RA. Quitting smoking is now recognized as an important part of 
managing arthritis. However, many people with arthritis find it difficult to stop smoking. 
This study aims to identify barriers to quitting smoking in patients with arthritis. This 




If you agree to participate in the study the PhD student (Pip Aimer) will contact you to 
arrange a time to attend a group discussion on smoking. This discussion will be based on 
several areas relating to smoking and quitting smoking. This discussion will be videotaped 
so we can analyse the discussion in detail at a later stage. 
You will be also asked to fill out a questionnaire about your arthritis and how it affects your 
life. You will have a blood test and your joints will be examined to see how many are 
swollen and tender. 
Once we have analysed the information from the discussion we will develop a specific quit 
smoking programme for people arthritis. If you are a current smoker you will be invited to 
participate in this. This may include telephone contact with an arthritis educator from 
Arthritis New Zealand as well as the PhD Student. It may also involve nicotine replacement 
in the form of gum or patches. 
Your participation is entirely voluntary and you may withdraw from the study at any stage 
without this affecting your treatment. 
Nature and Duration of the Study 
IF you agree to participate in this study you will need 





 Attend a focus group session to discuss aspects of smoking, smoking cessation and 
arthritis.  This will take approximately 2 hours.  
 The second part of the study involves a smoking cessation programme. This will entail 
monthly contact by phone and some visits to an arthritis educator 
 A sample of the blood will be stored indefinitely and may be used to measure other 
markers of arthritis that may be of interest. It may be necessary to send a sample of 
blood overseas to test for some markers of arthritis that we cannot test for in NZ. Once 
the samples have been sent overseas they will not be returned to NZ but will be 
destroyed after they have been tested for the markers of interest. 
 
Some Common Questions 
Will my GP be told I am in the study? If you agree to participate in this study your GP will 
be advised. 
 
What will happen at the end of the study? You will continue your treatment as prescribed 
by your doctor. You will continue to attend Outpatient clinics as required by your treating 
hospital specialist. 
 
Where can I get more information about the study? If at any time you have any concerns 
or questions about this study, do not hesitate to contact any of the study investigators or 
the PhD student.  
 
Are there any risks to me by being in the study? There is the potential for some participants 
in the focus groups to experience some distress when discussing their condition. The 
moderator will have guidelines on appropriate ways to deal with this situation should it 
arise, including stopping the audio recording if requested to, allowing individuals to leave 
the focus group if they wish to. 
 
It is possible that you may experience some bruising and discomfort after the blood sample 
is taken. 
 
Confidentiality: No material which could personally identify you will be used in any 
reports on this study. Your study records will be stored in a locked cabinet in the 
Department of Medicine/Rheumatology and stored for a maximum of 20 years.  
 
Results: Overall results of the study will be available from the investigators several 
months after the study has been completed. 
 
Compensation: In the unlikely event of a physical injury as a result of your participation 
in this study, you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act. ACC cover is not automatic and your case will need to be assessed 
by ACC according to the provisions of the 2002 Injury Prevention Rehabilitation and 
Compensation Act. If your claim is accepted by ACC, you still might not get any 
compensation. This depends on a number of factors such as whether you are an earner 
or non-earner. ACC usually provides only partial reimbursement of costs and expenses 
and there may be no lump sum compensation payable. There is no cover for mental injury 
unless it is a result of physical injury. If you have ACC cover, generally this will affect your 
right to sue the investigators. If you have any questions about ACC, contact your nearest 






Rights: If you have any queries or concerns regarding your rights as a participant in this 
research study you can contact an independent health and disability advocate. This is a 
free service provided under the Health and Disability Commissioner Act. 
 
Telephone (NZ wide): 0800 555 050. 
Free Fax (NZ wide): 0800 2787 7678 (0800 2 SUPPORT). 
Email (NZ wide): advocacy@hdc.org.nz  
Statement of Approval: This study has received ethical approval from the Multiregional 
Ethics Committee. 
Further Information 
If at any time you have concerns or questions about this study, do not hesitate to contact 
any of the study investigators.  
Prof Lisa Stamp  Phone (03) 364-0953 (work)  
Dr Simon Stebbings  Phone (03) 474-0999 ext. 8504 (work) 
Dr Gareth Treharne  Phone (03) 479-7630 (work)  

















Appendix 6: Standardised Participant information Form (Phase 1 












1. DOB. ______/______/_____ 
 
 
2. Diagnosis of RA: 
 
 Date: _________________ 
 
  
3. Rheumatoid Factor  positive / negative  
 
If positive titre____________________________ 
 
 
4. CCP   positive / negative  
 
If positive titre____________________________ 
 
 



















7. Current DMARDs 
 

























Appendix 7: Original Article: Developing a Tailored Smoking 















































































Appendix 9: Permission to use Quitline Smoking Cessation “Pip’s 
Tips” and Smoking Triggers Diary 
 
From: Pip Aimer [mailto:pip.aimer@vodafone.co.nz]  
Sent: Thursday, 1 November 2012 4:25 p.m. 
To: Jane MacPherson 




I am a PhD student at the Department of Medicine at the University of Otago (Christchurch).  I 
am currently designing a clinical trial for smoking cessation in rheumatoid arthritis (in 
conjunction with Arthritis NZ), which involves setting up a support webpage on the University’s 
website for participants to access during the trial.  It will be linked from the Arthritis NZ 
website.  I was wanting to have a helpful tip (“Pip’s Tips”) section that I would change weekly as 
a form of motivation.  Is it possible to use quotes from your website, e.g. tips to help quit 
smoking, reasons to quit etc., plus use of your logo as a referral and/or useful link. 
  
Many thanks for your help. 
  
Kind regards, Pip 
  
Pip Aimer 
PhD Student, Department of Medicine 
University of Otago, Christchurch 
PO Box 4345 
Christchurch 8140 
03 364-0496 DDI 




From: Jane MacPherson [mailto:jane.macpherson@quit.org.nz]  
Sent: Thursday, 1 November 2012 5:03 p.m. 
To: Pip Aimer 
Cc: Dominika White; Bruce Bassett 




Yes that is fine – can you show me a screen shot before you go live of how it would 
look please? 
I have cc’d in our web communication specialist Dominika – who can send you the 
best logo. 
We also may be able to provide a link on your site to ours where viewers can link 






Is there anything else we can provide to you – we have a resources section where 
people can download our marketing collateral also and in there are some great tips 




Jane MacPherson | Acting Manager Communications 
Quitline | Me Mutu 
DDI: 04 460 9885 
Email: jane.macpherson@quit.org.nz 
 
For Quitline phone service call 0800 778 778: 
Mon-Fri 8.00am - 9.30pm; Sun 10.00am - 7.30pm 




Please consider the environment before printing this email. 
This e-mail message and any accompanying attachments may contain information that is in-confidence. If you 
are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments. If 















Appendix 10: Smoking Cessation Email “Pip’s Tips” 
 
Sourced from Quitline NZ [197] 
 
Week 1: Smoking and your body (http://www.quit.org.nz/19/reasons-to-quit/smoking-and-
your-body)  
Week 2:  Stress, feeling down and cravings (http://www.quit.org.nz/47/staying-
quit/stress-feeling-down-and-cravings)  
Week 3:  Money benefits (http://www.quit.org.nz/21/reasons-to-quit/money-benefits)  
Week 4:  Social situations (http://www.quit.org.nz/49/staying-quit/social-situations)  
Week 5:  Weight gain (http://www.quit.org.nz/48/staying-quit/weight-gain-and-effects-
on-the-body)  
Week 6: The smoking addiction (http://www.quit.org.nz/63/help-to-quit/the-smoking-
addiction)  
Week 7:  Health benefits (http://www.quit.org.nz/20/reasons-to-quit/health-benefits)  
Week 8: Nicotine patches, gum and lozenges (http://www.quit.org.nz/62/help-to-
quit/nicotine-patches-gum-and-lozenges)  
Week 9:   Why get help? (http://www.quit.org.nz/64/help-to-quit/why-get-help)  
Week 10:  Set-backs and trying to quit again (http://www.quit.org.nz/50/staying-quit/set-
backs-and-trying-to-quit-again)  
Week 11:  Quit success stories (http://www.quit.org.nz/35/success-stories/quit-smoking-
stories)  





Appendix 11: Relationship between RA and Smoking Handout     
                                                                                                 




Did you know? 
 Rheumatoid Arthritis (RA) is a common disease affecting 1-2% of NZ 
population.   
 Research shows that smoking makes RA worse, however up to 30% of RA 
patients are currently smoking.  




What are the effects of smoking on RA? 
 
1. Smoking increases the risk of developing RA 
Smoking can increase the chances of developing RA by 40 times. If you have 
RA and your family smoke, it is important for them to be aware of this risk. 
 
 
2. Smoking reduces the effectiveness of the medication used to treat RA 
 You may need more drugs to treat your disease. 
 Smokers with RA are less likely to be able to stop their arthritis medications 
when they are in remission or free of symptoms. 
 
 
3. Smoking may worsen joint damage 
 Joint damage starts early in RA, and once this occurs, it is largely 
irreversible. 
 There is some evidence that smoking contributes to joint damage. 
 
 
4. Smoking leads to an increased risk of heart disease 
 Risks of heart disease is already increased in RA 
 Smoking adds to this risk 
 
 
5. Smoking contributes to osteoporosis (thinning of the bones) 
 The risk of osteoporosis is also raised because of RA and the use of 
steroids 
 
Want more information?   
 










Accessed 10 September 2015 
 
 
From: Natalia Valentino [mailto:Natalia.Valentino@arthritis.org.nz]  
Sent: Wednesday, 14 November 2012 3:42 p.m. 
To: Pip Aimer 
Subject: RE: Copyright permission for smoking and RA project 
  
Can we have only the cover page of our Exercise book on the website or link to our website – we 
have it there. 
  
Natalia Valentino 
Service Development Manager 
  
Arthritis New Zealand  
Kaiponapona Aotearoa 
  
PO Box 74581  |  Unit B, 383 Khyber Pass  |  Auckland   |   1546 
DDI: 09 5238907  | Mobile: 0272410979   |   Tollfree: 0800 663 463 
  
Donate to Arthritis New Zealand and help us support the 530,000 New Zealanders living with arthritis. 






Appendix 13: Exercise Resources for Smoking Cessation 
Intervention 
 
a) Permission to use Abbott Laboratories NZ Exercise Sheets  
 
http://www.arthritis.org.nz/information/resources/resource-brochures/  




From: Williams, Sheryl A [mailto:sheryl.williams@abbott.com]  
Sent: Monday, 19 November 2012 1:05 p.m. 
To: Natalia Valentino 
Cc: Sutherland, Lucy V; Taylor, Charles; Millard, Helen 




I am well and I hope that you are also? 
  
Yes we are happy to provide Abbott Laboratories NZ Ltd.’s permission for the exercise sheets to 
be used in this valuable research. 
  

























































Appendix 14: Smoking Triggers Diary 
 







Appendix 15: Conference Proceedings: A Pilot Randomized 
Controlled Trial of a Tailored Smoking Cessation Intervention for 
Rheumatoid Arthritis Patients [343] 
 
Pip Aimer1, Gareth J Treharne2, Simon Stebbings3, Chris Frampton1, Vicky Cameron1, 
Sandra Kirby4, Lisa Stamp1 
 
1Department of Medicine, University of Otago, Christchurch, 2Department of Psychology, 
University of Otago, 3Department of Medicine, Dunedin School of Medicine, University 
of Otago, 4Arthritis New Zealand, New Zealand. 
 
Background: Smoking adversely influences comorbidities in rheumatoid arthritis (RA) 
and may affect progression of RA. The combination of negative health effects makes a 
compelling case for smoking cessation in RA. The aim of this pilot study was to determine 
whether a targeted 3-month smoking cessation intervention for RA patients increases 
smoking cessation. 
 
Methods: Thirty-eight RA patients who were currently smoking were recruited and 
randomized on a 1:1 ratio. All participants were given the current local standard of care for 
smoking cessation (brief advice and subsidised NRT: ABC). Participants randomized to 
the intervention arm (ABC+) received additional advice from trained Arthritis New 
Zealand educators for 3 months. Advice was tailored to participants’ specific needs from a 
range of intervention tools developed from previous qualitative consultation and focused 
on education about smoking and RA, pain control, exercise, coping, and support. The 
primary outcome measure was smoking cessation at 6 months. The secondary outcome was 
sustained reduction in smoking at 6 months. The assessor was blind to intervention 







Results: Thirty-five participants completed the 6 month study; the 3 who withdrew were 
in ABC+. The overall smoking cessation rate was 24%. There was no significant difference 
in smoking cessation rate between the ABC+ and ABC groups (26% vs 21%; P=0.70). The 
mean number of cigarettes smoked per day reduced by 44% (P<0.001) but did not differ 
between ABC+ and ABC groups (41% vs 47% mean reduction; P=0.72). There was no 
difference in smoking cessation rates between participants with disease duration <2 years 
and disease duration >2 years (27% vs 22%; P=0.74). Successful quitters had a greater 
number of years in education beyond high school and had smoked less across their lifetime, 
but these differences were not statistically significant. No other demographic, disease or 
psychosocial variables predicted quitting (Table 1). 
 
Conclusions: This pilot randomized controlled study evaluated the effects of an 
individually tailored smoking cessation programme in patients with RA. The smoking 
cessation rate and reduction in number of cigarettes smoked were high compared to 
previous smoking cessation studies. The lack of added benefit of the tailored intervention 
suggests brief advice is the best practice supporting RA patients who wish to quit smoking. 
RA patients with fewer years of education or longer history of smoking may require 







Table 1: Baseline disease and psychosocial factors associated with smoking cessation. All 
data are presented as mean (SD) 








Education (years) 12.6 (1.9) 11.5 (1.3) 11.7 (1.5) 0.06 
Cumulative pack-years 
of smoking (years) 
25.6 (10.4) 41.7 (24.5) 37.8 (22.9) 0.07 
Current age (years) 55.2 (12.3) 56.9 (11.8) 56.5 (11.8) 0.72 
Socio-economic 
deprivation 
5.0 (3.3) 5.3 (2.6) 5.2 (2.8) 0.77 
ASES pain 6.9 (2.2) 6.2 (2.0) 6.3 (2.0) 0.36 
ASES mood 7.5 (2.0) 7.2 (2.1) 7.2 (2.1) 0.62 
HADS anxiety 6.7 (3.4) 6.7 (4.0) 6.7 (3.8) 0.97 
HADS depression 3.7 (1.9) 4.8 (3.5) 4.5 (3.2) 0.36 
PSS stress 19.0 (7.5) 22.5 (8.8) 21.7 (8.5) 0.29 
HAQ 0.6 (0.4) 0.9 (0.8) 0.8 (0.7) 0.26 
PI HAQ 2.0 (1.4) 2.5 (2.2) 2.3 (2.0) 0.52 
EQ VAS 76.3 (15.6) 70.8 (19.2) 72.1 (18.4) 0.44 
EQ-5D 0.7 (0.2) 0.7 (0.2) 0.7 (0.2) 0.31 
Smoking self-efficacy 
internal 
12.7 (6.0) 13.1 (6.4) 13.0 (6.2) 0.85 
Smoking self-efficacy 
external 
14.3 (3.5) 13.7 (6.2) 13.8 (5.6) 0.77 
Fagerström Nicotine 
Dependence 
3.8 (1.6) 4.3 (1.9) 4.0 (1.9) 0.72 
*Abbreviations: ASES, Arthritis Self-Efficacy Scale; HADS, Hospital Anxiety and 
Depression Scale; PSS, Perceived Stress Scale; HAQ, Health Assessment 
Questionnaire; PI-HAQ, Personal Impact Health Assessment Questionnaire; EQ-VAS, 







Appendix 16: Advertising for Pilot Study 
 
 
DO YOU HAVE RHEUMATOID ARTHRITIS? 
 
Volunteers wanted for:  
SMOKING CESSATION RESEARCH 
 
 
The University of Otago is currently conducting a study of patients with 
rheumatoid arthritis to determine how we can improve smoking cessation.  
If you have rheumatoid arthritis and are a smoker or have tried to quit 
smoking and failed, you are eligible. 
 
This study has ethical approval. 
 
If you are interested in being part of this research, please contact us 
to get more information: 
 
 
Pip Aimer (PhD student)  











Appendix 17: Informed Consent Form for Pilot Study  
 
 
CONSENT TO PARTICIPATE IN 
Smoking cessation in rheumatoid arthritis 
REQUEST FOR INTERPRETER 
 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 





Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko kupu E Nakai 
Sāmoan Ou te mana’o ia i ai se fa’amatala upu Ioe Leai 
Tokelaun Ko au e fofou ki he tino ke fakaliliu te gagana Peletania ki na 
gagana o na motu o te Pahefika 
Ioe Leai 
Tongan Oku ou fiema’u ha fakatonulea Io Ikai 
 
I have read the Information Sheet dated October 2012 and have had the study fully explained 
to me in a language that I understand.  
I have also had the opportunity for full discussion with one of the investigators, a person of 
my choice, and have had adequate time to consider participating in this study. 
 
I UNDERSTAND: 
 Taking part in this study is voluntary (my choice). I may withdraw from the study at 
any time and this will in no way affect my continuing health care. 
 My participation in this study is confidential and no material which could identify me 
will be used in any reports on this study. 
 I know who to contact if I have any questions about the study. 





 This study has received ethical approval from the Southern Health and Disability 
Ethics Committee. 
 I wish to receive a copy of the results.     YES / NO 
 I consent to my GP being informed of my participation in this study YES / NO 
 I consent to the use of my data for future  related studies, which have been given 
ethical approval from a New Zealand Accredited Ethics Committee YES/NO 
 I consent to being contacted in the future for follow-up studies  YES/NO 
 
I …………………………………………. (Full name) hereby consent to take part in this study. 
 
Signature: …………………………………………….                Date:    /    /   . 
Project explained by………………………………… 
Signature ……………………………………………… 
Signature of investigator: ……………………………   Date:    /    /   . 
 
Christchurch 
Ms Pip Aimer Phone (03) 364-0496 (work) or 021-048-3885 
Prof Lisa Stamp Phone (03) 364-0953 (work)  
 
Arthritis New Zealand 






Appendix 18: Information Sheet for Pilot Study 
 
 
Smoking cessation in rheumatoid arthritis 
INFORMATION SHEET 
Investigators 
Ms Pip Aimer, PhD Student, University of Otago 
Prof Lisa Stamp, Rheumatologist, Christchurch Hospital 
 
You are invited to participate in a study looking at smoking cessation in patients with 
rheumatoid arthritis (RA). Recent evidence has shown that smoking has a number of 
effects on rheumatoid arthritis. Smoking can increase the risk of developing RA, it can 
make rheumatoid arthritis more severe and it can make rheumatoid arthritis more difficult 
to treat. In addition, smoking is a recognized risk factor for heart disease, which is 
significantly increased in patients with RA.  
Quitting smoking is now recognized as an important part of managing arthritis. However, 
many people with arthritis find it difficult to stop smoking. This study aims to determine 
whether a targeted six month smoking cessation intervention programme for people with 
Rheumatoid Arthritis will increase smoking cessation rates.  If you agree to participate you 
will either be allocated to the standard smoking cessation advice arm or the intervention 
arm. This is done randomly and we will not know which arm you will be in.  All participants 
will be given the current standard of care for smoking cessation at Christchurch Hospital 
(the ABC programme).  
Study Procedure 
If you agree to participate in the study the PhD student (Pip Aimer) will contact you to 
arrange a time to attend an initial meeting. This meeting will explain the study in more 
detail and you will have the chance to ask any questions. You will be also asked to fill out 
a questionnaire about your arthritis and how it affects your life, and sign a consent form.  
You will also receive the ABC programme from one of the rheumatology nurses.  You may 
also receive nicotine replacement in the form of gum, lozenges and/or patches if you wish. 
Your participation is entirely voluntary and you may withdraw from the study at any stage 
without this affecting your treatment. 
Nature and Duration of the Study 
IF you agree to participate in this study you will need to: 
 Attend an initial meeting with Ms Pip Aimer (PhD student) to discuss aspects of the 





smoking history.  Follow-up contact will be made by the PhD student at month 3 and 
month 6 
 Attend a visit at Christchurch Hospital outpatients to receive the ABC programme.  
You may also receive a targeted six month smoking cessation intervention 
programme to run concurrently with the ABC programme. 
 
Some Common Questions 
Will my GP be told I am in the study? If you agree to participate in this study your GP will 
be advised. 
What will happen at the end of the study? You will continue your treatment as prescribed 
by your doctor. You will continue to attend Outpatient clinics as required by your treating 
hospital specialist. 
Where can I get more information about the study? If at any time you have any concerns 
or questions about this study, do not hesitate to contact any of the study investigators or 
the PhD student.  
Are there any risks to me by being in the study? Physical nicotine withdrawal symptoms 
are temporary, but it can be an unpleasant phase. Symptoms may mimic a cold or mild 
flu.  However, these discomforts are short-lived. Nicotine patches, gum and lozenges are 
very safe, and serious side effects are rare.  Sometimes patches can cause a slight 
reddening and itching of the skin. This is less likely if you change the area that you apply 
the patch to.  Gum or lozenges might give you a slightly irritated mouth and throat and 
more spit than usual. If you chew or suck the gum or lozenges too often, you much swallow 
too much nicotine and this can cause wind, hiccups and indigestion. 
Confidentiality: No material which could personally identify you will be used in any 
reports on this study. Your study records will be stored in a locked cabinet in the 
Department of Medicine/Rheumatology and stored for a maximum of 20 years.  
Results: Overall results of the study will be available from the investigators several 
months after the study has been completed. 
Compensation: In the unlikely event of a physical injury as a result of your participation 
in this study, you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act. ACC cover is not automatic and your case will need to be assessed 
by ACC according to the provisions of the 2002 Injury Prevention Rehabilitation and 
Compensation Act. If your claim is accepted by ACC, you still might not get any 
compensation. This depends on a number of factors such as whether you are an earner 
or non-earner. ACC usually provides only partial reimbursement of costs and expenses 
and there may be no lump sum compensation payable. There is no cover for mental injury 
unless it is a result of physical injury. If you have ACC cover, generally this will affect your 
right to sue the investigators. If you have any questions about ACC, contact your nearest 
ACC office or the investigator. 
Rights: If you have any queries or concerns regarding your rights as a participant in this 
research study you can contact an independent health and disability advocate. This is a 
free service provided under the Health and Disability Commissioner Act. 
Telephone (NZ wide): 0800 555 050 
Free Fax (NZ wide): 0800 2787 7678 (0800 2 SUPPORT) 





Statement of Approval: This study has received ethical approval from the Southern 
Health and Disability Ethics Committee. 
Further Information 
If at any time you have concerns or questions about this study, do not hesitate to contact 
any of the study investigators.  
Pip Aimer (PhD student) Phone (03) 364-0496 (work) or (021) 048-3885 
Prof Lisa Stamp  Phone (03) 364-0953 (work)  
Arthritis New Zealand  






Appendix 19: Pilot Study RCT Participant Needs Assessment 
Checklist (week 0) 
  
Pilot Study: Smoking Cessation  
and Rheumatoid Arthritis 
 
 
Arthritis Educator: _______________________________  
 
Date: ______/______/________  Randomisation #_______________ 
 
Initial Contact: Phone□   Skype□    Face-to-face □   
Member of Arthritis NZ?  Yes□   No□   
 
Surname: _________________________  
 











Assessment:  prompts: fatigue, disturbed sleep, pain, feeling down, difficulty with ADL’s 
 











































Link between smoking and rheumatoid arthritis handout   
  
 Exercises to keep you moving  
 Hand exercises for RA (Abbott Handout) 
General exercises for RA (Abbott Handout) 
 Arthritis: exercises to keep you moving booklet (ordered or website link) 
 DVD: Home based Exercise (ordered) 
 Community Exercises Classes handout 
 Hydrotherapy Classes handout 








 Pain Management  
Managing your pain booklet 
 
Advice provided from Arthritis NZ:   
Keep a journal of pain and look for patterns___________________________ 
 Complementary therapies_________________________________________ 
Pacing _______________________________________________________ 
 Take meds as advised___________________________________________
 Managing fatigue_______________________________________________
 Sleep hygiene__________________________________________________ 
Referral to GP _________________________________________________ 
 
Pain ranges from 1 (low) to 10 (high) ___________ 
 




Restricted movement: _________________________________ 
 
What makes it worse? ______________________________________________ 
 
What makes it better? ______________________________________________ 
 
 
 Coping Strategies 
 Smoking triggers diary handout 































 Available Support 
Weekly email reminders 
 Live with Family     Lives Alone Other Support Person 
 


































Appendix 20: Pilot Study RCT Participant Follow-up Checklist 
(weeks 1, 4 and 8) 
      
Pilot Study: Smoking Cessation  
and Rheumatoid Arthritis 
 
 
Arthritis Educator: _______________________________  
 
Date: ______/______/________  Randomisation #_______________ 
 
Initial Contact: Phone□   Skype□    Face-to-face □   
Member of Arthritis NZ?  Yes□   No□   
 
Surname: _________________________  
 











Intervention Follow-up Notes:   
 
Follow-up Week # _________________ 
 































 Exercises to keep you moving  
 Hand exercises for RA (Abbott Handout) 
General exercises for RA (Abbott Handout) 
 Arthritis: exercises to keep you moving booklet (ordered or website link) 
 DVD: Home based Exercise (ordered) 
 Community Exercises Classes handout 
 Hydrotherapy Classes handout 
























 Pain Management  
Managing your pain booklet 
 
Advice provided from Arthritis NZ:   
Keep a journal of pain and look for patterns___________________________ 
 Complementary therapies_________________________________________ 
Pacing _______________________________________________________ 
 Take meds as advised___________________________________________
 Managing fatigue_______________________________________________
 Sleep hygiene__________________________________________________ 
Referral to GP _________________________________________________ 
 
Pain ranges from 1 (low) to 10 (high) ___________ 
 




Restricted movement: _________________________________ 
 
What makes it worse? ______________________________________________ 
 



























 Coping Strategies 
 Smoking triggers diary handout 




















































 Available Support 



















































Appendix 21: Three- and Six-Month Follow-up Interviews 
3 / 6 MONTH  FOLLOW-UP                       Control Group / Intervention 
Group 
 
Study number……………………………………..                             
A. Subject: Changes to your smoking over the last 3 months 
1.   Are you still smoking?                                                                                    YES / NO 
a. If NO, when did you quit? (Date)………………………………………………. 
 
b. If YES, have you stopped smoking for any time during the last 3 months?        YES / NO 
 
i. If YES, what date did you quit (Date)………………………………….. 
 
ii. How long did you stop smoking for? (comment) 
 
 
2. Over the last 4 weeks have you been (1) No, not smoking- not a single puff 
Over the last 4 weeks have you had  (2) Yes, a few puffs but not a whole cigarette 
Over the last 4 weeks have you had  (3) Yes, between 1 and 5 cigarettes 
Over the last 4 weeks have you had  (4) Yes, more than 5 cigarettes 
 
 
3. How many cigarettes do you currently smoke per day? …………………………………… 
 
 
4. Have you made any changes to your smoking habits over the last 3 months (since 3 
month follow-up)                                                                                                    
                                                                                                                                        YES / NO 
 
5. If YES, what other changes have you made to your smoking habits?  
 
 












































i. Other (comment)                                                                                           YES / NO  




6. Do you now do something else before/instead of smoking?                YES / NO  
 
a. If YES, what do you do instead of smoking? (prompts: walk, drink, deep breaths, 



























B. Subject: Use of smoking cessation medications 
1. During the last 3 months have you used NRT (patches, gum, lozenges, or similar 
medication) to help reduce the number of cigarettes smoked per day?  
                                                                                                                       YES / NO 
2. During the last 3 months have you used NRT (e.g. patches, gum, lozenges, or similar 
medication) to try and quit?                                                                                  YES / NO                                                                                                                                                              
 
3. Are you still using NRT?                                                                                      YES / NO 
a. If YES, what? 
Nicotine Patch …..….mg   Zyban or bupropion medication Yes/No 
Nicotine Gum …..……mg Champix/Varenicline medication Yes/No 
Nicotine Lozenge …..…….mg  Didn’t use anything Yes/No 
 







Smokers, lapsers or relapsers ONLY 
1. Are you planning to quit smoking within the next month?                                       YES / 
NO 
 
2. Do you think you will quit during the next 6 months                                                YES / 
NO 
 
3. Sometime in the future?                                                                                          YES / 
NO 
 










C. Subject: Success of Interventions 
Intervention Arm only 
1. Did you receive support by phone from Arthritis New Zealand?                 YES / NO 
If YES, then:  
 
2. Have you continued with any of the support/activities offered?                 YES / NO 
If YES, then what specifically? 
 
THEME INTERVENTION Useful Why? 
Education Handout   
Exercises  Handouts   
Booklets   
DVD   
Community classes   
Hydrotherapy   
Physio/Diet ref   











Managing Pain   
Managing fatigue   
Managing Meds   
Weekly Emails   
UOC Website   
Coping 
Strategies  
















4. Did you access any other smoking cessation programmes and/or support? 
                                                                                                                                 YES / NO 






5. Did you find these other services useful?                                                     YES / NO 
 





6. On a scale of 1 to 10 how motivated do you think you were to quit smoking? 
 
  1 2 3 4 5 6 7 8 9 10 
  Not Motivated Extremely Motivated 
 














Control Arm Only 
1. Did you access any other smoking cessation programmes and/or support during the 
last 3 months?                                                                                          YES / NO 
 




2. Did you find these other services useful?                                                  YES / NO 
 
a. If YES, which aspects did you find useful? 
 
 




3. On a scale of 1 to 10 how motivated do you think you were to quit smoking? 
 
  1 2 3 4 5 6 7 8 9 10 
  Not Motivated Extremely Motivated 
 

















Appendix 22: Exit Interviews with Educators 
 
Sourced from [360] 
 
Findings of exit interviews with Arthritis Educators who delivered 
a tailored smoking cessation intervention for people with rheumatoid arthritis 
 
Report prepared for Arthritis New Zealand 
to support the implementation report to the Health Research Council 
 
Dr Gareth J. Treharne1, Ms Pip Aimer2, Prof Lisa K. Stamp2 
1 Department of Psychology, University of Otago, Dunedin 
2 Department of Medicine, University of Otago, Christchurch 
 
Background 
It is useful to carry out exit interviews with staff who have delivered a research intervention 
in order to 1) investigate the pragmatics of delivering the planned intervention and 2) 
determine the staff’s views on what worked well with the intervention and what could be 
improved for future trials or roll-out. Qualitative exit interviews allow the emergence of 
unexpected themes and useful insights into the delivery of the intervention (see e.g., Hale 
et al., 2013; Mulligan et al., 2013; Smith et al., 2013). These findings supplement the main 
quantitative and qualitative findings with trial participants by providing information about 
both sides or the intervention – delivery as well as receipt. In this framework, ‘exit 
interview’ refers to an interview at the end of the intervention trial. 
 
The aim of this report is to detail the themes that evident within exit interviews with the 
two experienced Arthritis New Zealand Educators who were trained to deliver a novel 
smoking cessation intervention for people with rheumatoid arthritis (RA). The intervention 
incorporated findings of a consultation phase in which smokers and ex-smokers with RA 
were asked about what is important for successful smoking cessation in focus groups and 
interviews (see Aimer et al., submitted; Aimer et al., in preparation). Five sets of 





cessation raised during the consultation phase: 1) lack of awareness of the potential impact 
of smoking on their disease, 2) uncontrollable pain, 3) trouble exercising, 4) smoking to 
cope, and 5) isolation from support. Both Arthritis Educators delivered the intervention to 
around 10 participants with rheumatoid arthritis between November 2012 and September 
2013. 
 
The starting research questions for the qualitative analysis were: 
1. What were the Arthritis Educators’ experiences of delivering the smoking cessation 
intervention? 
2. What aspects of the intervention seemed most helpful for participants? 
3. What aspects of the intervention were challenging for delivery? 
4. What are the Arthritis Educators’ recommendations for the future of the intervention? 
 




Semi-structured interviews were carried out with the two Arthritis Educators in December 
2013, approximately 3 months after the final trial participant was recruited and after all 
planned contact for the intervention was completed. The interviews were run by the 
postgraduate student (PA) who has been leading the intervention data collection, who 
trained the Arthritis Educators in delivering the intervention, and who has extensive 
experience of interviewing. 
 
The questions for the semi-structured exit interviews were devised by the researchers (PA, 
GJT a health psychology researcher, and LKS a rheumatology professor and consultant). 
The questions covered the aims of the project and were asked in approximately the order 
planned (see appendix), but allowing for lines of questioning to be taken up earlier in the 
interview if the interviewee raised a point that was planned for later in the interview. This 
style of interviewing is essential for intervention exit interviews in order to discover 
unexpected issues that would be missed by strict structured questioning (see Hale et al., 
2008). The interviewer (PA) had not yet been unblinded to the intervention allocation of 






The interviews were audio recorded and were transcribed by a professional transcription 
service who work to a confidentiality protocol. The transcripts were checked for accuracy 
but a research fellow who had not been present at the interview but was familiar with the 
overall study. 
 
Thematic analysis was used to extract common themes across the two interviews (following 
Braun & Clarke, 2006). The analysis was led by a researcher who was not present at the 
interviews (GJT) with verification by the interviewer (PA) and project lead (LKS). The 
specific type of thematic analysis applied involved a realist stance in seeking semantic 
themes within the experiential feedback given by the Arthritis Educators. An inductive 
approach was used to find themes that were not necessarily expected and to interrogate the 
existence of thematic issues in both interviews (confirmation across informants). 
 
The thematic analysis was focused on the aspects of the dataset that inform the specific 
reflections on delivering the intervention and recommendations for applying the 
intervention. Six themes were devised to explain the feedback from the two Arthritis 
Educators: 1) participants’ personal responsibility; 2) smoking is an ingrained habit; 3) 
generic facilitators and barriers to smoking cessation; 4) specific local barriers to smoking 
cessation; 5) what worked well within the intervention; and 6) keeping the Arthritis 
Educators in the loop. 
 
Results 
Theme 1: “It was up to them” – Participants’ personal responsibility 
Both Arthritis Educators a strong notion of participants ultimately having personal 
responsibility for smoking cessation, which captured to balance of providing support but 
making sure that the support provided self-management skills. 
 
The inherently positive work role of providing support was important to the Educators:  






The Educators had noticed a range in participants’ stage of change. For those who would 
be at the ‘preparation’ stage of change (see Prochaska et al., 2005), the intervention was 
seen as “catalyst” to go ahead and move into the ‘action’ stage of change: 
P2: Others were more than ready to give up and I think this was a catalyst. 
P2: If they themselves were actually ready and wanted to do it, they would do it. 
 
The Educators noted that determination to stay in the ‘action’ stage of change and continue 
with the research was helpful to some participants: 
P2: [The participants who quit] were very, very determined to continue with it. 
 
Some participants valued the follow-up process of the intervention because it meant the 
personal responsibility for quitting was monitored, providing some external motivation: 
P1: A lot of [participants] quite liked being accountable to someone they’d met. 
 
Not all participants value this kind of monitoring of their personal responsibility (see 
Theme 2). The unsuccessful participants had a contrasting pattern of personal 
responsibility. The Educators noted that the range of intervention tools made the 
intervention flexible (see Theme 5) but these were turned down by many participants: 
P2: I think yeah there were definitely plenty of options for people to take up if they wanted 
to. 
P1: A lot of people didn’t take up the opportunities. 
P2: On the whole yes, I think they were quite excited about hearing the information to start 
with. But again, very individual whether they took it up. 
 
The Educators rationalised this rejection of the intervention tools as perhaps being too much 
to expect participants to take up immediately, but it was participants’ personal 
responsibility to make use of the tools later if not immediately: 
P2: I think sometimes with people you can give them the information and because we had 
them for only that eight week period really was a relatively short amount of time, 
sometimes it can be quite a bit after the event if you like that the information, they’ll 
use it. 
P2: We can only present that information to them and umm whether they actually take it 






Part of the issue of personal responsibility was a reluctance to withdraw that led participants 
to be difficult to contact: 
P1: I think sometimes people not returning the calls was their way of saying “No thanks.” 
 
The structure of the contact process for the intervention was noted to be different from the 
Educators’ routine practice, emphasising the personal responsibility they expect from 
clients: 
P2: Normally we would just have one contact with [a client] and give them the option of 
whether they want to have more information. And, yeah, put it back on them to come 
back to us rather than us continually following up. 
 
The risk with emphasising personal responsibility is that it allows smokers to blame 
‘information fatigue’ from continuous messages about the importance of quitting: 
P2: They’ve been told for many years that they should stop smoking. But at the end of the 
day it was completely up to them whether they wanted to or not. 
P2: Yeah some of them were “I know that information, you don’t need to tell me again that 
I need to give up smoking, it’s not good for me.” 
 
Overall, the theme of personal responsibility captures the Educators’ awareness of 
participants’ readiness to change and raises issues of how monitoring and accountability 
might supplement participants’ determination to quit. This readiness and determination 
was, however, not universal across participants. 
 
Theme 2: “They’re a bit resistant to make changes” – Smoking is an ingrained habit 
Some RA-specific barriers to smoking cessation were evident in trial participants, many of 
whom were wanting to quit but were resistant to engaging with the intervention options: 
P1: They’re a bit resistant to change with stopping smoking and some people are like that 
when you’re talking to them when they’re in a lot of pain and they’re a bit resistant to 
make changes as far as start moving despite the pain or take paracetamol coz it might 
help. You know so that same that same kind of resistance but a lot of them actually 





P2: For some they felt that their smoking was part of their coping with their rheumatoid. 
A stress reliever. 
 
These RA-specific barriers reiterate the findings of the consultation process used to develop 
the intervention (Aimer et al., submitted). One of the Educators here particularly noted that 
the resistance seemed to arise from their being the management of their arthritis, but it was 
also noted by that Educator that the trial participants did not have the high levels of pain 
typical of their usual clients. 
 
Another part of the resistance to change was that participants had smoked for a long time: 
P2: For a majority of them they had lived with the rheumatoid for a long, long time so they 
had their own ways of coping and their own ways of dealing with things [...] and they 
have been smoking for many, many, many years. And I think equally they could see 
that they probably should stop smoking. They’ve been told for many years that they 
should stop smoking. 
P1: A lot of people had smoked a very long time and knew it was bad for them but still 
quite enjoyed it I think. [...] “It hasn’t killed me yet so you know why bother and I’ve 
got to enjoy something in life.” 
 
A common expectation is that all smokers want to quit and do not like smoking, but here 
the Educator raises the point that part of the resistance to quitting might be that participants 
enjoy smoking and have a fatalistic attitude. 
 
Even when participants were surprised by the new information about possible links 
between smoking and their arthritis, they were resistant to seeing the future potential for 
increased wellness:  
P2: Some certainly were quite surprised with the links to you know medication being less 
effective umm and also had some comments that “Well it’s, this information’s not 
really much good for me now, I’ve already got rheumatoid arthritis.” 
 
In summary, despite having enrolled for a trial of smoking cessation, some participants 






Theme 3: Generic facilitators and barriers to smoking cessation 
In addition to the resistance identified in Theme 2, there were some facilitators and barriers 
noted by the Arthritis Educators. These facilitators and barriers are generic in that they are 
not necessarily specific to people with arthritis. 
 
The Educators used their experience to counsel participants as per the trial protocol and the 
intervention tool of support: 
P1: I think people appreciated being listened to. [...] they did want to talk about life and 
their reasons why they smoke. [...] Yeah and I think some of them did feel a little bit 
accountable because they’d justify straight away, “I haven’t given up, don’t ask me 
about smoking.” But then they’d talk about you know their life so I think yeah. And 
then you could kind of twist it back round again afterwards. 
P1: What worked well? I think actually meeting people and them realising they’re not 
alone and that there is support available. Ah I think that was really, really good. Coz 
some people seemed quite isolated and not just in their environment, but also in their 
knowledge of things. 
 
Support went beyond the support delivered by the Educators, with one Educator noting the 
importance of family support for one participant who had successfully quit: 
P1: And her partner was going to give up with her. So she was probably overall was more 
motivated, had more motivating factors. 
 
Support was also delivered by electronic communications – a facilitator of the intervention: 
P1: I think the resources for online you know the emails, were really, really good, [but] 
that wasn’t kind of fully utilised for some of [the older] generation 
P2: And certainly not everybody had access to internet. 
 
However, here it is noted that access to electronic communications is a barrier to some 
participants, particularly the older participants. Overall, support was delivered by the 
Educators and other individuals, and through means other than face-to-face contact, which 






Theme 4: Specific local barriers to smoking cessation 
In addition to generic barriers, specific barriers existed due to local circumstances. These 
barriers centred on the aftermath of earthquakes but also include other minor local issues 
that highlight how the intervention tools have to be considered in terms of the ability for 
them to be delivered in various locations. 
 
The earthquake was noted to have ongoing impact: 
P1: Like one lady was having her street renovated and every time the digger went past the 
house shook. So it was just all too much. She was quite traumatised I think actually. 
P1: And it was really obvious there was a lot of stress relating to earthquakes and I mean 
that if it’s redeveloped is different isn’t it? Because at the time I kept thinking “Gosh, 
there could be more supports here for those people for those issues.” But I didn’t really, 
I kept saying “Go back to your GP.” 
 
Coming back to lack of internet access, it was noted than another contributor to electronic 
isolation was earthquake disruption to housing: 
P1: Coz they just didn’t have access to the internet some of them. [...] I wonder if some of 
it was coz of the earthquakes though. Some people had shifted a lot and either not got 
stuff up and going again or they just didn’t have it. 
 
One very important local barrier was the closure of the hydrotherapy pool, which was meant 
to be offered as one intervention tool to allow participants to exercise as a compensation to 
stress-relief of gained from smoking: 
P1: Probably the one thing people would have done was the pool, and it wasn’t available 
so that didn’t help. 
P2: Unfortunately with the hydrotherapy, with the pool being closed for earthquake repairs 
that was not an =option= which I think is unfortunate because umm, maybe that, yeah 
that would have been something that people did take up. I mean who knows, but we 
didn’t have; we ended up not having that as an option. 
 
A more localised point about availability of exercise classes provides important insight into 





participants were working – this issue may exist in other locations, and some locations may 
have no classes at all. If classes were available at other times then participants could have 
attended: 
P2: Quite a number of people were working so some of the exercise classes again were 
ruled out, or some, some of our arthritis exercise classes were ruled out but whether 
they took up other external exercise because of it umm. 
 
In summary, the impact of the earthquakes highlighted how local facilities are important 
for this smoking cessation intervention, particularly if it is to be rolled out to other locations 
that may also have varying access to exercise classes, internet etc. 
 
Theme 5: “There were definitely plenty of options” – What worked well within the 
intervention 
The range of options provided within the intervention was raised by both Arthritis 
Educators as one of the biggest specific facilitators of its delivery: 
P2: I think it worked well and I think it was, yeah, like I said before, there was a wide range 
of resources, media to present it in and I think it probably covered most bases. 
 
However, one of the Educators noted that the generic resources that were used as 
intervention tools to support smoking cessation were things participants had already tried 
or were already aware of: 
P1: Most of those people that were internet savvy had already looked at [the pre-existing 
arthritis self-management resources that were emphasised]. [...] So for future umm, if 
it was redesigned? Probably divide them into internet savvy and non-internet savvy 
 
The notion of focusing on the internet savvy mooted here then would perhaps imply a need 
to have a wider range of high quality internet resources about issues such as finding 
manageable forms of exercise in addition to the Arthritis New Zealand resources and other 
resources used. Other Educators may already facilitate this kind of active information 
seeking with clients. 
 
The specific information about the potential impact of smoking on the severity of RA and 





P2: And I think you know hearing that link between medications, the effect of the 
medication, I think for some that that was actually quite alarming. And maybe for the 
ones that were struggling a wee bit umm, yeah. 
P1: The younger person had, I can’t remember how old she was, maybe early thirties and 
had a son, a school kid and it was to do with going on new medication and she thought 
if she smoked she would have to go on a higher dose of medication and didn’t want to. 
So she’s quite highly motivated. 
 
The specifics here of the information being “alarming” or used to trade off the ramping up 
of medication dosage links back to the themes on personal responsibility (Theme 1) and 
resistance (Theme 2) but shows how the tools was used appropriately in relevant cases. 
 
Another point of flexibility was the venue or means of communicating: 
P1: And a couple of people I did that with as well, I met them at the hospital because umm 
they were coming in from out of town, some were coming from [town] or somewhere 
a little bit further away. 
 
Similarly, one of the Educators noted difficulties liaising with people who were working 
but was even willing to work flexible hours to overcome this: 
P2: From the point of view of trying to get hold of people who are working, coz certainly 
for a lot of rheumatoid people, they are working so trying to catch them when they’re, 
1) not working, and 2) actually available and relaxed enough to be able to talk to you 
and yeah. [...] So if it is out of hours then you know I can work my work hours around 
that so, I don’t see that so much of as a problem 
 
When asked if the intervention could be flexible enough to work in other locations, both 
Educators were positive: 
R: And do you think this intervention could be used in other parts of New Zealand? 
P2: Oh absolutely. Yeah for anyone with arthritis, no matter where. Yep. 
 
R: And umm, do you think this intervention could be used by other Arthritis New Zealand 





P1: Yeah absolutely. Yeah. It could be more tailor-made for Māori people and probably 
look at more groups as =opposed= to individual connections with people but maybe 
running a group. 
 
Here one of the Educators raises the possibility of further tailoring/tool, particularly the 
possibility of group meetings (which were not part of this intervention due to the reluctance 
of some participant who smoke to attend focus groups in the consultation phase: Aimer et 
al., submitted). Overall, the intervention was seen as positive, mostly due to its planned 
flexibility and as added by the Educators. 
 
Theme 6: “Hopefully that’s what you can tell us” – Keeping the Arthritis Educators in the 
loop 
The final theme encompasses some of the suggestions raised by the Arthritis Educators, the 
information about the results that they were not aware of, and the points they raised that 
have implications for training. 
 
It was evident that the Educators were not aware of the outcome of the study. They had not 
been informed of the individual participants’ outcomes or what tools they had taken up, 
and the Educators only knew what they had garnered informally from interactions: 
P1: I got one person to stop (laughs) smoking I think. 
P2: A number of people said they were interested in the DVD, the exercise DVD. But again 
I’m not sure whether they actually did take that up. 
 
One of the Educators raised issues with the data collection forms. Firstly, they had realised 
they were not using the appropriate form for follow-up data gathering: 
P1: Halfway through the study I realised I was using the wrong form for something. 
 
Secondly, they reported finding the form repetitive, cumbersome and/or irrelevant to many 
participants because the questions ask for very precise information without removing 
questions that are irrelevant based on initial answers: 
P1: On the form when you’re going through it, umm, it seemed quite repetitive. Like umm 






It was also noted that the problems getting in touch with participants led to concerns about 
the protocol to follow: 
P1: Yeah the other thing was getting hold of people. Sometimes that was really hard and 
so you know [name] and I used to think “Well how many times do you ring?” So we’d 
kind of ring three times and then we’d wait and then, do you give up or not? You know 
so it was sort of, it was a little unclear how much, how many times we’d ring. 
 
Here, the difference between the Educators’ routine practice and the specific data collection 
practices of the research protocol are again evident. This theme is summed up by one 
Educator’s response to a question requesting an overall evaluation of the intervention tools: 
R: So how successful do you think the interventions were? 
P2: I don’t know, I honestly don’t know. Hopefully that’s what you can tell us with your 
research in the end. 
 
Having the staff who deliver the intervention in the loop about what is working as the trial 
progresses is questionable from a perspective of bias reduction but it is important to 
disseminate the findings of the trial so that the evidence may be put into practice. 
 
Conclusions 
The findings of these exit interviews provided six themes that capture a range of issues 
about the delivery of the intervention and possible reasons for the success or difficulties 
experienced by individual participants. The following conclusions are posed as tentative 
suggestions for future application of the information arising from each theme. 
 
1) Participants’ personal responsibility 
Delivery of the smoking cessation intervention relies on participants who are ready to quit. 
Indeed, the Arthritis Educators noted that participants needed to be “determined” to quit. 
Motivational interviewing may be a useful framework to be added to the intervention and 
training of the Educators (see Shannon & Hillsdon, 2007). Seeing participants as personally 
responsible for making use of the intervention tools could be supported by a structured 
motivational discussion about the participants’ reasons for and against use of the tools, 





certain cases, be another tool that participants would value, but would need to be delivered 
with clear guidance about respecting participants’ withdrawal from the intervention. 
 
2) Smoking is an ingrained habit 
The resistance to quitting due to smoking being an ingrained and enjoyed habit was not 
expected given these participants had agreed to take part in the intervention trial. However, 
this finding is in line with our previous research on the RA-specific barriers to smoking 
cessation (Aimer et al. submitted). Emphasis on smoking being a risk factor for the onset 
of RA should perhaps be put aside in favour of emphasis on the possible health gains of 
smoking cessation. Older individuals may particularly benefit from additional information 
about the health gains they could still achieve from smoking cessation. 
 
3) Generic facilitators and barriers to smoking cessation 
The Educators’ skills in listening to participants should not be overlooked. The value of an 
educated listener outside the family unit is a core component of the intervention. Family 
support was also raised as a key facilitator and this had not been factored into the 
intervention, which was planned only to focus on the individual with RA. Support by 
electronic communication was important but not universally accessible by participants. 
 
4) Specific local barriers to smoking cessation 
The situation with the local earthquake and its ongoing impact highlighted how the 
intervention was tested in only one location and how location is a very important frame for 
the tools provided in the intervention. Planning the availability of tools in other locations 
would be important for rolling out this intervention, and may be facilitated by an 
information network approach to log available resources and problem-solve where 
resources are not available in a specific location. 
 
5) What worked well within the intervention 
The range of resources was seen as one of the key strengths of this intervention – what 
worked for one person might not work for another and so having many options covered 
more participants’ needs. A difference between the “internet savvy” participants and others 
without access of information gathering skills should not be overlooked. Making 





motivational underlies that provision of the information. The Educators were positive about 
rolling out the intervention and suggested it could possibly apply to anyone with a form of 
arthritis, although further research would be needed to investigate that broadening and build 
a case for disease-specific delivery (e.g., the information about smoking possibly effecting 
RA treatment efficacy is not relevant beyond RA). 
 
6) Keeping the Arthritis Educators in the loop. 
The Educators noted that they were not in the loop about the success of participants and 
they were keen to know the results of the main quantitative component of the trial, including 
which resources were made use of. Further refining of the data collection forms may be 
required and would benefit from the input of Educators and participants to ensure the 
relevance of the questions and determine what questions are essential to ask. It may help to 
use an online data collection protocol that could be access directly by participants with 
internet access or could be completed by the Educator in person or over the telephone. 
Differentiating what is needed for research evaluation from what is needed for routine 
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Appendix: Questions for the semi-structured exit interviews 
1. What was your overall impression about the structure of the smoking cessation 
interventions? 
2. How successful do you think the interventions were? 
3. How did interactions with this patient group differ from the normal patient interactions 
you have with RA patients? 
4. What do you think was different between people who were successful or not successful 
at smoking cessation during this trial? 
5. What do you see as the future of this kind of intervention programme? 
6. Would you be happy to continue with this intervention programme? 
7. Do you think this intervention could be used by Arthritis New Zealand in other parts of 
New Zealand? 
8. What worked well with this pilot study? 
9. What didn’t work well with this pilot study? 
10. If you had the opportunity to redesign the interventions, what would you do? 
 
 
